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Abstract 
Embryo implantation represents a complex process vital in ensuring the normal 
development of pregnancy.  Whether embryo implantation is the goal of natural conception 
or assisted reproductive treatment, the environment within the uterine cavity must be 
optimised in order to increase the chance of pregnancy.  
 
This thesis uses a mixture of research methods to investigate potential approaches to 
improving embryo implantation.  Below are the key findings from this thesis: 
1. The vitamin D status in women undergoing assisted reproductive treatment is 
important.  An interventional trial would prove or disprove the merits of vitamin D 
deficiency treatment in these women. 
2. There is not enough evidence to suggest a clear association between vitamin D and 
recurrent miscarriage, however there is a strong argument for biological plausibility. 
3. The use of endometrial fluid collected at the time of embryo transfer in women 
undergoing assisted reproductive treatments for metabolomics analysis is possible.  
4. Women with hydrosalpinx associated tubal infertility should be offered 
salpingostomy as a treatment option as the natural conception rates are similar to 
that achieved in in vitro fertilisation treatment. 
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CHAPTER 1: THESIS INTRODUCTION 
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Embryo implantation 
 
For many people, having children and a family is an ambition from a young age.  However, 
many physiological processes must occur for pregnancy to be achieved.  One of the most 
delicate and complex of these processes is embryo implantation.   The complexities of the 
implantation process commence with fertilisation of an ovum and ends with embedding of 
the blastocyst into the endometrium.  A series of precise steps ensures that placentation can 
occur to support the embryo throughout the gestation.  Without the preceding step 
occurring normally, subsequent steps cannot follow. The steps involved for successful 
pregnancy to be initiated are divided into five stages1: 
1. The fertilisation of the ovum 
2. Division of the zygote  
3. Entry of the morula into the endometrial cavity, with further development into a 
blastocyst 
4. Blastocyst adherence and penetration into the endometrial stroma 
5. Placentation 
For the purposes of this introduction stages three and four will be considered in more detail. 
 
Entry of the morula into the endometrial cavity 
The pre-implantation blastocyst enters the endometrial cavity 72-96 hours after fertilisation 
of the ovum in the fallopian tube2.  Cross talk between the blastocyst and the endometrium 
occurs immediately on entry in to the endometrial cavity.  Further maturation of the 
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blastocysts occurs and it hatches from the zona pellucida3 allowing contact between the 
trophoblast cells and the endometrium.  It is important to note that at this stage, many 
blastocysts will never cause a clinically recognised pregnancy due to failure of the embryo to 
implant into the endometrium4.  This is because successful embryo implantation can be 
prevented by a variety of factors making human reproduction relatively inefficient when 
compared with other mammalian species.  These factors include karyotypical defects (which 
would not allow normal maturation of a zygote into a blastocyst), anatomical abnormalities 
within the female reproductive organs, and inflammation (which leads to an environment 
too hostile to allow implantation to take place)5.  However, even in the absence of these 
factors, successful embryo implantation also depends on the synchrony in the development 
of both the embryo and the endometrium.   
 
Blastocyst adherence and penetration 
Transition of a free blastocyst within the endometrial cavity to implantation requires initial 
adherence of the blastocyst with the endometrium.  This is initiated with apposition and 
then penetration of the endometrium1 (see figure 1).  Very little is known regarding this in 
humans due to the delicate nature of the processes.  However, data from animal research 
suggests that apposition occurs five to six days after fertilisation, and is characterised by the 
close approximation of the plasma membranes of the trophoblast cells of the blastocyst with 
the plasma membranes of the surface epithelial cells of the endometrium6.  A microfilament 
structure develops between the two cell surfaces allowing a cell to cell stable apposition.   
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Figure 1. The stages of human implantation1
 
The bonds formed in apposition are relatively weak, so implantation may still not occur6.  It 
is only after penetration of the blastocyst that implantation is completed.  Penetration in 
humans is thought to occur by outward processes of the syncitiotrophoblast invading in to 
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the spaces between the surface epithelial cells of the endometrium.  Invasion causes the loss 
of inter-cellular junctions between the epithelial cells and the formation of new junctions 
between the syncitiotrophoblast cells and the epithelial cells.  Invasion continues until the 
basement membrane of the endometrium is reached7.  
 
If pregnancy is to be achieved following blastocyst penetration, the placenta must form to 
provide an adequate blood supply to the blastocyst.  Briefly, early placentation occurs 
between seven and 13 days after fertilisation1.  Trophoblastic development results in the 
formation of cytotrophoblasts and syncytial trophoblasts.  Further invasion occurs, with 
trophoblastic invasion into the maternal uterine blood vessels so that maternal blood floods 
spaces between the trophoblasts called lacunae.  Placental villi develop and further anchor 
the pregnancy to the maternal endometrium1. For the purposes of this thesis introduction, 
the process of placentation will not be explained in any more detail. 
 
The importance of the endometrium in embryo implantation 
The complex processes of embryo implantation are described above.  However, the 
importance of the endometrium in implantation cannot be understated.  It must be 
receptive and prepared to allow effective cross talk with the blastocyst and for adherence 
and penetration to occur.   
 
The endometrium is a dynamic structure, changing on a daily basis under the influence of a 
number of hormones.  In a physiological menstrual cycle, these hormones cause recurring 
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proliferation and differentiation with the aim of supporting a potential pregnancy.  The 
menstrual cycle consists of three phases; the menstrual phase, the proliferative phase and 
the secretory phase.   
 
Menstruation begins on the first day of the menstrual cycles and is caused by progesterone 
withdrawal.  The proliferative phase results from the growth of the endometrium from the 
endometrial basalis layer under the influence of oestrogen secreted by the growing cohort 
of ovarian follicles.  Once a dominant follicle has emerged, ovulation is triggered by a surge 
in luteinising hormone from the anterior pituitary gland.  The secondary oocyte is then 
released into the fallopian tube ready for fertilisation.  The follicular remnant, or corpus 
luteum, produces high levels of progesterone and oestrogen, resulting in the differentiation 
of the endometrium to form secretory changes.  Aside from the oestrogen and 
progesterone, endometrial changes are also caused by secondary autocrine and paracrine 
hormonal effects and by cell mediators such as cytokines8,9.  At a histological level, the early 
secretory phase is characterised by the development of vacuoles within the endometrial 
cells.  During the mid-secretory phase (six to ten days after ovulation), decidualisation occurs 
and the apical epithelium develops finger like protrusions called pinopodes10,11.  It is during 
the mid-secretory phase of the menstrual cycle when embryo implantation is most likely to 
occur, and this is termed the “window of implantation”12.  If implantation does not occur, no 
human chorionic gonadotrophin is produced by trophoblastic tissue; causing the 
endometrium to enter the late secretory phase, when preparations are made for 
menstruation.  Progesterone production reduces from the corpus luteum leading to a 
breakdown in the endometrium causing menstruation and the cycle begins again. 
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Importantly, the mid-secretory phase and the “window of implantation” occur at the same 
time that a morula enters the endometrial cavity, if fertilisation of an ovum has occurred.  
The synchrony between the endometrium and the embryo is critical for implantation and 
pregnancy to occur.  Asynchrony or abnormalities in the intrinsic factors outlined above 
manifests as infertility. 
 
Infertility as a disease 
Infertility is a cause of high anxiety and stress for one in seven couples in the United 
Kingdom (UK)13.  Depending on the cause of infertility, women may suffer physical, 
psychological and emotional symptoms.  Furthermore, the inability to have a family can 
cause breakdown of relationships leading to further negative health impact14.  In women 
under the age of 40, having regular unprotected sexual intercourse, 80% of couples will have 
conceived at 12 months.  After 24 months the cumulative pregnancy rate increases to 90%13.   
 
The National Institute for Health and Care Excellence (NICE) recommends that in couples not 
conceiving after 12 months, initial investigations and clinical assessments should be 
conducted.  These investigations include a pituitary hormone profile, mid-luteal 
progesterone, rubella immunity testing, a fallopian tube assessment, pelvic ultrasonography, 
and a semen analysis.  These investigations are performed to identify the cause of infertility.   
Causes of infertility 
The causes of infertility can be divided into male and female causes.  Male infertility may be 
caused by primary testicular dysfunction, obstruction to the vas deferens, endocrine factors 
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(e.g. hypogonadotrophic hypogonadism and hyperprolactinaemia), autoimmune factors (e.g. 
anti-sperm antibodies), and drugs (e.g. tobacco, alcohol, steroid use and chemotherapy)15. 
 
Female infertility can be caused by anovulation (due to dysfunction of the hypothalamic-
pituitary ovarian axis), endocrine factors (e.g. hyperprolactinaemia and thyroid dysfunction), 
tubal damage, and uterine factors13.   
 
In up to one third of couples no cause is found and this is termed unexplained infertility.   
Irrespective of the cause of infertility, the health impact is vast.  Many couples have 
longstanding wishes to become parents and most couples would not expect difficulties in 
conceiving.  This leads to detrimental effects on the psychological wellbeing of both the 
female and male partners.  Furthermore, some causes of infertility, such as endometriosis, 
fibroids and endometrial polyps can also cause physical symptoms in the form of 
dysmenorrhoea, dyspareunia or abnormal menstruation16,17.   
 
Treatment of infertility 
Once the cause of infertility is identified, treatment can commence.  The nature of the 
treatment will depend on the type of infertility.  This can range from lifestyle advice and mild 
medical treatments in the form of oral medications to more invasive treatments such as IVF 
and ICSI or even surgery to correct anatomical abnormalities.    
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Some couples may require very mild treatments to help them conceive.  For example, in 
polycystic ovarian syndrome, all that may be required is advice regarding weight loss.  In 
women where weight loss does not achieve regular menstruation, ovulation induction 
agents such as clomiphene can be used18.  
 
In couples where simple treatments have not been successful, more invasive medical 
treatments such as in vitro fertilisation (IVF) or intra-cytoplasmic sperm injection (ICSI) may 
be required. There are a number of indications for the use of IVF and ICSI treatment.  These 
include; male factor infertility, tubal infertility unsuitable for surgical correction, anovulation 
refractory to ovulation induction agents, and unexplained infertility.   The use of these high 
technology assisted reproductive treatments (ART) is increasing and the most recently 
published data from the Human Fertility and Embryology Authority (HFEA) states that in 
2014, 52,288 women had a total of 67,708 cycles of IVF/ICSI in the UK.  This represents a 
consistent five per cent rise in the number of IVF cycles performed each year19.   
 
Lastly, in some women with infertility, surgery may represent a treatment option.  Before 
the availability of IVF and ICSI was widespread, fertility surgery was the only available option 
for many infertile couples.  Uterine abnormalities such as fibroids or endometrial polyps 
were removed surgically.  This was then followed by efforts at natural conception.  Modern 
reproductive medicine now uses surgical correction of uterine abnormalities as a tool to 
optimise the uterus before IVF and ICSI treatment is performed.  Tubal infertility can also be 
treated with fallopian tube conserving surgery.  Surgery may offer some infertile couples the 
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chance of long lasting efforts at natural conception without depending on IVF or ICSI 
treatment once abnormal reproductive tract anatomy has been corrected20. 
 
Fertility treatment funding 
Simple medical treatments and fertility surgery are funded by the National Health Service 
(NHS).  However, if IVF or ICSI treatment is required, funding for these high technology 
treatments varies geographically according to local Clinical Commissioning Group (CCG) 
funding regulations13.  This can mean that in some areas NHS funding is provided for up to 
three IVF cycles whilst in others there is no funding for fertility treatment at all.  Once 
funding has been allocated and used up, subsequent attempts are self-funded by the 
infertile couple.  Strict funding restrictions also apply; meaning that couples must fulfill 
certain criteria to be eligible to receive NHS funded IVF treatment.  Examples of these 
criteria include; both partners being non-smokers, both partners having a body mass index 
of 30 or less, and neither partner having any living children13.   
 
IVF and embryo implantation 
IVF was first performed successfully in 1978.  Louise Brown was born after a natural 
treatment cycle with no exogenous pituitary hormones administered. Sir Robert Edwards, 
who later won the Nobel Prize for Physiology in 2010, pioneered IVF.  IVF involves the 
fertilisation of an oocyte by a sperm in vitro.  The ovaries are stimulated by exogenous 
follicular stimulating hormone and luteinising hormone to induce the growth of multiple 
ovarian follicles.  Final maturation of the oocyte is then triggered using a human chorionic 
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gonadotrophin injection.  This is followed by ultrasound guided oocyte retrieval.  Sperm is 
then prepared and used to inseminate the oocytes. The fertilised oocytes are cultured, and 
the best embryo is transferred into the uterine cavity.  The goal is to achieve embryo 
implantation and subsequently pregnancy by ART that substitute the physiological processes 
mentioned above.   
 
Major advancements have occurred since the first IVF treatment cycles and success rates 
have improved steadily over the past four decades.  Major advancements have included the 
development of ultrasonography, which is now used to monitor ovarian stimulation, as well 
as the increase in knowledge regarding embryology.  Indeed, reproductive embryology is 
now a large branch of biology, which has benefitted from a great deal of research.  This has 
led to a greater understanding of how normal embryos should develop allowing 
embryologists to select embryos with the best fertility potential with a high degree of 
confidence21.  Most recently, time-lapse embryology has been developed further improving 
the ability of embryologists to choose the embryos with the greatest potential to cause 
pregnancy22.   
 
Despite these advancements, recent improvement in IVF treatment success has plateaued.  
Many patients fail to become pregnant with IVF treatments despite the transfer of high 
quality embryos5. Although our understanding of the developing embryo has gained clarity, 
knowledge concerning embryo implantation is not as clear.  The implantation process is 
difficult to study as it is delicate and can easily be disrupted.  It is now understood that for 
pregnancy to be achieved the endometrium must be at optimal conditions to allow for 
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implantation. As mentioned above, this is the case in natural conception when there is a 
putative ‘window of implantation’ in each physiological menstrual cycle.  In ART, the goal is 
to mimic those intrauterine conditions found in the natural ‘window of implantation’.  
 
This thesis aims to highlight several approaches that may improve embryo implantation in 
both natural conception and in artificial reproductive treatments.   
 
Vitamin D and IVF treatment  
The first two chapters of this thesis explore the association between vitamin D status in 
women undergoing IVF and ICSI treatment and the likelihood of treatment success.  Vitamin 
D and health has recently been the subject of a great amount of research due to the 
discovery that vitamin D may have more health impact than its classical role in bone and 
calcium homeostasis23.  In reproductive health, vitamin D is thought to have a role in 
obstetric medicine as well as in gynaecology. In particular, vitamin D receptors have been 
found in the endometrium leading to many in the field of reproductive medicine to consider 
vitamin D as an important regulator for implantation24.   
 
In the second thesis chapter, the importance of vitamin D in IVF treatment is explored by a 
systematic review and meta-analysis of existing literature.  The methods, findings and 
inferences of a cohort study, performed to identify an association between vitamin D and 
IVF treatment outcome, are presented in the third thesis chapter. 
 
13 
 
Vitamin D and recurrent miscarriage 
The high levels of interest in vitamin D and embryo implantation may also have implications 
for miscarriage.  In some women, conceiving is not the primary problem that causes 
childlessness.  Instead, it is the inability to maintain pregnancy. In patients with recurrent 
miscarriage, the main issue is not with embryo implantation.  However, there has been a 
great deal of research that has suggested that the extravillous trophoblastic invasion that 
occurs after initial embryo implantation is affected by vitamin D.  As a clinical population 
women with recurrent miscarriage lie adjacent to the population with infertility, being 
treated by the same reproductive medicine clinicians, therefore it was felt necessary to 
investigate the relationship between vitamin D and recurrent miscarriage further. 
 
Recurrent miscarriage affects one per cent of couples and is diagnosed when three or more 
miscarriages have been suffered consecutively.  In half of women with recurrent miscarriage 
a potential cause is identified.  These causes include karyotypical abnormalities, 
thrombophilias and uterine anomalies.  However, in the remaining half of women diagnosed 
with recurrent miscarriage a cause may not be found25,26.  In order to improve 
understanding of the link between vitamin D and recurrent miscarriage, a systematic 
narrative review was undertaken.  This is presented in the fourth thesis chapter. 
 
The use of endometrial fluid in predicting IVF treatment outcome 
The fifth and sixth thesis chapters explore the use of endometrial fluid in predicting IVF 
treatment outcome.  As mentioned above, knowledge regarding the optimum environment 
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for embryo implantation lags behind advancements in embryology.  Novel techniques to 
distinguish between the receptive versus the non-receptive endometrium are desperately 
required in order for continued improvement in IVF treatment success rates.  One of these 
innovative techniques is to investigate the fluid within the endometrial cavity.  This fluid 
represents the environment in which the embryo must implant and has been studied by 
many research groups who aim to uncover the optimum conditions for the implantation 
process to progress successfully in IVF treatment.  A systematic narrative review was 
performed to identify the existing literature and this is presented in thesis chapter five.   
The narrative review presented in thesis chapter five demonstrates that endometrial fluid 
has been used to investigate the protein, genetic and immunological constituents of 
endometrial fluid sampled during IVF treatment27.  However, there was no published 
evidence of endometrial fluid being used to explore metabolic profiling.  A proof-of-principle 
cohort study is therefore presented in thesis chapter six.  In this chapter, endometrial fluid 
from women undergoing IVF treatment is used for metabolomics profiling.  This is a 
relatively new systems biology technique, which allows for the interrogation of the 
metabolic signature of bio-fluids.  The aim of this cohort study was to confirm the feasibility 
of using endometrial fluid sampled in women undergoing IVF treatment for metabolomics 
analysis.  Additionally, the study aimed to identify a panel of metabolites predictive of 
successful implantation. 
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Salpingostomy in the treatment of hydrosalpinx 
Tubal infertility is caused by fallopian tube obstruction, which does not allow for in vivo 
fertilisation of the oocyte by sperm.  Tubal obstruction is usually preceded by inflammation 
of the tubal mucosa.  This inflammation of the fallopian tubes can be due to endometriosis 
or pelvic infection.  With severe tubal obstruction, hydrosalpinx (fluid trapped in the tube 
causing swelling) can result.  IVF treatment was initially developed for women with tubal 
infertility.  In the case of tubal infertility caused by hydrosalpinx, it has been discovered that 
the fluid within the fallopian tube must be kept separated from the endometrial cavity so 
that the embryo fertilised in vitro has an increased likelihood of implanting28,29.  The 
hydrosalpingeal fluid is thought to be toxic to the embryo and also cause a mechanical 
washout effect if allowed to communicate with the uterine cavity.  Importantly, it is 
understood that the hydrosalpingeal fluid alters inflammatory cytokines, prostaglandin 
concentrations as well as endometrial natural killer activity, hindering embryo implantation.   
As a consequence it has become common practice to remove or disconnect the fallopian 
tubes affected with hydrosalpinx prior to beginning IVF treatment.  Unfortunately this means 
that women with bilateral hydrosalpinges can be rendered sterile and reliant on IVF 
treatment for any further efforts at pregnancy.  Before the widespread availability of IVF 
treatment, conservative tubal surgery was performed to correct hydrosalpinx30.  The tube 
was drained by salpingostomy and couples were encouraged to continue efforts at natural 
conception.  This treatment strategy is now rarely used but was effective.  To investigate the 
effectiveness of salpingostomy in the treatment of hydrosalpinx a systematic review and 
meta-analysis was performed and this is presented in thesis chapter seven.  Investigating the 
merits of tubal conservative surgery is an important approach to improving embryo 
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implantation in those with hydrosalpinx associated tubal infertility.  This is the reason for 
investigating the efficacy of salpingostomy treatment for women with hydrosalpinx. 
 
Conclusions drawn 
This thesis seeks to explore the approaches that may be taken to improve the chances of 
embryo implantation in natural conception and in IVF treatment.  The final chapter (chapter 
eight) summarises all of the findings of the thesis and highlights the potential directions that 
future research could take in this exciting and clinically important domain. 
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CHAPTER 2: VITAMIN D AND ASSISTED REPRODUCTIVE 
TREATMENTS – SYSTEMATIC REVIEW AND META-ANALYSIS 
 
This work has been submitted to the British Medical Journal for publication.  Reviewers’ 
comments are awaited.  
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Introduction 
In the UK, one in seven women have difficulties in conceiving pregnancy31.  IVF treatment 
represents a viable treatment option in a significant proportion of these women.  However, 
there are funding restrictions in place as well as strict criteria that couples must fulfill in 
order to access public funds.  Furthermore, in many geographical regions in the UK, couples 
may only be entitled to funding for a single cycle of IVF treatment32.  This has meant that it 
has become increasingly important to identify factors that can be improved in order to 
maximize the chances of IVF treatment success.  Research into IVF outcome improvement 
has become an important research domain.  One potential factor identified has been one of 
vitamin D status23,24.   
 
Many cohort studies have been published to substantiate an association between vitamin D 
status and IVF treatment success.  Vitamin D deficiency is common in temperate countries 
such as the United Kingdom.  Its prevalence has been reported as high as 49.5% in pregnant 
women33 and has been found to be especially high in women of reproductive age with 
polycystic ovaries34.   
 
Vitamin D is a secosteroid hormone that exerts many biological effects35.  Human intake is 
mainly through ultraviolet light skin exposure causing precursor conversion of 7-
dehydrocholesterol into provitamin D3.  In turn, provitamin D3 undergoes isomerization into 
cholecalciferol and is carried to the liver by vitamin D binding protein to the liver where it 
undergoes hydroxylation by 25-hydroxylase to 25-hydroxy vitamin D36,37.  Further 
hydroxylation is carried out in the kidneys producing 1,25-dihydroxyvitamin D, which is the 
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biologically active form of vitamin D35.  The biological actions are mediated by vitamin D 
receptors leading to activation of target genes through the retinoid receptor X38,39.  An 
overview of vitamin D metabolism and its actions are provided in figure 240. 
 
.  
 
 
Vitamin D status is ascertained by collecting blood serum and measuring 25-hydroxy vitamin 
D by a reliable assay.  This is the most dependable method of investigating vitamin D status 
due to the long half-life of 25-hydroxy vitamin D (two to three weeks).  The Endocrine 
Society and Institute of Medicine’s classifies vitamin D deficiency as <50nmol/L, insufficiency 
is 50-75nmol/L and replete status is >75nmol/L41.  
 
Figure 2. Metabolism of vitamin D and its physiological actions 
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The traditional role of vitamin D is in its importance in bone and calcium metabolism; 
however, more recently wider biological functions have been identified42.  These include its 
roles in cancer, autoimmune disorders and cardiovascular disease43.  In addition, vitamin D 
seems to be important in female reproductive physiology. This has been hypothesized as 
vitamin D receptors and the enzymes required for vitamin D metabolism have been found 
within the ovaries, placenta and endometrium44,45.  Furthermore, vitamin D deficient mice 
are found to have reduced mating success with decreased litter sizes and uterine 
hypoplasia46.    
 
Vitamin D’s immunomodulatory role is thought to be due to its effects on cytokine profiles 
within tissues.  The presence of vitamin D allows for a preference to the T-helper 2 subset of 
cytokines including interleukin-4 (IL-4), IL-5 and IL-13 whilst also inhibiting the T-helper 1 
cytokine response of IL-1, IL-2, interferon gamma (IF-ϒ) and tumour necrosis factor alpha 
(TNF-α)47,48.  It is postulated that this dampening of immune response within the 
endometrium allows for a more favourable environment for the embryo to implant and 
develop into a pregnancy49. Further immunomodulatory biological evidence is seen in 
decidual cells where vitamin D reduces natural killer cells release of pro-inflammatory 
cytokines such as Colony Stimulating Factor-2 (CSF2), IL-1, IL-6 and TNF-α50. 
 
Further studies have found that endometrial homeobox-leucine zipper protein 10 A 
(HOX10A) gene expression reflects vitamin D levels within the body and both have also been 
found to increase mid-cycle in naturally menstrual cycles51.  In addition to HOX10A gene 
21 
 
expression, vitamin D also regulates gene expression for calbindin and osteopontin.  Both of 
these genes are thought to be critical in embryo implantation and placentation50.   
 
This biological evidence above has prompted many research groups to investigate the 
actions of vitamin D on the endometrium, and specifically how vitamin D may influence the 
likelihood of IVF treatment success. The aim of this systematic review and meta-analysis was 
to compare the chances of clinical pregnancy in vitamin D deficient patients undergoing IVF 
treatment with the chances of clinical pregnancy in patients with a normal vitamin D status. 
 
Methods 
Literature Search  
The population of interest was women undergoing any form of ART (IVF, ICSI and frozen 
embryo transfer [FET]) who had their vitamin D status checked.  This could either be through 
serum blood testing or follicular fluid assay.  The primary outcome was clinical pregnancy 
(the appearance of fetal heart activity at approximately seven weeks gestation after embryo 
transfer).  Secondary outcomes included pregnancy test positive rates, miscarriage rates and 
live birth rates.   
 
The following electronic databases were searched: MEDLINE, EMBASE, Cochrane Central 
Register of Controlled Trials and CINAHL (from inception to November 2015).  A wide search 
strategy was developed based on the following key words and/or medical subject heading 
(MeSH) terms: pregnancy, in vitro fertilization, intracytoplasmic sperm injection, assisted 
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reproductive techniques and vitamin D (see appendix 1).  The references of all included 
primary and review articles were examined to identify relevant articles not captured by the 
electronic searches.  No language restrictions were applied in any of the searches or study 
selection. 
 
Study Selection 
Criteria for inclusion in the study were established a priori.  Study selection was carried out 
by two independent reviewers.  Firstly, the titles and abstracts identified by the electronic 
searches were examined by the reviewers.  Examination of each title and abstract allowed 
the inclusion or exclusion of the article independently according to the predefined inclusion 
criteria; any disparities regarding inclusion between the two independent reviewers were 
resolved by a further independent reviewer.  Full manuscripts of the titles and abstracts that 
were considered to be relevant for inclusion were obtained.  When there was a duplicate 
publication, the most recent and complete version was selected and included. Studies that 
did not explicitly report results from assisted reproductive treatments in patients having 
their vitamin D status measured were excluded.   
 
Further exclusion of full manuscripts was conducted if they did not meet inclusion criteria.  
Finally the relevant data from the final included full manuscripts were extracted by the two 
independent reviewers. 
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Validity Assessment 
Two independent reviewers used the Newcastle-Ottawa Quality Assessment Scales for 
observational studies to complete a quality assessment of the included manuscripts.  The 
Newcastle-Ottawa scale ranges from zero to nine, awarding one star for all categories (case-
cohort representative, ascertainment of exposure, outcome negative at commencement of 
study, outcome assessment, duration of follow up and adequacy of follow up) except 
comparability by design or analysis where two stars can be awarded. An arbitrary score was 
allocated assuming that all items have equal weighting.  Each study received a score from 
each of the reviewers.   
 
Statistical Analysis 
Clinical pregnancy, live birth, miscarriage and ectopic pregnancy rates were extracted from 
each study.  The log of the ratio and its corresponding standard error for each study was 
computed.  Meta-analysis using inverse-variance weighting was performed to calculate the 
random-effects summary estimates. The square root of this number is the estimated 
standard deviation of the underlying effects across studies. Because we had relative 
measures of effect, the confidence intervals were centered on the natural logarithm of the 
pooled estimate and the limits exponentiated to obtain an interval on the ratio scale. Forest 
plots were created for each outcome, showing individual study proportions with confidence 
intervals (CIs) and the overall DerSimmonian-Laird pooled estimate. Vitamin D insufficient 
and deficient data were combined in each study and compared against the data from 
participants replete in vitamin D. Heterogeneity of the treatment effects was assessed 
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graphically with forest plots and statistically analyzed using the χ2 test. Statistical analyses 
were performed using Stata 12.0 (StataCorp, College Station, TX). 
 
Lastly, we performed a stratified analysis splitting studies that reported findings in women 
who had received a donor oocyte embryo and studies that reported findings in women using 
own oocyte embryo.  This analysis was performed in an attempt to isolate the effect of 
vitamin D on endometrial implantation alone, thereby eliminating the effects of oocyte and 
embryo quality on the assisted reproductive treatment outcomes.  
 
Results 
The PRISMA flow diagram52,53 of the review process is presented in figure 3.  The search 
strategy yielded 4615 citations.  Of these 4505 publications were excluded as it was clear 
from scrutinizing the title and abstract that they did not fulfil the selection criteria.  This 
meant that 110 full manuscripts were obtained and examined.  Of these, 110 full 
manuscripts 35 were review articles, 24 were publications not specific to assisted 
reproductive treatments, 17 were studies where vitamin D was not measured, four studies 
investigated the impact of vitamin D deficiency on sperm and male infertility, four were 
animal studies, four were conference abstracts and had no extractable data, three studies 
had data unsuitable for extraction, three were letters, two were duplicate publications, and 
one was a study protocol with no results. This left a total of 13 citations for final inclusion in 
this review54–66. Three interventional studies67–69 were also identified between the time of 
the literature search and preparation of the thesis. 
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Study characteristics 
The study characteristics of the 13 included manuscripts are presented in Table 1.  The 
studies varied in publication date between 2010 and 2014.  All 13 included studies were 
cohort studies; seven were retrospective and six were prospective in design.  Sample sizes 
varied between 64 women to 517 women.   Ten of the 13 included studies reported the ages 
of their study population.  Eight studies had a mean age of below 37 years and two had a 
higher mean age of 40.5 and 40.9 years.  The included studies varied in their method of 
investigating vitamin D status.  Nine included studies used serum measurement of vitamin D, 
three used both follicular fluid and serum vitamin D (finding that there was high correlation 
between the follicular fluid vitamin D and serum vitamin D in their participants) and one 
study only used follicular fluid for vitamin D measurement. Of the 13 included studies, ten 
studies reported ART where women had used autologous oocytes.  Three reported results 
from women who were donor egg recipients.  One study used pre-implantation genetic 
diagnosis to ensure that patients had karyotypically normal embryos transferred into their 
endometrial cavities.  One study chose to only study women that underwent a single 
blastocyst transfer.   
 
Table 2 shows the results of the Newcastle-Ottawa Quality Assessment.  All studies scored 
well achieving a score between 7 and 9.
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Author (year) Study 
design 
 
Study population 
 
Age of study 
population 
Method of 
vitamin D 
investigation 
Autologous or 
donated  
oocyte 
Summary of results Conclusions 
Aleyasin et al., 
(2011) 
Prospective 
Cohort 
82 women undergoing 
IVF in Iran 
Mean age 
29.8 +/-4.3 
years 
 
Vitamin D in 
follicular fluid 
and serum 
Autologous 
 
Clinical 
pregnancy 
24/82 deficient 
group 
0/0 insufficient 
group 
0/0 replete 
group 
 
Pregnancy test 
positive 
29/82 deficient 
group 
0/0 insufficient 
group 
0/0 replete 
group 
 
Miscarriage 
Data not provided 
 
 
 
Live birth 
19/82 deficient 
group 
0/0 insufficient 
group 
0/0 replete group 
Significant correlation between serum 
and follicular fluid and vitamin D.  No 
significant differences in IVF outcome 
when participants were divided into 
tertiles by vitamin D 
 
Anifandis et 
al., (2010) 
Prospective 
Cohort 
101 women 
undergoing IVF in 
Greece 
Not reported Vitamin D in 
follicular fluid 
Autologous 
 
Clinical 
pregnancy 
10/31 deficient 
group 
16/49 
insufficient 
group 
3/21 replete 
group 
 
Pregnancy test 
positive 
Data not 
provided 
 
Miscarriage 
Data not provided 
 
 
 
Live birth 
Data not provided 
 
Follicular fluid vitamin D levels 
significantly correlated to the quality 
of the embryos.  Data suggested that 
high levels of vitamin D led to a 
decreased chance of clinical 
pregnancy 
 
Table 1. Characteristics of included studies. Vitamin D and IVF treatment systematic review and meta-analysis 
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 Fabris et al., 
(2014) 
Retrospective 
Cohort 
267 women 
undergoing donor 
oocyte IVF in Spain 
Mean age 
40.5 years 
Vitamin D in 
serum 
 Donated 
 
Clinical 
pregnancy 
68/92 deficient 
group 
94/134 
insufficient 
group 
29/41 replete 
group 
 
Pregnancy test 
positive 
60/92 deficient 
group 
85/134 
insufficient 
group 
25/41 replete 
group 
 
Miscarriage 
8/92 deficient 
group 
9/134 insufficient 
group 
4/41 replete group 
 
Live birth 
56/92 deficient 
group 
71/134 insufficient 
group 
23/41 replete 
group 
No significant difference in 
implantation or clinical pregnancy 
rates between deficient, insufficient 
and replete vitamin D groups 
 
Firouzabadi et 
al., (2014) 
Prospective 
Cohort 
221 women 
undergoing IVF in Iran 
Mean age 
29.2 years 
 
 
Vitamin D in 
follicular fluid 
and serum 
Autologous 
 
Clinical 
pregnancy 
23/50 deficient 
group 
47/155 
insufficient 
group 
4/16 replete 
group 
 
Pregnancy test 
positive 
Data not 
provided 
 
Miscarriage 
Data not provided 
 
 
 
Live birth 
Data not provided 
 
No significant correlation between 
follicular fluid or serum vitamin D and 
clinical pregnancy rate.  Significant 
correlation between follicular fluid 
vitamin D levels and serum vitamin D 
levels (NOTE***USED <25NMOL = 
DEF, 25-75NMOL = INSUFF, >75NMOL 
= REPLETE) 
 
Franasiak et 
al., (2014) 
Retrospective 
cohort 
517 women 
undergoing IVF with 
euploid blastocyst 
Mean age 
35.0 years 
Vitamin D in 
serum 
Autologous 
 
Clinical 
pregnancy 
144/206 
Miscarriage 
32/206 deficient 
group 
Vitamin D status unrelated to 
pregnancy rates in women undergoing 
euploid blastocyst transfers 
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transfer in USA deficient group 
151/215 
insufficient 
group 
64/96 replete 
group 
 
Pregnancy test 
positive 
163/206 
deficient group 
162/215 
insufficient 
group 
74/96 replete 
group 
 
29/215 insufficient 
group 
14/96 replete 
group 
 
Live birth 
131/206 deficient 
group 
133/215 
insufficient group 
60/96 replete 
group 
 
Fru et al., 
(2014) 
Retrospective 
Cohort 
102 women 
undergoing IVF in USA 
Not reported 
 
Vitamin D in 
serum 
Autologous 
 
Clinical 
pregnancy 
6/18 deficient 
group 
24/47 
insufficient 
group 
37/58 replete 
group 
 
Pregnancy test 
positive 
Data not 
provided 
 
Miscarriage 
1/6 deficient group 
9/24 insufficient 
group 
12/37 replete 
group 
 
Live birth 
5/18 deficient 
group 
15/47 insufficient 
group 
25/58 replete 
group 
Higher vitamin D levels correlated 
with increased likelihood of positive 
pregnancy test.  Overall live birth 
rates highest in vitamin D replete 
group.  
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Garbedian et 
al., (2013) 
Prospective 
Cohort  
173 women 
undergoing IVF in 
Canada 
Mean age 
34.5 years  
Vitamin D in 
serum 
Autologous 
 
Clinical 
pregnancy 
33/95 deficient 
and insufficient 
groups 
combined 
41/78 replete 
group 
 
Pregnancy test 
positive 
Data not 
provided 
 
Miscarriage 
Data not provided 
 
 
 
 
Live birth 
Data not provided 
 
Implantation and clinical pregnancy 
rates are higher in the vitamin D 
sufficient group (>75nmol/L).  
Statistical significant difference in 
clinical pregnancy rate, no statistical 
difference in pregnancy positive rate.  
NOTE*** DEF AND INSUFF 
(<75NMOL) PUT TOGETHER VERSUS 
REPLETE (>75NMOL) 
 
Ozkan et al., 
(2010) 
 
Prospective 
Cohort 
84 women undergoing 
IVF in Turkey 
Mean age 
34.4 years 
Vitamin D in 
follicular fluid 
and serum 
Autologous 
 
Clinical 
pregnancy 
5/23 deficient 
group 
6/30 insufficient 
group 
15/31 replete 
group 
 
Pregnancy test 
positive 
3/23 deficient 
group 
4/30 insufficient 
group 
8/31 replete 
group 
 
Miscarriage 
Data not provided 
 
 
 
Live birth 
Data not provided 
 
Serum and follicular fluid strong 
correlated.  Higher implantation and 
clinical pregnancy rates in insufficient 
(20-30ng/ml) and replete levels 
(>30ng/ml) when compared to 
deficient group - highest in replete 
group 
 
Paffoni et al., 
(2014) 
Prospective 
cohort 
335 women 
undergoing IVF in Italy 
Mean age 
36.9 years 
Vitamin D in 
serum 
Autologous 
 
Clinical 
pregnancy 
30/154 deficient 
group 
33/117 
insufficient 
Miscarriage 
Data not provided 
 
 
 
Live birth 
Analysis suggested those with a vit D 
>75nmol/L had the highest chance of 
clinical pregnancy when compared 
with those with vitamin D deficiency 
or insufficiency.  
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group 
23/64 replete 
group 
 
Pregnancy test 
positive 
34/154 deficient 
group 
36/117 
insufficient 
group 
25/64 replete 
group 
 
29/154 deficient 
group 
28/117 insufficient 
group 
19/64 replete 
group 
Polyzos et al., 
(2014) 
Retrospective 
cohort 
368 women 
undergoing IVF 
resulting in single 
blastocyst embryo 
transfer in Belgium 
Mean age 
30.6 years 
 
 
Vitamin D in 
serum 
Autologous 
 
Clinical 
pregnancy 
98/239 deficient 
group 
70/129  
insufficient and 
replete group 
combined 
 
Pregnancy test 
positive 
124/239 
deficient group 
86/129 
insufficient and 
replete groups 
combined 
 
Miscarriage 
44/239 deficient 
group 
25/129 insufficient 
and replete groups 
combined 
 
Live birth 
78/239 deficient 
group 
61/129 insufficient 
and replete groups 
combined 
Clinical pregnancy rate significantly 
lower in vitamin D deficient group 
p=0.015.  Controlled for 16 
confounding factors.  NOTE*** 
INSUFF (50-75NMOL) AND REPLETE 
(>75NMOL) PUT TOGETHER VERSUS 
DEFICIENT (<50NMOL) 
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Rudick et al., 
(2011) 
Retrospective 
cohort 
64 women undergoing 
donor oocyte IVF in 
USA  
Not reported 
 
Vitamin D in 
serum 
Donated 
 
Clinical 
pregnancy 
7/18 deficient 
group 
10/26 
insufficient 
group 
14/20 replete 
group 
 
Pregnancy test 
positive 
Data not 
provided 
 
Miscarriage 
Data not provided 
 
 
 
Live birth 
Data not provided 
 
Lower CPRs in those with vitamin D 
deficiency suggesting that the effects 
are localised within the endometrium.  
NOTE*** CONFERENCE ABSTRACT SO 
LIMITED RESULTS 
 
Rudick et al., 
(2012) 
Retrospective 
cohort 
188 women 
undergoing IVF in USA  
Mean age 
36.0 years 
 
Vitamin D in 
serum 
Autologous 
 
Clinical 
pregnancy 
14/39 deficient 
group 
29/70 
insufficient 
group 
34/79 replete 
group 
 
Pregnancy test 
positive 
Data not 
provided 
 
Miscarriage 
3/39 deficient 
group 
7/70 insufficient 
group 
8/79 replete group 
 
Live birth 
11/39 deficient 
group 
22/70 insufficient 
group 
26/79 replete 
group 
Vit D deficiency associated with lower 
CPR in non-hispanic whites but not in 
Asians 
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Rudick et al., 
(2014) 
 99 women undergoing 
donor oocyte IVF in 
USA 
Mean age 
40.9 years 
 
Range 21-39  
Vitamin D in 
serum  
Donated 
 
Clinical 
pregnancy 
9/26 deficient 
group 
16/38 
insufficient 
group 
26/35 replete 
group 
 
Pregnancy test 
positive 
Data not 
provided 
 
Miscarriage 
1/26 deficient 
group 
3/38 insufficient 
group 
6/35 replete group 
 
Live birth 
8/26 deficient 
group 
13/38 insufficient 
group 
20/35 replete 
group 
Lower CPRs in those with vitamin D 
deficiency suggesting that the effects 
are localised within the endometrium 
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Table 2. Appraisal of methodological quality (Newcastle-Ottawa Scale) of included studies. Vitamin D and IVF treatment systematic review and 
meta-analysis 
 
Study Case 
representative 
Control 
representative 
Ascertainment 
of exposure 
Outcome 
negative at 
start 
Comparability by 
design or analysis 
Outcome 
assessment 
Duration 
of follow 
up 
Adequacy of 
follow up 
Score 
Aleyasin et al., (2011) * * * * ** * * * 9 
Anifandis et al., (2010) * * * * ** * * x 8 
Fabris et al., (2014) * * * * * * * * 8 
Firouzabadi et al.,  
(2014) 
 
* * * * x * * * 7 
Franasiak et al., (2014) * * * * * * * * 8 
Fru et al., (2014) * * * * x * * * 7 
Garbedian et al., (2013) * * * * * * * * 8 
Ozkan et al., (2010) * * * * ** * * * 9 
Paffoni et al., (2014) * * * * * * * * 8 
Polyzos et al., (2014) * * * * ** * * * 9 
Rudick et al., (2011) * * * * x * * * 7 
Rudick et al., (2012)  * * * * x * * * 7 
Rudick et al., (2014) * * * * ** * * * 9 
*Indicates that a feature is present. X that a feature is absent.  For comparability by design or analysis this 
checklist awards the maximum of two stars (**), one (*) or none if the feature is completely absent (x). 
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Clinical pregnancy  
All 13 studies (n=2601) reported on clinical pregnancy rate (the presence of fetal heart 
activity at seven weeks gestation) as an outcome (figure 4).  As the study by Aleyasin et al., 
did not include any women with a serum vitamin D level >50nmol/L, their data could not be 
used in this meta-analysis.  However, pooling of the clinical pregnancy outcomes from the 
remaining 12 studies showed an improved chance of clinical pregnancy in the vitamin D 
replete population when compared to the vitamin D deficient and insufficient population.  
The relative risk of achieving a clinical pregnancy in the vitamin D deficient and insufficient 
population was 0.78 (95% CI 0.66 to 0.91) when compared to the vitamin D replete 
population.  There was a moderate level of statistical heterogeneity in these studies 
indicated by an I2  value of 67.1%, p=<0.001.   
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Clinical pregnancy rates according to source of oocyte used 
The 13 included studies were divided into two groups according to the source of the oocyte 
used to form the embryo for transfer (figure 5).  The population of women in the first group 
of studies used autologous oocyte embryos.  The second group of studies consisted of 
women who received a donor oocyte embryo.  Meta-analysis of the studies in two groups 
was performed to try and elucidate whether there was a different association between 
vitamin D and clinical pregnancy rate achieved in women using their own oocytes compared 
to women using donor oocytes.  In theory women using donor oocytes would use higher 
quality oocytes from young healthy donors.  This would therefore eliminate poor fertility 
treatment outcomes due to poor oocyte quality; placing more emphasis on the effect that 
vitamin D has on implantation.  Ten studies reported fertility outcomes in infertile women 
receiving an autologous oocyte embryo.  As mentioned above, because the study by Aleyasin 
et al., did not include any women with insufficient or replete levels of vitamin D, their data 
could not be used in the meta-analysis.  In the remaining nine studies (n=2171) where 
infertile women received an autologous oocyte embryo, the chances of achieving a clinical 
pregnancy was higher in the vitamin D replete population when compared to the vitamin D 
deficient and insufficient population.  The relative risk of clinical pregnancy was 0.82 (95% CI 
0.68 to 0.99 in the vitamin D deficient women compared to vitamin D replete women. Again, 
there was moderate heterogeneity in these studies with an I2  value of 62.9%, p=0.006.  
In the three studies (n=430) where women received a donor oocyte embryo, no significant 
difference was found when comparing the clinical pregnancy in women receiving a donor 
oocyte embryo who were vitamin D deficient or insufficient when compared to women  
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Figure 6 Clinical pregnancy outcomes from studies that have only used serum for vitamin D assessment. 
Vitamin D and assisted reproductive techniques systematic review and meta-analysis 
40 
 
receiving a donor oocyte embryo who were also replete in vitamin D.  The relative risk was 
0.68 (95% CI 0.42 to 1.11).  The I2 value was 83.7%, p=0.002, indicating a high level of 
heterogeneity in these three studies.  
Clinical pregnancy rates according to biofluid used to assess vitamin D status 
Nine studies used (n=2358) used blood serum as the biofluid that was examined to ascertain 
vitamin D status.  These studies showed that women who are vitamin D replete are more 
likely to achieve a clinical pregnancy when compared with women that are vitamin D 
deficient or vitamin D insufficient.  The relative risk of achieving a clinical pregnancy was 0.78 
(95% CI 0.66 to 0.92) in the vitamin D deficient and insufficient women when compared to 
the vitamin D replete population.  The nine studies showed a moderate level of statistical 
heterogeneity with an I2 value of 69.5%, p=0.001. 
 
Live birth  
Eight studies (n=1958) reported the live births achieved by women when categorized by 
vitamin D (figure 6).  These studies showed that women who are vitamin D replete have a 
higher chance of achieving a live birth from ART when compared with women with vitamin D 
deficiency or insufficiency.  The relative risk of achieving a live birth was 0.85 (95% CI 0.74 to 
0.99) in the vitamin D deficient and insufficient population when compared to the vitamin D 
replete population.  These studies showed a low level of heterogeneity indicated by an I2 
value of 32.2%, p=0.183.   
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Implantation 
Five studies (n=1700) reported number of women that achieved a positive pregnancy test 
approximately two weeks after embryo transfer for the three vitamin D categories.  The 
relative risks of embryo implantation in the vitamin D deficient and insufficient population 
versus the vitamin D replete population are presented in figure 7.  When the data from the 
five studies are pooled, the relative risk of achieving an implanted embryo in the vitamin D 
deficient and insufficient population is 0.90 (95% CI 0.77 to 1.05) versus the vitamin D 
replete population.  There was a moderate heterogeneity between these studies, the I2 
value was 52.5%, p=0.077.   
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Figure 7 Live birth outcomes forest plot. Vitamin D and assisted reproductive techniques systematic review and 
meta-analysis 
43 
 
 
Figure 8 Embryo implantation rate forest plot. Vitamin D and assisted reproductive techniques systematic review 
and meta-analysis 
44 
 
Miscarriage 
Six studies (n=1635 women) reported on the outcome of miscarriage (figure 8).  When the 
data from these six studies are pooled, the chance of miscarriage in the vitamin D replete 
women is similar to that of vitamin D deficient and insufficient women.  The relative risk of 
miscarriage in vitamin D deficient and insufficient population is 0.92 (95% CI 0.71 to 1.19) 
compared to miscarriage in vitamin D replete women.  These six studies showed a low level 
of heterogeneity with an I2 value of 0.00% p=0.754.  
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Figure 9 Miscarriage rate forest plot. Vitamin D and assisted reproductive techniques systematic review and 
meta-analysis 
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Discussion 
This systematic literature search identified 13 relevant studies.  Meta-analysis of the data 
from these studies suggests that the chances of achieving a clinical pregnancy in vitamin D 
are higher in vitamin replete women compared to women with vitamin D deficiency or 
insufficiency.  Furthermore, the chance of live birth is higher in the vitamin D replete women 
when compared to vitamin D deficient and insufficient women.  The effect of vitamin on 
embryo implantation is not proven with a relative risk which does not reach statistical 
significance. Lastly, the meta-analysis shows that vitamin D does not have an effect on 
miscarriage. 
 
This review has shown that many research groups share the same hypothesis; that vitamin D 
status is important in patients undergoing IVF treatment.  All of the cohorts identified have 
been published since 2010, and the results have been encouraging, suggesting that the 
association between vitamin D and IVF treatment outcome exists.  With the recent rapid 
increase in publications linking vitamin D to various disease states70, the association 
between vitamin D and IVF treatment success is reinforced by sound biological plausibility. 
In its immunomodulatory role as a suppressor of adverse inflammatory adaptive immunity, it 
is reasonable to consider that vitamin D has an important function specific to 
implantation47,71.   Three of the studies identified by this review have specifically tested this 
hypothesis by presenting data from oocyte recipient IVF treatment cycles. 
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This systematic review and meta-analysis has been strengthened by a number of factors.  A 
comprehensive search strategy was used, employing relevant research databases.  
Additionally, a valid data synthesis method was implemented.  No language barriers were 
applied to ensure further comprehensiveness of the literature search and therefore there 
can be maximum confidence that all relevant studies have been captured.  Furthermore, 
assessment of the quality of the included cohort studies using the Newcastle-Ottawa Quality 
Assessment Scale showed high scores, suggestive of a low risk of bias in our analysis. 
 
There are also weaknesses to the present study, which mainly stem from the clinical 
heterogeneity of the publications that were used in the meta-analysis.  As the enquiry into 
the association between vitamin D and IVF treatment success is an area of research that is 
relatively new, some degree of heterogeneity is to be expected as no standard methodology 
has been set.  The clinical and statistical heterogeneity between the included studies does 
increase the risk that the findings could be due to chance.  Ideally one would want all studies 
to be homogeneous from a clinical and statistical perspective to increase the strength of the 
overall findings of this systematic review and meta-analysis.   However, this is not necessarily 
a disadvantage as some degree of clinical heterogeneity can increase the generalizability and 
applicability of the findings to wider infertility populations.  
 
The cohort studies included in the analysis varied in the timing of vitamin D assessment.  It is 
well documented that vitamin D status does not fluctuate a high degree over time unless 
vitamin D deficiency or insufficiency is actually treated24.  Therefore, the importance of the 
timing of the assay reduces.  Additionally, the studies varied according to the methods used 
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to ascertain vitamin D status.  Some studies measured vitamin D in the follicular fluid 
aspirated at the time of oocyte retrieval whereas others used blood serum for vitamin D 
measurement. However, a number of previously published studies have found that assays of 
vitamin D in follicular fluid or blood serum produce results that are highly correlative54,55,57 
61.  This means that, although four of our included studies used follicular fluid vitamin D 
assay, our results remain reliable.  Furthermore, when we analysed the data from studies 
where serum vitamin D was used as the biofluid, and excluded studies where follicular fluid 
was used, our meta-analysed results show that women who were vitamin D replete are 
more likely to achieve a clinical pregnancy.  From a practical and clinical perspective, this is 
an important finding, as measuring serum vitamin D would be more convenient for the 
patient and clinician.  This is because correction of vitamin D deficiency is feasible when 
vitamin D status is checked in peripheral blood.  In contrast, vitamin D deficiency treatment 
when the follicular fluid is collected at transvaginal oocyte retrieval will be too late to illicit 
any clinical benefit in reproductive outcomes. 
 
The definition of vitamin D deficiency, insufficiency and normal status is still debated.  All of 
our studies used the Endocrine Society’s definitions41, however, in reporting their results, 
some authors chose to group women according to vitamin D status in two groups instead of 
three.  This occurred in two studies. In the study by Garbedian et al.,60 the vitamin D 
deficient and insufficient groups were combined and compared to the IVF treatment results 
in the vitamin D replete group.  The study by Polyzos et al.,63 compared the IVF treatment 
results of the vitamin D deficient group versus that of the insufficient and replete groups.  
Although the authors were contacted to retrieve data for the three vitamin D categories, no 
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response was received.  It would be advisable that further studies aiming to identify the 
association between vitamin D and IVF treatment outcome report results using the 
Endocrine Society’s definition of the three vitamin D categories.   
 
Although the total number of women from the meta-analysis totaled 2601 patients 
undergoing ART, the sample sizes in each cohort varied leading to further clinical 
heterogeneity.  In addition, there was also variability in the sample population with regards 
to age, body mass index and also the type of IVF treatment performed.  However, this 
should aid the generalisability of the findings from our final meta-analysis.   
 
Four studies58,63,64,66 conducted logistical regression to adjust for potential confounding 
factors that could affect vitamin D status and pregnancy rate after IVF.  The cohort studies 
performed by Rudick et al.,64,66 adjusted for race and body mass index (BMI).  Results 
indicated that when race and BMI were adjusted, the association between vitamin D and IVF 
outcome persisted.  Franasiak et al.,58 adjusted for a range of potential confounders 
including; BMI, number of previous IVF cycles, timing of embryo transfer, ethnicity, age and 
number of embryos transferred.  They found that there was no difference in ongoing 
pregnancy rates among strata of vitamin D level.  In contrast, Polyzos et al.,63 performed a 
logistic regression analysis to identify whether vitamin D deficiency was independently 
associated with clinical pregnancy rates controlling for 16 potential confounders in their 
cohort of 368 women.  The results showed that vitamin D deficiency was independently 
associated with lower clinical pregnancy rates with an odds ratio of 0.61 (95% CI 0.39-0.95).   
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Of particular interest, three included studies investigated the association between vitamin D 
status and IVF treatment outcome amongst women undergoing oocyte recipient treatment 
cycles56,64,66.  Although meta-analysis of the data from these three studies did not show a 
statistically significant difference in chance of clinical pregnancy between the vitamin D 
replete and vitamin D deficient and insufficient populations, the data does show a trend 
towards a higher chance of clinical pregnancy in the vitamin D group.  It is likely that the 
failure to reach statistical significance is due to the low number of studies and therefore 
participants (n=430).  Further studies into the reproductive outcomes of oocyte recipient IVF 
patients would be helpful to clarify whether there is a clear association between vitamin D 
and pregnancy outcome in this sub-population.  If this were the case then it would support 
the hypothesis that vitamin D status exerts its effects mainly on the endometrium, 
increasing the chance of implantation rather than any other prognostic factors, such as 
oocyte retrieval number or oocyte quality.    
 
To a certain degree, the embryo implantation rates seen in the forest plot presented in 
figure 7 supports the hypothesis that vitamin D is key in initial embryo and endometrial 
interaction.  Although the pooled risk ratio for embryo implantation does not reach 
statistical significance, the data suggests that implantation is more likely in a woman that is 
vitamin D replete when compared to a woman that has vitamin D deficiency or insufficiency.  
However, firm assumptions cannot be made from the pooled implantation risk ratio as the 
95% confidence interval does cross the line of unity. This lack of statistical significance is 
likely to be due to there being an insufficient number of women in the six studies where 
implantation is reported.      
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Apart from the 13 cohort studies identified by this systematic review, three interventional 
studies were also found after the literature search was performed.  The first trial, by Choi et 
al.,67 was a conference abstract describing a trial aimed at elucidating whether treatment of 
vitamin D deficiency aids clinical outcome in IVF treatment.  In this trial of 100 patients 
undergoing treatment, women were divided into two groups; one group received no vitamin 
D supplementation and the other received vitamin D treatment without assessment of 
vitamin D status.  Unsurprisingly, the study found no statistical differences in implantation, 
clinical pregnancy or miscarriage rates between the treatment and control groups.  Similarly, 
a trial by Polak di Fried et al.,68 of 52 women undergoing IVF, administered vitamin D 
treatment in half of their population and placebo in the other half without measuring 
vitamin D status.  Again no significant differences were found in endometrial thickness, 
number of oocytes retrieved, implantation and clinical pregnancy rates between the 
treatment and placebo group.  Lastly, Aflatoonian et al.,69 performed a randomized trial in 
106 women undergoing frozen embryo transfer.  All women included in the trial had a serum 
vitamin D of less than 75nmol/L.  Half the population received 50,000 units of vitamin D on a 
weekly basis, with the other half receiving placebo.  This study found no improvement in 
pregnancy rate in the treatment group.  However, the authors conceded that this study was 
underpowered and that larger trials should be conducted to further investigate whether 
treatment of vitamin D deficiency and insufficiency could improve IVF treatment outcomes.  
As all three of these trials were yet to be published at the time of the systematic review, the 
data from these studies have not been included in the meta-analysis presented in this thesis 
chapter. 
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The findings of this review suggest that a large robustly performed randomised clinical trial 
should be performed to investigate the merits of vitamin D insufficiency treatment in the IVF 
population.  Assessment of vitamin D is cheap and widely available72.  If the results of a trial 
confirmed that correction of vitamin D insufficiency led to more favorable ART outcomes, 
vitamin D assessment could become a standard baseline investigation of all women suffering 
with infertility.  Furthermore, treatment regimens such as that from the Institute of 
Medicine or Endocrine Society could be implemented (which are safe and carry low cost) 
before IVF treatment is commenced.  However, the design of such a trial is complex.  As the 
risks of vitamin D deficiency are well documented and wide ranging (e.g. osteoporosis, 
diabetes and certain cancers)73, it would be difficult to justify not treating women identified 
as being deficient.  One trial methodology that could be used to bypass this ethical dilemma 
would be to perform a cluster stepped wedge randomised controlled trial74.  This would 
involve commencing vitamin D ‘test and treat’ policies in similar IVF units at a randomly 
assigned time.  In this way unit wide clinical pregnancy rates could be collected, with a 
comparison of success rates before and after the implementation of the vitamin D ‘test and 
treat’ policy (i.e. with each unit acting as its own control).   
 
Summary 
Vitamin D deficiency is common and the health implications are gaining increasing clarity.  
Knowledge regarding the importance of vitamin D in reproductive processes such as ovarian 
steroidogenesis, polycystic ovarian syndrome, endometriosis and implantation is growing at 
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a rapid pace75.  For infertile women, desperate to start a family, any effort to improve their 
treatment prognosis is welcomed.  A simple, safe, and cost effective method in achieving this 
could be in the treatment of vitamin D deficiency prior to starting IVF treatment.  This review 
has shown an association between vitamin D status and IVF outcome.  Further investigation 
of the benefits of vitamin D deficiency treatment is justified and should be achieved by 
performing a robustly designed trial.  
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CHAPTER 3: VITAMIN D AND IVF TREATMENT OUTCOMES – A 
PROSPECTIVE COHORT STUDY 
 
This work has been submitted to the British Medical Journal for publication.  Reviewers’ 
comments are awaited.  
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Introduction 
There has been recent interest in the role of vitamin D in reproductive physiology due to 
findings that illustrate the high prevalence of vitamin D deficiency42.  Studies have shown 
that as much as 20 to 52% of women of reproductive age are deficient in vitamin D76–78.   
In human beings, the main source of vitamin D, a fat soluble steroid hormone, is from 
sunlight.  Only a small amount is obtained from our diet. The majority of the body’s vitamin 
D is in the form of vitamin D3 (cholecalciferol).  This is photo-chemically synthesized in the 
skin. Cholecalciferol is bound to serum vitamin D binding protein (VDBP). The cholecalciferol 
is hydroxylated by the liver to 25-hydroxyvitamin D (25[OH]D), also known as calcidiol. The 
second hydroxylation occurs primarily in the kidney and forms the biologically active 1,25-
dihydroxyvitamin D (1,25[OH]2D), also known as calcitriol (1α,25(OH)2D3)
79.   
 
Although 1α,25(OH)2D3 is the biologically active form of the hormone, vitamin D levels are 
usually measured according to the serum 25 (OH) D3 concentration. Serum concentration of 
25(OH)D3 is the best indicator of vitamin D status as it best reflects vitamin D produced in 
the skin and the smaller amount obtained from food and supplements41.  25(OH)D3 also has 
a relatively long circulating half-life of 15 days.  
 
There is still great debate over the definition of vitamin D deficiency and the levels required 
for adequacy for bone health, and optimal overall health. However, most nutritional bodies 
of expertise have concluded that people are at risk of the detrimental effects of vitamin D 
deficiency at serum 25(OH)D3 concentrations of less than 50 nmol/L (less than 20ng/mL). A 
level of 50 to 75 nmol/L (21 to 29 ng/mL) is considered insufficient and greater than 
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75nmol/L (greater than 30 ng/ml) is considered vitamin D replete78,80–82. Serum 
concentrations greater than 150 ng/mL (greater than 374 nmol/L) are associated with 
toxicity and adverse effects.  
 
The established role of Vitamin D is to promote calcium absorption in the gut and maintain 
adequate serum calcium and phosphate concentrations and promote bone 
mineralisation41 . Without sufficient vitamin D, bones can become thin, brittle, or misshapen. 
Vitamin D at sufficient levels prevents rickets in children and osteomalacia in adults. 
Together with calcium, vitamin D also helps protect older adults from osteoporosis. 
However, the discovery that most tissues and cells in the body possess a vitamin D 
receptor42 suggests this hormone has more widespread function.  
 
In reproductive physiology, vitamin D deficient animals have decreased fertility capacity, 
impaired neonatal growth, hypogonadism, uterine hypoplasia, impaired folliculogenesis and 
pregnancy complications, implying that vitamin D may have a crucial role in conception and 
in pregnancy46,83–85. Vitamin D may also have an effect on endometrial decidualisation and 
placental function80–82. This function is the most studied aspect of vitamin D in reproduction, 
with vitamin D deficiency linked to poor placentation (due to abnormal inflammatory 
responses and endothelial dysfunction) causing hypertensive disorders of pregnancy and 
fetal growth restriction.  More recently, it has been proposed that vitamin D may be a 
regulator of target genes associated with implantation and trophoblast invasion86–88. 
Studies have been conducted to investigate the importance of vitamin D and subfertility.  
Human studies in women with polycystic ovarian syndrome (PCOS) have shown patients 
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deficient in vitamin D have a higher incidence of metabolic risk factors such as insulin 
resistance and obesity34,89,90. Clinical trials with vitamin D supplementation in patients with 
PCOS have used small sample sizes but have shown positive effects on the metabolic profile 
and menstrual cycles of these patients91–95. 
 
The biological plausibility for vitamin D playing an important role in implantation and 
trophoblastic invasion has led many research groups to investigate the importance of 
vitamin D in patients undergoing IVF treatment.  The findings of these studies have been 
meta-analysed in chapter two of this thesis.  Some of these studies have found that a replete 
level of vitamin D leads to an increase in clinical pregnancy and live birth rates60–62,64,65.  
However, others have found conflicting evidence suggesting that vitamin D has no bearing 
on the outcome of IVF treatment54–58.  None of these studies have been conducted in the 
UK.  Some have also been of small sample size and been retrospective in their design and 
therefore have not offered a strong enough evidence base to confirm the benefit of 
measuring vitamin D in the IVF population in clinical practice.  In this present chapter we 
prospectively examined the vitamin D levels of a diverse population of women undergoing 
ART at an assisted conception unit in Birmingham, UK. 
 
Specific human data on the role of vitamin D in reproduction is lacking. However, 
considering the expected high levels of vitamin D deficiency in Birmingham (due to the 
multiethnic population), it was felt that it would be important to evaluate the role of vitamin 
D in achieving pregnancy. The aim of the cohort study was to identify whether there is an 
58 
 
association between serum blood levels of 25-hydroxy vitamin D and fertility treatment 
outcomes. 
 
Methods 
Study Design 
Before beginning this cohort study, the aim was to recruit 490 patients undergoing IVF, ICSI 
or FET treatment.  A clinical pregnancy rate of 35% for patients was hypothesized for women 
with replete serum vitamin D and 25% for patients with insufficient or deficient serum 
vitamin D levels.  This gives an absolute risk difference of 10%.  A 10% attrition rate was 
anticipated.  Aiming for 90% power with a 5% type 2 error rate, the sample size required was 
calculated as 490.   
 
The study was approved by the National Research Ethics Service (NRES) Committee West 
Midlands – Black Country (REC 13/WM/0258) (see appendix 2). A total of 504 patients who 
underwent ART at the Birmingham Women’s Fertility Centre from September 2013 to 
December 2014 were recruited.   
 
All patients that were referred for IVF, ICSI and FET treatment met the inclusion criteria and 
were approached to participate.  Those that consented to participation in this study were 
included.  Prospective participants were approached at their IVF consent signing 
appointment.  A participant information sheet was provided and written consent obtained 
(see appendix 3 and 4).  Vitamin D assay for total 25-hydroxy vitamin D, 25-hydroxy vitamin 
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D2 and 25-hydroxy vitamin D3 were measured using blood serum samples taken at the time 
of consent.  Assays used a liquid-liquid extraction method using highly sensitive liquid 
chromatography mass spectrometry (Waters Premier XE MS detector with ACQUITY Ultra 
Performance LC).   Patients were allocated into three groups according to their total 25-
hydroxy vitamin D levels; vitamin D deficient group (25-hydroxy vitamin D less than 
50nmol/L), vitamin D insufficient group (25-hydroxy vitamin D 50-75nmol/L) and vitamin D 
replete group (25-hydroxy greater than 75nmol/L) according to the Endocrine Society 
definitions41.  
 
After embryo transfer the result of the vitamin D assay was communicated with the 
participant and the General Practitioner to initiate treatment and supplementation of 
vitamin D if required (see appendix 4).   
 
The primary outcome was clinical pregnancy (presence of a fetal heartbeat on ultrasound 
scan at seven weeks gestation).  Secondary reproductive treatment outcomes included 
implantation rates (positive pregnancy test rates prior to ultrasound), live birth rates and 
miscarriage rates.  Secondary fertility treatment outcomes included FSH dose requirements, 
endometrial thickness at last monitoring pelvic ultrasound, number of oocytes retrieved, and 
quality of embryo transferred.  
IVF, ICSI and FET treatments 
 
All participants undergoing fresh cycle IVF or ICSI received either a short antagonist protocol 
or a long down regulation protocol using Cetrotide (Merck Serono, France) or Buserelin 
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(Sanofi-Aventis, France) respectively.  After complete down regulation (checked by 
transvaginal ultrasonography to ensure endometrial thickness less than 4mm and inactive 
ovaries), participants underwent ovarian stimulation with recombinant follicular stimulating 
hormone (Gonal-F [Merck Serono, France] or Menopur [Ferring, France]).  Starting doses 
depended on the patient’s age. The starting doses were 150iU of menopur if women were 
less than 35 years, 225iU is women were 36-38 years, 300iU if women were 39-42 years and 
300 to 450iU in the woman was over the age of 42.  Additionally, if baseline FSH was greater 
than 10iU/ml in women less than 31 years, the start dose of menopur would be increased to 
225iU.  In women with a baseline FSH greater than 10iU/ml over 31 years, the start dose of 
menopur would be increased to 300iU. In women with anovulatory cycles with polycystic 
ovarian syndrome, an individualized stimulation protocol was planned.  Previous poor 
responders would also have a higher starting menopur dose.   
Doses of follicular stimulating hormone were then modified according to the patient’s 
ovarian response tracked by transvaginal ultrasonography.  The endometrial thickness was 
also measured using transvaginal ultrasonography at each ovarian response monitoring visit.  
When at least three follicles reached a diameter of at least 17 mm, 250 micrograms/0.5ml 
choriogonadotropin alfa Ovitrelle (Merck Serono, France) was used as a trigger for ovulation.  
In the event of ovarian hyperstimulation or inadequate ovarian stimulation, the treatment 
was abandoned if clinically required.  In women with a suitable ovarian response to follicular 
stimulating hormone, transvaginal oocyte retrieval was performed 36 hours after trigger 
injection.  Morphological grade of all embryos was assessed on days two, three and five post 
oocyte retrieval.  Embryos were graded according to the degree of fragmentation and the 
regularity of blastomeres.  Day five blastocyst grading was according to the development 
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stage, inner cell mass quality and trophectoderm quality.  Fresh embryo transfer was 
conducted in line with the Birmingham Women’s Fertility Centre single embryo transfer 
policy.   
 
All participants having frozen embryo transfer treatment underwent down-regulation using 
Buserelin (Sanofi-Aventis, France) followed by oestrogen (Progynova [Bayer, UK] and 
progesterone administration in the form of Gestone injections (Nordic Pharma, France) or 
Cyclogest pessaries (Actavis, UK) to prepare the endometrium prior to embryo transfer.   
 
Statistical analysis  
The baseline characteristics and outcomes for the vitamin D deficient, insufficient and 
replete groups were analyzed using Mann–Whitney U-tests for non-parametric data and 
Pearson x2 tests for categorical data. Analysis of outcomes between the groups was 
performed by logistic regression to compute odds ratios with their 95% confidence intervals 
(CIs) adjusting for potential confounding factors. Missing data were handled by complete 
case analysis for vitamin D levels and fertility outcomes and by multiple imputation for 
confounding variables. All analyses were performed using STATA Version 12.1 (Stata Corp, 
College station, TX, USA). 
 
Results 
Figure 9 shows the flow of participants through the study.  A total of 504 women were 
recruited to the study and had serum collected for vitamin D assay.  Four blood samples 
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could not be processed for serum vitamin D status as the clinical chemistry laboratory 
reported that the blood sample was inadequate or the sample was misplaced.  Thirty-six 
recruited participants never commenced their planned treatment.  The remaining 464 
participants commenced their treatment and had their reproductive treatment outcomes 
collected.  Of these 30 underwent a planned frozen embryo transfer, 424 underwent a 
transvaginal oocyte retrieval, two participants had their treatment converted to intrauterine 
insemination treatment (as only one follicle grew in the upregulation phase of IVF 
treatment), and eight participants had their treatment cycles cancelled as there was no 
ovarian response to FSH.  Of the 424 women that had oocyte retrieval, 23 had 
cryopreservation of embryos as there was a risk of ovarian hyperstimulation syndrome. 
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Figure 10. Vitamin D and IVF cohort study participant flow chart 
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Vitamin D status 
The vitamin D status of the 500 recruited participants is shown in figure 10.  Vitamin D 
deficiency (total vitamin D 0-49.9nmol/L) affected 266 out of 499 (53.3%) 
participants.  Vitamin D insufficiency (total vitamin D 50-75nmol/L) affected 154 of 499 
participants (30.9%).  Eighty out of the 499 participants (16.0%) were replete in vitamin D 
(>75nmol/L). 
 
Figure 11. Vitamin D and IVF cohort study. Vitamin D results distribution 
 
Baseline characteristics 
The baseline characteristics of the participants, the season at which the IVF treatment was 
performed, and the smoking status of participants are shown in table 3.  The three vitamin D 
groups were similar in mean age (p=0.196).  The mean age of the deficient group was 33.2 
years (SD 4.9 years).  The mean age of the insufficient group was 33.7 years (SD 4.4 years) 
and the mean age of the replete group was 34.2 years (SD 4.6 years).   
Serum vitamin D (nmol/L) 
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The mean BMI for the three vitamin D groups were also comparable (p=0.182).  The mean 
BMI for the deficient, insufficient and replete groups were 24.7 (SD4.0), 25.1 (SD 3.6) and 
24.1 (SD 3.1) respectively.  
 
The serum vitamin D levels varied according to race.  More South Asian and Black women 
were vitamin D deficient, 71.8% and 66.7% respectively).  Vitamin D status was more evenly 
distributed amongst White participants (36.0% deficient, 39.2% insufficient and 24.8% 
replete).   
 
 
 
 
 
 
 
 
 
 
  
Vitamin D Category  
 
 
 
p-value 
 Deficient 
(<50nmol/L) 
N=266 
Insufficient 
(50-75nmol/L) 
N=154 
Replete 
(>75nmol/L) 
N=80 
Age -
years(SD) 
33.2 (4.9) 33.7 (4.4) 34.2 (4.6) 0.196 
BMI (SD) 24.7 (4.0) 25.1 (3.6) 24.1 (3.1) 0.182 
Race (%)     
White* 93 (36.0) 101 (39.2) 64 (24.8) <0.001 
South Asian 125 (71.8) 37 (21.3) 12 (6.9) 
Black 20 (66.7) 8 (26.7) 2 (6.6) 
  Chinese 5 (62.5) 2 (25.0) 1 (12.5) 
Other  23 (76.7) 6 (20.0) 1 (3.3) 
Season (%)     
Winter 76 (59.4) 41 (32.0) 11 (8.6) <0.001 
Spring 77 (61.6) 39 (31.2) 9 (7.2) 
Summer 31 (31.0) 40 (40.0) 29 (29.0) 
Autumn  82 (55.8) 34 (23.1) 31 (21.1) 
Smoking (%)     
Non-
smokers 
250 (52.7) 148 (31.2) 76 (16.1) 0.639 
Smokers 16 (61.5) 6 (23.1) 4 (15.4) 
Table 3. Vitamin D and IVF cohort study. Baseline characteristics of participants 
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Vitamin D status was unevenly distributed when comparing differing ethnicities and this 
reached statistical significance (p<0.001).   
Seasonal vitamin D changes 
A statistically significant difference was found when comparing vitamin D status with the 
season that the IVF treatment was performed.  Vitamin D was more likely to be deficient in 
the participants in the Winter (59.4%) and Spring (61.6%) when compared to the Summer 
(31.0%) (p<0.001). 
Smoking status 
Only 26 of the participants smoked.  The proportion of smokers in the vitamin D deficient, 
insufficient and replete groups were comparable (p=0.639). 
Fertility History 
The fertility history variables are displayed in table 4.  Amongst the participants, the duration 
of infertility was found to be longer in the vitamin D deficient group when compared to the 
vitamin D insufficient and replete groups.  The median durations of infertility for the 
deficient, insufficient and replete groups were 48 months (IQR 36-72 months), 36 months 
(IQR 24-60 months), and 36 months (IQR 24-60 months).  The differences in the durations of 
infertility were statistically significant (p=0.044).  The type of infertility (primary or 
secondary) was comparable between the three groups (p=0.627).  In the deficient group, 
55.3% of participants had primary infertility, the insufficient group had 57.5% of participants 
with primary infertility and 50.7% of the replete group had primary infertility. 
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Table 4. IVF treatment cycle variables by vitamin D categories 
Vitamin D Category  
 
 
 
p-
value 
 Deficient 
(<50nmol/L) 
N=266 
Insufficient 
(50-75nmol/L) 
N=154 
Replete 
(>75nmol/L) 
N=80 
Duration of infertility in 
months (Median-IQR) 
48 (36-72) 36 (24-60) 36 (24-60) 0.044 
Type of infertility (%)     
Primary 136 (55.3) 81 (57.5) 39 (50.7) 0.627 
Secondary 110 (44.7) 60 (42.5) 38 (49.3) 
Cause of infertility (%)     
Unexplained 47 (19.0) 37 (26.2) 15 (19.5) 0.771 
An ovulatory 24 (9.7) 13 (9.2) 9 (11.7) 
   Tubal disease 39 (15.7) 16 (11.4) 15 (19.5) 
Uterine or peritoneal  15 (6.1) 6 (4.3) 5 (6.5) 
Male factor 91 (36.7) 51 (36.2) 21 (27.3) 
Mixed aetiology 24 (9.8) 15 (10.6) 9 (11.7) 
Other cause 6 (2.4) 3 (2.1) 3 (3.9) 
Mean FSH (iU/ml) (SD) 7.9 (2.9) 7.6 (2.9) 7.9 (4.0) 0.725 
Mean AMH (SD) 18.7 (21.7) 22.6 (27.4) 14.3 (14.1) 0.341 
Parity – Nulliparous (%)     
No 48 (19.5) 30 (21.3) 15 (19.5) 0.908 
Yes 198 (80.5) 11 (78.7) 62 (80.5) 
Treatment type (%)     
IVF 99 (40.2) 54 (38.3) 40 (52.0) 0.367 
ICSI 130 (52.9) 78 (55.3) 33 (42.9) 
FET 17 (6.9) 9 (6.4) 4 (5.1) 
Treatment protocol (%)     
Long 175 (76.4) 83 (62.9) 47 (64.4) 0.036 
Flare 12 (5.3) 13 (9.9) 9 (12.3) 
Short 42 (18.3) 36 (27.3) 17 (23.3) 
Starting FSH dose (%)     
150 or less 97 (42.4) 55 (41.7) 28 (38.4) 0.402 
225-300 78 (34.1) 51 (38.6) 22 (30.1) 
300 or more 54 (23.6) 26 (19.7) 23 (31.5) 
Mean number of FSH 40.7 (18.7) 37.4 (19.6) 42.0 (19.0) 0.171 
68 
 
 
The causes of infertility were also similar between the three groups (p=0.771).  Male factor 
infertility was found to be the most common single cause of infertility in all three groups. 
Ovarian reserve using day two to five follicular stimulating hormone as a marker was similar 
in the three vitamin D categories (p=0.725).  The mean follicular stimulating hormone levels 
in the deficient, insufficient and replete groups were 7.9 (SD 2.92), 7.6 (SD2.88) and 7.9 
(SD3.97) respectively.   
 
The three groups were comparable with regards to the index treatment (IVF, ICSI or FET) 
(p=0.367).  However, there was a statistical difference between the treatment protocol (long 
down regulation, short antagonist and flare) used (p=0.036).  Women in the vitamin D 
ampoules (SD) 
Mean endometrial 
thickness (mm) (SD) 
10.9 (2.3) 10.6 (2.6) 10.4 (1.8) 0.242 
Mean number of oocytes 
retrieved (SD) 
10.3 (6.6) 10.4 (5.6) 9.7 (5.8) 0.744 
Abandoned cycles (%)     
No 209 (85.0) 123 (87.2) 71 (92.2) 0.256 
Yes 37 (15.0) 18 (12.8) 6 (7.8) 
Number of embryos 
transferred at day 5 post 
oocyte retrieval (%) 
    
No 111 (53.4) 57 (46.7) 31 (43.7) 0.275 
Yes 97 (46.6) 65 (53.3) 40 (56.3) 
Number of embryos 
transferred (%) 
    
Single  153 (73.6) 79 (64.8) 51 (71.8) 0.230 
Double  55 (26.4) 43 (35.2) 20 (28.2) 
Top grade embryo transfer      
No 39 (18.7) 29 (23.8) 15 (21.1) 0.551 
Yes 169 (81.2) 93 (76.2) 56 (78.9) 
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deficient group were more likely to receive the long down regulation protocol than the 
vitamin D insufficient and replete groups (p=0.036). 
 
Treatment Cycle Variables 
The IVF treatment cycle variables are also displayed in table 4.  The starting follicular 
stimulating hormone doses used for ovarian stimulation were similar between the three 
vitamin D groups (p=0.402).  Furthermore, the mean number of follicular stimulating 
hormone ampoules used for ovarian stimulation was 40.7 ampoules (SD18.7) in the deficient 
group, 37.4 ampoules (SD19.6) in the insufficient group and 42.0 ampoules (SD19.0) in the 
replete group.  Therefore the total FSH required for stimulation in all vitamin D groups were 
comparable (p=0.171). 
 
During the last monitoring scan in the participants’ index treatments, the endometrial 
thickness was similar in all three of the vitamin D groups (p=0.242).  The endometrial 
thicknesses in the vitamin D deficient, insufficient and replete groups were 10.9mm 
(SD2.33mm), 10.6mm (SD2.60mm) and 10.4mm (SD1.77mm) respectively.   
 
The numbers of abandoned cycles were similar for all three vitamin D categories (p=0.256).  
Thirty-seven of 246 participants (15.0%) with vitamin D deficiency had their treatment cycle 
cancelled due to under or over ovarian stimulation.  Eighteen out of 141 vitamin D 
insufficient participants (12.8%) had their treatment cycle cancelled.  Lastly, six out of 77 
vitamin D replete participants (7.8%) had to discontinue their cycle.   
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Oocyte retrieval yielded comparable number of oocytes in all three vitamin D groups 
(p=0.744).  The mean number of oocytes collected in the deficient, insufficient and replete 
vitamin D groups were 10.3 (SD6.60), 10.4 (SD5.56) and 9.7 (SD5.77) respectively. 
The quality of embryos cultured was largely similar in the three vitamin D groups (p=0.275).  
Comparable proportions of participants in the deficient, insufficient and replete groups 
underwent a day five blastocyst transfer, 46.6%, 53.3% and 56.3% respectively.  Similar 
proportions underwent a single embryo transfer, 73.6% in the deficient group, 64.8% in the 
insufficient group and 71.8% in the replete group (p=0.230).  Most participants received a 
top grade embryo and transfer.  Of the participants with deficient vitamin D, 81.2% received 
a top grade embryo, 76.2% of vitamin D insufficient women underwent a top grade embryo 
transfer, and 78.9% of vitamin D replete women had a top grade embryo transfer (p=0.551). 
 
IVF treatment outcomes  
The IVF treatment outcomes are shown in table 5 and figure 11.  In the vitamin D deficiency 
group the clinical pregnancy rate was 26.0% (95% CI 20.6-32.0).  In the vitamin D insufficient 
group the clinical pregnancy rate achieved was 31.9% (95% CI 24.3-40.3).  In women with a 
replete vitamin D result, the clinical pregnancy rate was 41.6% (95% CI 30.4-53.4).  This 
difference in clinical pregnancy between the three groups is statistically significant 
(p=0.031).  It should be noted that any subsequent reproductive outcomes resulting from 
frozen embryos that resulted from the index treatment each participant received were not 
recorded. 
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Table 5: Reproductive treatment outcomes by vitamin D category 
 
  
Reproductive 
treatment outcome 
Vitamin D category 
(nmol/L) 
Point estimate  % 
(95% CI) 
P-value 
 
Clinical pregnancy 
(Primary outcome) 
<50 26.0 (20.6-32.0)  
0.031 50-75 31.9 (24.3-40.3) 
>75 41.6 (30.4-53.4) 
 
Biochemical 
pregnancy 
<50 32.5 (26.7-38.8)  
0.041 50-75 39.0 (30.9-47.6) 
>75 48.1 (36.5-59.7) 
 
Live birth 
<50 23.2 (18.0-29.0)  
0.043 50-75 27.0 (19.8-35.1) 
>75 37.7 (26.9-49.4) 
 
Biochemical 
pregnancy loss 
<50 20.0 (11.9-30.4)  
0.697 50-75 18.2 (9.1-30.9) 
>75 13.5 (4.5-28.8) 
 
Clinical pregnancy 
loss 
<50 10.9 (4.5-21.2)  
0.666 50-75 15.6 (6.5-29.5) 
>75 9.4 (2.0-25.0) 
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Figure 12: Reproductive treatment outcomes by vitamin D category
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Implantation rates (the percentage of women in each vitamin D group achieving a positive 
pregnancy test) in deficient, insufficient and replete groups were 32.5% (95% CI 26.7-38.8), 
39.0% (95% CI 30.9-47.6) and 48.1% (95% CI 36.5-59.7) respectively (p=0.041).  The 
implantation rates show a statistically significant difference between the three groups.  Of 
the women achieving a positive pregnancy test, the biochemical pregnancy loss rates for 
vitamin D deficient, insufficient and replete vitamin groups were 20.0% (95% CI 11.9-30.4), 
18.2% (95% CI 9.1-30.9) and 13.5% (95% CI 4.5-28.8) respectively (p=0.697).   
Women achieving clinical pregnancy had comparable miscarriage rates in the vitamin D 
deficient, insufficient and replete groups; 10.9% (95% CI 4.5-21.2), 15.6% (6.5-29.5) and 9.4% 
(95% CI 2.0-25.0) respectively (p=0.666).  Finally, live birth rates in the vitamin D groups 
were significantly different.  The live birth rates in the deficient, insufficient and replete 
groups were 23.2% (95% CI 18.0-29.0), 27.0% (95% CI 19.8-35.1) and 37.7% (95% CI 26.9-
49.4) respectively (p=0.043). 
 
Reproductive outcomes if implantation achieved  
In participants who achieved a biochemical pregnancy, the chance of progressing to a clinical 
pregnancy and live birth were comparable between the three vitamin D groups (figure 12).  
The clinical pregnancy rate in women achieving biochemical pregnancies in the vitamin D 
deficient, insufficient and replete groups were 80.0% (95% CI 69.6-88.1), 81.8% (95% CI 69.1-
90.9) and 86.5% (95% CI 71.2-95.5) respectively (p=0.697).  The proportion of women 
progressing to a live birth who achieved a biochemical pregnancy in the vitamin D deficient, 
insufficient and replete groups were 71.3% (95% CI 60.0-80.8), 69.1% (95% CI 55.2-80.9) and 
78.4% (95% CI 61.8-90.2) respectively (p=0.606).   
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Figure 13: Reproductive outcomes of participants that achieve a positive pregnancy test by vitamin D category 
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IVF treatment outcomes adjusted by ethnicity 
The IVF treatment outcomes were adjusted according to ethnicity, as vitamin D deficiency 
was more prevalent in the non-White population.  The statistically significant trends seen in 
clinical pregnancy and live birth rates between the three vitamin D groups was lost after 
adjustment analysis was performed.  The adjusted clinical pregnancy rates in the vitamin D 
deficiency, insufficiency and replete groups were 26.0%, 31.2% and 41.5% respectively 
(p=0.227).  The adjusted live birth rates for the vitamin D deficiency, insufficiency and 
replete groups were 21.5%, 24.7% and 36.3% respectively (p=0.212).   
 
The White population   
We performed a post-hoc analysis of the IVF treatment outcomes in the White population 
alone.  This was performed to ascertain whether vitamin D is an independent variable that 
affects IVF treatment outcome in our largest ethnic group.  When comparing vitamin D 
deficient and insufficient White women with vitamin D replete White women, the clinical 
pregnancy rates and live birth rates showed clear trends, however, the trend did not reach 
statistical significance.  The clinical pregnancy rates in vitamin D deficient, insufficient and 
replete White women were 31.4%, 35.2% and 46.8% respectively (p=0.147).  The live birth 
rates in vitamin D deficient, insufficient and replete White women were 29.1%, 30.8% and 
43.6% respectively (p=0.144).   
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Discussion 
This prospective cohort study indicates that serum vitamin D status is associated with IVF 
treatment outcomes.  This finding confirms what other research groups have found60–65,96,97 , 
that women with vitamin D replete status are more likely to become pregnant through their 
IVF treatment than those who are vitamin D deficient or insufficient.  Moreover, these 
findings suggest an association between vitamin D status and IVF treatment outcomes in the 
White population, although in the Asian and Black population this association was lost.  The 
loss of a the association between vitamin D and IVF treatment outcome in the Asian and 
Black population is likely to be due to the low numbers of women of dark pigmented skin 
(Asian and Black women) that had a normal serum vitamin D.  
  
Study strengths 
There were several strengths to this present study.  Compared to other similar cohort 
studies, this is large in number and a sample size calculation was conducted prior to the 
commencement of the study.  This reduces the likelihood for our association to be due to 
chance. Additionally, we conducted this study with inclusivity in mind meaning that all 
patients that underwent IVF treatment were approached for recruitment.  This enables our 
findings to have greater generalisability and widens applicability.  Furthermore, the 
population that we recruited was ethnically diverse, increasing representativeness for the 
rest of the UK population and specifically all other UK IVF care providers.   
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Study weaknesses 
This study also had weaknesses.  As mentioned above, the biological plausibility that vitamin 
D affects IVF treatment outcome stems from its effects on the endometrium.  Ideally, in 
order to prove the hypothesis that vitamin D exerts its effects on treatment outcome via the 
endometrium; serum for vitamin D assay should have been obtained on the day of embryo 
transfer.  This ensures that vitamin D status is as close temporally to the time of embryo 
transfer as possible.  In our study, women were approached at the start of their IVF 
treatment.  Therefore there may have been changes and fluctuations to the serum vitamin D 
level during IVF treatment after the assay was performed.  However, this is unlikely as 
changes in vitamin D levels only occur when vitamin D deficiency or insufficiency is treated. 
All of the participants would have been taking preconception vitamins at the time the blood 
test was obtained and would have continued this supplementation throughout their IVF 
treatment. However, this is not at a dose high enough to correct vitamin D deficiency or 
insufficiency. 
 
Another weakness in the study is the fact that it is observational in nature.  This means that, 
although an association between vitamin D and IVF treatment outcome is demonstrated, no 
clear causal pathway can be elucidated.  
 
Seasonal variation in conception 
Seasonal variations in conception rates have already been established98 with higher 
conception rates found in the Summer and Autumn.  However, although many hypotheses 
have been postulated to explain this phenomenon (e.g. reduced ovulation rates and sperm 
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quality in darker months) the exact mechanism behind this has not been explained.  It is 
possible that an increase in sun exposure and greater sunlight luminosity increases the 
body’s store of vitamin D, thereby yielding higher conception rates in Summer and Autumn.   
 
The debate regarding the importance of vitamin D in human beings continue, however, its 
impact on immunomodulation with a resultant dampening of active inflammatory cytokines 
is now well understood42.  Additionally, the expression of vitamin D receptors at the level of 
the endometrium and the role of vitamin D in the transcription of HOX10A gene, which has 
been found to be of key importance in implantation, suggest that the immunomodulatory 
effects of vitamin D may have a direct impact on implantation and therefore the likelihood 
of reproductive treatment success.   
 
These theories would explain why in the population studied, vitamin D levels were strongly 
associated with the season at which IVF treatment was performed and why those with a 
normal serum vitamin D level were more likely to achieve a clinical pregnancy. 
 
Reproductive outcomes 
Interestingly, vitamin D status did not have an impact on IVF treatment itself, only on its 
outcome.  In our cohort of infertile women, patient demographic was comparable when the 
population was divided into the three vitamin D categories (deficient, insufficient and 
replete).  The cohort was also homogeneous with regards to the types of infertility (primary 
or secondary) suffered as well as the cause of infertility when participants were divided into 
the three vitamin D groups.  The only statistically significant difference between the three 
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vitamin D groups in our cohort was the duration of infertility.  This is one of many important 
prognostic markers for the success of IVF treatment.  The duration was significantly 
increased in the vitamin D deficient group, further supporting the theory that vitamin D 
deficiency could reduce endometrial receptivity.  Most importantly, when divided into 
vitamin D deficient, insufficient and replete categories, the women in our cohort faired 
similarly during the IVF treatment, with important prognostic factors such as requirement 
for follicular stimulating hormone, endometrial thickness and availability of top grade 
embryo for transfer being similar.   
 
In the present cohort study, vitamin D seemed to have the most profound effects on the 
treatment outcomes themselves.  Furthermore, the data shows that if participants are able 
to achieve implantation (by achieving a biochemical pregnancy) the chances of the 
implanted embryo progressing to become a clinical pregnancy and a live birth are 
comparable between the three groups.  This substantiates the belief that vitamin D’s 
function in fertility is mainly in initial implantation of the embryo.   
 
Other studies have investigated the link between vitamin D status and implantation further.  
Some research groups have attempted to isolate the effects of vitamin D on the 
endometrium and implantation by studying women undergoing donor oocyte IVF treatment 
cycles. In such cycles, one would expect all oocyte prognostic determinants to be nullified, as 
only good quality oocytes are used.  In effect endometrial receptivity and implantation alone 
are tested.  Examples of such studies include the study by Fabris et al.,56 (who did not find an 
association between vitamin D and implantation in women undergoing IVF treatment using 
80 
 
donor oocytes), and the study by Rudick et al.,64 who found a strong association between 
the vitamin D status of donor oocyte recipients and the IVF treatment success.  
 
When reproductive outcomes were adjusted for ethnicity, the associations between vitamin 
D and clinical pregnancy, live birth, and miscarriage rates were lost.  The results do 
demonstrate that women of Asian or Black origin were far less likely to be replete in vitamin 
D status when compared to White women.  In this study, there are low sample sizes in each 
ethnic group. This would have caused under-powering leading to the loss of association after 
adjustment for ethnicity.  However, in other published studies, ethnicity has been found to 
be a prognostic marker for IVF treatment success on its own99.  Perhaps the reason for this 
could be due to higher prevalence of vitamin D deficiency in these ethnic groups due to 
darker pigmented skin, absorbing a lower level of ultraviolet light in the UK.  Consequently, 
this would reduce the stores of vitamin D in Asian and Black women.  Vitamin D receptor 
gene polymorphisms have already been identified in the Asian population which may act as 
a confounding or modifying factor100,101.  
 
Interestingly, when the IVF treatment outcomes were analysed in isolation in the White 
population, women with replete vitamin D levels achieved an increased rate of clinical 
pregnancy and live birth when compared to those with vitamin D deficiency/insufficiency.  
Although strong conclusions cannot be drawn from observational data, this would suggest 
that in White women, vitamin D does play an important independent role in predicting IVF 
treatment success.  This could be via its actions within the endometrium promoting 
implantation or as a surrogate marker for another variable. 
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Summary 
 
In many countries like the UK, strict government funding restrictions apply to the provision 
of IVF treatment to infertile couples.  The identification of treatable factors that can improve 
the chances of each IVF treatment success is therefore crucial.  Vitamin D serum testing is 
relatively cheap and widely available.  Furthermore, treatment of deficiency or insufficiency 
with subsequent maintenance therapy is not costly.   Additionally, it is now well understood 
that vitamin D deficiency during pregnancy may also increase the risk of obstetric 
complications such as gestational diabetes102,103, pre-eclampsia104–106, and fetal growth 
restriction107,108.  Treatment of vitamin D deficiency pre-conceptually could be the goal in the 
future, extending to pregnancies achieved through natural conception as well and therefore 
having far reaching public health implications.  However, before population based vitamin D 
screening and treatment of deficiency can be implemented, a randomized controlled trial is 
required to ensure that treatment of vitamin D deficiency does improve reproductive 
treatment outcomes.  Moreover, more understanding is needed regarding the different 
vitamin D requirements in the Asian and Black populations, as vitamin D deficiency 
treatment in these sub-populations may be different to that of the White population. 
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CHAPTER 4: VITAMIN D AND RECURRENT MISCARRIAGE – 
SYSTEMATIC NARRATIVE REVIEW 
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Introduction 
Vitamin D is a fat soluble secosteroid that human beings mainly source from skin production 
as a result of sunlight exposure37,109.  The precursor 7-dehydrocholesterol is converted to 
provitamin D3 by UVb light42.  Spontaneous isomerisation produces cholecalciferol or 
vitamin D3.  This provides 80-90% of total body vitamin D45.  Diet in the form of plants, fungi 
and fatty fish provides the remaining 10-20%42.  Vitamin D3 is transported bound to VDBP to 
the liver where it is metabolised into 25-hydroxy vitamin D by 25-hydroxylase.  Further 
metabolism then converts 25-hydroxy vitamin D into 1-25-dihydroxyvitamin D3 in the 
kidneys47.  This is the biologically active form of vitamin D and exerts its biological actions by 
activation of target genes through the retinoid X receptor110. 
 
Vitamin D deficiency has been found to be highly prevalent in areas of low sunlight and has 
been found to be especially prevalent in women at reproductive age42.   This is postulated to 
be due to a reduction in sun exposure due to lifestyle changes and also because of rising 
prevalence of obesity (as vitamin D is sequestered in adipose tissue)111.  The importance of 
this epidemiological problem is far reaching.  It is well recognised that vitamin D is essential 
in calcium and phosphorous homeostasis as well as bone metabolism.  Severe vitamin D 
deficiency can lead to rickets in childhood and osteomalacia in adulthood112.  However, more 
recently the role of vitamin D in other non-skeletal pathological processes such as cancer, 
infections, autoimmune disorders and cardiovascular disease has been called into 
question113,114. It is thought that vitamin D has a role in immunomodulation, reducing T-
helper 1 cells and their production of inflammatory cytokines such as IL-2, TNF-α and IF-ϒ.   
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Additionally, vitamin D is also thought to increase the action of T-helper 2 cells leading to 
further suppression of inflammatory responses115.   
 
Vitamin D receptors and enzymes required for its metabolism have been found to be 
widespread in female reproductive organs.  The ovaries and uterus have been found to 
contain these enzymes and receptors23,116,117.  Due to the immunomodulatory role of vitamin 
D it has been suggested that vitamin D has a key role in implantation, placental formation 
and progression to a health pregnancy40,44,118.  Published research has investigated vitamin 
D’s role in ART58,69,96, PCOS119,120, endometriosis121,122, uterine fibroids123,124 as well pre-
eclampsia, gestational diabetes mellitus and intrauterine growth restriction125,126.  Interest in 
the areas of ART, pre-eclampsia and fetal growth restriction stem from the belief that 
vitamin D has a crucial role in ensuring the dampening of inflammation required to ensure 
that normal and effective fetal-maternal interface is formed at the time of implantation.  It is 
thought that deficiency in vitamin D may lead to poor endometrial decidualisation leading to 
poor trophoblastic invasion47 poor IVF treatment outcomes and pregnancy complications. 
 
Recurrent miscarriage is the loss of three or more consecutive pregnancies before 20 weeks 
gestation.  It affects 1% of women in their reproductive age and can have severe physical 
and emotional effects127.  In approximately 50% of patients with recurrent miscarriage the 
cause of the condition is known.  Recurrent miscarriage is associated with parental 
karyotypical abnormalities, uterine anomalies, thrombophilia, and dysfunction of the 
immune system as well as endocrine diseases such as thyroid dysfunction or diabetes 
mellitus.  However, in the 50% of patients where a cause is not found there may be a 
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combination of unidentifiable risk factors128,129.  One such risk factor may be deficiency in 
vitamin D.  Improper implantation may lead to increased risk of recurrent miscarriage.  
  
The purpose of this systematic review was to identify and examine all published literature 
that has investigated the association between vitamin D and recurrent miscarriage.   
 
Methods 
Literature Search 
Literature of interest consisted of journal publications reporting on the association between 
vitamin D and recurrent miscarriage.   
 
The following electronic databases were searched: MEDLINE, EMBASE, Cochrane Central 
Register of Controlled Trials and CINAHL.  Databases were searched from inception to 
November 2015.  A search strategy was developed based on the following key words and or 
MeSH terms: vitamin D, cholecalciferol, ergocalciferol, vitamin D deficiency, recurrent 
miscarriage and pregnancy.   The reference lists of all primary and review articles were 
examined to identify relevant articles that had not been identified by the electronic 
searches.  No language restrictions were applied to the searches or study selection.   
Study selection 
Prior to the literature searches criteria for inclusion into the review were established.  Study 
selection was performed by two independent reviewers. The titles and the abstracts were 
scrutinised by the independent reviewers and included and excluded independently 
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according to the preset criteria.  Any disagreements regarding inclusion were resolved by a 
third reviewer. The full manuscripts of the abstracts identified as relevant for inclusion were 
retrieved and examined.  In the scenario where duplication publications were found then the 
most recent and complete versions were selected.  Studies that did not explicitly report 
findings for recurrent miscarriages were excluded.  Similarly, studies that did not explicitly 
report findings for vitamin D were also excluded.   
 
Studies were divided into two groups.  The first group included studies that reported on 
findings from clinical research.  The second group reported findings from basic science 
research. 
Results 
The PRISMA flow diagram52,53 of the review process is presented in figure 13.  The search 
strategy generated 4615 citations.  Of these, 4529 of these citations were excluded because 
it was clear from the title and abstract that they did not fulfill the search criteria.  A total of 
86 full manuscripts were retrieved for further examination.  A further 67 of these 
publications were excluded because 42 were not specifically concerning recurrent 
miscarriage and 23 were not specifically concerning vitamin D.  Two publications were 
duplicate articles.  Therefore the total number of studies included in the review was 19. 
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Figure 14. PRISMA flow diagram for study selection.  Vitamin D and recurrent miscarriage 
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Study characteristics 
Of the 19 studies that are included in the review, eight are clinical studies and 11 are basic 
science studies. As the studies that were found to satisfy inclusion criteria were low, 
conference abstracts were also included. 
 
Clinical Studies 
Eight clinical studies fulfilled the criteria of the search.   
 
One small randomised controlled trial published by Ibrahim et al., in 2013 investigated the 
benefits of using vitamin D supplementation in women with a history of unexplained 
recurrent miscarriage130.  In this trial, 40 women with a history of recurrent miscarriage were 
recruited at less than six weeks gestation to either receive vitamin D3 supplementation at a 
dose of 0.25 micrograms twice daily or no treatment.  This group of patients did not have 
their serum vitamin D measured.  The primary outcome was the outcome of the index 
pregnancy.  The authors did not find a statistically significant difference between the 
treatment and control groups but did find the risk of miscarriage was 15% lower in the 
treatment group than the control group.  As a surrogate marker of immunomodulation, this 
study found that the serum level of IF-ϒ was significantly higher in the control group.  The 
group also concluded that their findings warranted further investigation by way of a larger 
trial.   
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Several observational cohort studies have investigated the effects of plasma vitamin D on 
early pregnancy outcomes in women with a history of recurrent miscarriage.  A study by 
Moller et al., in 2012 on women with recurrent miscarriage, did not find an association 
between pre conception plasma vitamin D levels and miscarriage in an index pregnancy, 
although they did find a statistically significant association between low plasma vitamin D 
and second trimester miscarriage131.   
 
In 2013, Charatcharoenwitthaya et al., published a cohort of 120 women who had been 
previously diagnosed with recurrent miscarriage.  All 120 women were followed up during a 
subsequent pregnancy.  Only 10 women had a miscarriage.  132.  Out of the ten women who 
had miscarriages, nine had low vitamin D (four had vitamin D deficiency and five had vitamin 
D insufficiency).  Only one out of the ten women who had a miscarriage was vitamin D 
replete.  Other studies have shown no association between vitamin D status and subsequent 
miscarriage in recurrent miscarriage patients.  Most recently, Schneuer et al., found that 
there was no relationship between vitamin D and miscarriage in an index pregnancy in 
2014133.  This was a large study of 5109 women where serum vitamin D was measured in the 
first trimester of pregnancy.  Although this study found that vitamin D deficiency was highly 
prevalent in the recurrent miscarriage (being present in 80.4% of their population), index 
pregnancy miscarriage was seen in equal proportions in women with varying ranges of 
serum vitamin D.  Flood Nichols et al., also found no relationship between vitamin D 
deficiency and adverse pregnancy outcomes including miscarriage in a small retrospective 
cohort study of 108 women diagnosed with recurrent miscarriage who had plasma collected 
and stored in the first trimester of pregnancy134.   
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Ota et al., performed a retrospective cross-sectional study of 133 women with a history of 
recurrent miscarriage in 2014135.  They investigated the prevalence of auto and cellular 
immune abnormalities in women with low vitamin D when compared with those that have a 
normal vitamin D level.  The authors found a significantly higher prevalence of 
antiphospholipid antibody, antinuclear antibody, anti-single-strand DNA antibody and 
thyroperoxidase antibody in women with vitamin D deficiency.   Interestingly, natural killer 
cytotoxicity was also found to be higher in the vitamin D deficient group when compared to 
the vitamin D replete group.  High natural killer cytotoxicity has been implicated in the 
aetiology of unexplained recurrent miscarriage136 and is offered as a test in some recurrent 
miscarriage clinics.    In summary, this study found that a high proportion of women with 
recurrent miscarriage have vitamin D deficiency and that vitamin D deficiency has 
immunological implications.    
 
Natural killer cytotoxicity was also found to be higher in vitamin D deficient women with 
recurrent miscarriage by Kim et al.,137.  This article reported that there was increased vitamin 
D receptor expression in peripheral blood natural killer cells in women with vitamin D 
deficiency when compared to those who were vitamin D replete. This infers that natural 
killer cell activity is dependent on vitamin D status of women with recurrent miscarriage.  
  
A case-control study by Kashani et al., suggested that vitamin D was higher in patients with 
recurrent miscarriage when compared to healthy controls without a history of recurrent 
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miscarriage138.  This author group found that there was a higher proportion of vitamin D 
replete women in the recurrent miscarriage group when compared to healthy cohorts.   
The last clinical article was a review of all immunomodulatory therapies that are used in the 
treatment of recurrent miscarriage.  Published in 2012, Bansal et al., discuss the value and 
basis of potential immune therapies in this patient group139.  Along with glucocorticoid 
therapy, immunoglobulin therapy, anti-TNF-α therapy and intralipid therapy, Vitamin D is 
one of the therapies discussed.  Its value in reducing adverse decidual inflammatory 
cytokines and increase the number of regulatory T-cells is recognised. 
 
Basic Science Studies 
Of the 19 included studies in the review, 11 were basic science studies.   
 
Most recently Gysler et al., investigated the trophoblastic cell line (HTR8) secretion of 
inflammatory cytokines (IL-8 and IL-1β) when they were treated with vitamin D140–142.  This 
study found that when trophoblastic cells are treated with vitamin D alone, or in 
combination with low molecular weight heparin, the antiphospholipid antibody induced 
trophoblast inflammatory response in the HTR8 cells was attenuated.  The study called for 
further research into the benefits that may be gained by using vitamin D to prevent faulty 
antiphospholipid antibody induced trophoblast invasion and recurrent miscarriage. 
 
Tavakoli et al., investigated the immunomodulatory effect of 1,25(OH)2 vitamin D3 on 
cytokine production by the endometrial cells of women with unexplained recurrent 
miscarriage143.  In this study endometrial samples were collected from 48 women with 
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recurrent miscarriage and also eight healthy controls by biopsy curette.  The main outcome 
measure was the production of IF-ϒ, IL-10, transforming growth factor beta (TGF-β), IL-17, IL-
6 and IL-8 by endometrial stromal cells when in the presence and in the absence of 
1,25(OH)2 vitamin D3.  Interestingly, this study found that the cytokine profile of 
endometrial cells of women with recurrent miscarriage had a tendency towards a T-helper 2 
phenotype after treatment with 1,25(OH)2 vitamin D3. The authors suggest that treatment 
with vitamin D could make the endometrial cavity more amenable to embryo implantation in 
women with a history of unexplained recurrent miscarriage.  The study concluded that more 
clinical studies should be done to investigate the beneficial effects of 1,25(OH)2 vitamin D3 
on women with recurrent miscarriage. 
 
Tavakoli’s research group went on to investigate the expression of vitamin D receptors and 1 
– a – hydroxylase and 25 – hydroxylase in the endometrium of women who had a history of 
recurrent miscarriage when compared to endometrium of healthy controls144.  The 
expression of vitamin D receptors and enzymes required for vitamin D metabolism was 
found to be comparable in both groups.  This study only investigated eight patients with 
recurrent miscarriage and eight healthy controls and therefore strong inferences could not 
be made.  In addition, there were also no differences between the serum vitamin D levels 
between the group of participants with recurrent miscarriage and the group of health fertile 
controls.  This would explain the comparable findings within the endometrium.   
 
Murine experiments performed by Halhali et al., suggested a clear role of vitamin D in 
implantation145.  The authors injected 1,25(OH)2 vitamin D3 into the horns of mice uteri and 
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found greater decidualisation in the horns that had received the injections compared to the 
controls.   
 
In 2004, Bubanovic postulated that the immunomodulatory effects of vitamin D were vital in 
the prevention of recurrent miscarriage115.  In a hypothesis article, the effect of vitamin D in 
establishing a T-helper 2 phenotype response, with a resultant increase in T-helper 2 
cytokine production of IL-3, IL-4 and IL-10 is described.  The increase of these cytokines is 
postulated to lead to a rise in the natural killer suppressor cells which reduce the activity of 
natural killer cells that cause an abortogenic immunological cascade when miscarriage 
occurs.  The effect of vitamin D on the suppression of T-helper 1 cells subset and the 
subsequent decrease in IL-2 and IF-ϒ with resultant reduction in natural killer activation of 
macrophages at the feto-maternal interface is also described.  The author concludes that the 
use of vitamin D should be seen as a novel treatment of recurrent miscarriage.    
 
Other author groups have reinforced the theory of cytokine augmentation by vitamin D.  
Evans et al., found that both 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 have a 
profound effect on cytokine production in human decidual cells49,50.  When decidual natural 
killer cells were treated with bioactive 1,25-dihydroxyvitamin D3 or precursor 25-
hydroxyvitamin D3 there was a reduction in cellular production of granulocyte-macrophage 
CSF2, TNF-α as wells as IL-6.  The authors suggest that this allows for regulation of the 
acquired and innate immune responses at the fetal-maternal interface. Similar to the 
findings of Tavakoli et al., several enzymes of vitamin D metabolism (including 1-alpha-
hydroxylase) were found within the maternal decidua of first trimester pregnancies.  
94 
 
Furthermore, the synthesis of 1,25-dihydroxyvitamin D3 was significantly higher in first 
trimester decidual cells when compared with third trimester decidual cells, suggesting an 
important role in early pregnancy and implantation. 
 
Extravillous trophoblastic cells are equally as affected.  Chan et al., and Canovas et al.,146,147 
demonstrated this in 2013.  Isolated extravillous trophoblast cells from first trimester human 
placentae were treated with increasing doses of 1,25-dihydroxyvitamin D3.  The degree of 
invasion was quantified and this study demonstrated that higher levels of 1,25-
dihydroxyvitamin D3 (at a concentration of 0.1 nanomole to 1 nanomole) led to a two-fold 
increase in invasion into maternal endometrial tissues.  This provided circumstantial 
evidence that 1,25-dihydroxyvitamin D3 promotes extravillous trophoblast invasion and that 
malplacentation may occur when serum 1,25-dihydroxyvitamin D3 levels are low.  Although 
this study suggested that this finding was relevant for the pathogenesis of pre-eclampsia in 
pregnancy, abnormal placentation caused by low vitamin D levels could also affect the 
continuation of pregnancy in the first trimester in women with recurrent miscarriage 
 
 
 
Discussion 
 
This systematic review identified 19 articles that investigated the association between 
vitamin D and recurrent miscarriage.  There were eight clinical studies and 11 basic science 
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articles.  A clear biological plausibility has been investigated by several author groups but 
there are only a small number of clinical studies that have been published to confirm 
whether an association exists.  According to the literature searches conducted in this review, 
this is the first systematic review investigating the association between vitamin D and 
recurrent miscarriage. 
 
The present systematic review was strengthened by several factors.  An extensive search 
strategy was used and a large number of citations were identified decreasing the possibility 
that relevant articles were missed and not included.   No language restrictions were applied 
and the research databases were searched from date of inception.  This means that our 
search is comprehensive.   
 
However, only low level inferences can be made from the findings of this systematic review.  
The number of studies that were included in our results was low therefore firm conclusions 
cannot be drawn.  In particular, there is a clear lack of clinical studies with only one small 
randomized controlled trial investigating the effectiveness of vitamin D treatment in women 
with a history of recurrent miscarriage130.  This trial only recruited 40 women and the 
research group did not measure the participants’ serum vitamin D and therefore it fails to 
answer the research question.  Aside from this small trial there were only several 
observational studies that aimed to identify whether vitamin D deficiency was more 
common in women who had been diagnosed with recurrent miscarriage131–134.   The findings 
from these studies were mixed, with some observational data suggesting a link between 
vitamin D deficiency and miscarriage and other studies finding no such association.  
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Additionally, the case control study conducted by Kashani et al., found that vitamin D levels 
were higher in women with recurrent miscarriage when compared to controls138. Therefore 
strong clinical conclusions cannot be made.  
The biological plausibility for an association between vitamin D and recurrent miscarriage 
has been investigated more extensively with a larger number of basic science publications.  
Basic science findings have centred on the immunomodulatory effects of vitamin D115,139–142 .  
In particular, authors have investigated the effects on cytokine production that vitamin D has 
when it is used to treat endometrial cells.  The studies that were identified by this review 
have reported similar findings, confirming that there is a reduction in the production of pro-
inflammatory cytokines (IL-1B, IL-6, IL-8, IL-10, IL-17, IF-ϒ, TGF-β and TNF-α).  These studies 
showed that higher vitamin D levels produce an immunological reaction within the 
endometrium more akin to a T-helper 2 phenotype.  Additionally, vitamin D appears to steer 
the immune response away from a T-helper 1 phenotype due to modification of natural 
killer cell activity.  The importance of natural killer cell activity in recurrent miscarriage has 
been further investigated previously148. 
 
In addition to the important immunomodulatory actions, the role of vitamin D in the 
implantation and maintenance of normal pregnancy has been identified by the presence of 
enzymes that are key in vitamin D metabolism within endometrial and decidual cells.  
Several authors have demonstrated that the presence of these enzymes is greatest in the 
first trimester146,147.  Trophoblastic invasion has also been found to be greatly affected by the 
dose of vitamin D that trophoblastic cells lines are treated with146. 
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The basic science studies identified in this review have suggested that there is a clear 
biological relationship between vitamin D and the processes of implantation, 
decidualisation, trophoblastic invasion and placentation.  This association has been 
investigated more extensively in other conditions where these processes are defective (e.g. 
pre-eclampsia, intra-uterine growth restriction, IVF treatment) by the conduct of robust 
clinical research.  As unexplained recurrent miscarriage also stems from these processes 
being faulty it would seem prudent to explore the association further by performing well 
designed clinical research.  A large prospective cohort study investigating the prevalence of 
vitamin D deficiency in recurrent miscarriage populations and the outcomes of pregnancy 
would be an ideal starting point.  If an association is found then a trial of vitamin D 
deficiency treatment would be the next logical step.   For patients who have recurrent 
miscarriage, where there is currently no treatment which has been found to be effective, all 
possible research avenues must be explored.   Vitamin D deficiency treatment is one of these 
avenues.  Its treatment is simple, safe (with minimal side effects) and also cheap.  Along with 
the biological plausibility found in laboratory research, the importance of vitamin D repletion 
in recurrent miscarriage patients is a research priority. 
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CHAPTER 5: THE USE OF ENDOMETRIAL FLUID FOR PREDICTING IN 
VITRO FERTILISATION TREATMENT SUCCESS – A SYSTEMATIC 
NARRATIVE REVIEW 
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Introduction 
In some couples suffering with infertility the only viable treatment option in achieving 
pregnancy is ART.  In the UK, 52,288 women had a total of 67,708 cycles of IVF or ICSI in 
201431.  The number of IVF and ICSI cycles undertaken in the UK is increasing due to the rise 
in the prevalence of infertility.  Despite advances in the technology used for IVF treatment 
the success rates for all cycles (regardless of the age of the woman undergoing treatment) 
remains approximately 35%31.  This causes great emotional upset to many couples. 
 
Failure of an IVF treatment cycle can be caused by a number of factors.  It may be related to 
oocyte and embryo quality or implantation.  Oocyte and embryo quality has been well 
researched with clear and ample evidence to guide selection of the best embryo with the 
highest potential to cause pregnancy149.  However, investigation of the process of 
implantation has not been as fruitful and understanding of the processes required allowing 
for successful embryo implantation lags behind that of embryo biology.  This is due to the 
delicate and intricate nature of the process of implantation and the limitations with studying 
it in vivo.  Identifying the optimum environment for implantation by improving our 
understanding of the implantation process has the potential to increase the success rates 
from IVF treatment150.   
 
Implantation is dependent on three delicate processes.  The first is apposition, when the 
blastocyst initially unites with the endometrium6.  This is an unstable union formed by 
molecular bonding.  The second is adhesion when firmer bonds are made that represent a 
stronger association between the blastocyst and the endometrium.  Characteristically there 
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is increase in the vascularity at the basement membrane of the endometrium at the site of 
adhesion.  Lastly, penetration occurs, whereby trophoblastic invasion reaches the maternal 
uterine vasculature151. 
 
Endometrium that is receptive to pregnancy implantation occurs physiologically, occurring 
during the mid-luteal phase for a short time window in every menstrual cycle.  This short 
period of receptivity is known as the ‘window of implantation’ and occurs approximately six 
days after ovulation and lasts for four days152,153.  This is when the endometrium is most 
receptive to implantation of a blastocyst.  Outside of this time window the endometrium is 
not receptive and pregnancy is unlikely.   
 
Similar to physiological menstrual cycles, in IVF treatment the uterine endometrium is 
dynamic.  The endometrium responds to fluctuating concentrations of oestrogen and 
progesterone and will therefore change its receptivity to embryo implantation throughout 
the IVF treatment cycle.   It is already understood that correct dating of the endometrium is 
key to successful implantation152.  However, the only widely used method of gauging the 
receptivity of the endometrium is by measuring its thickness and examining its 
morphological appearances with ultrasonography154,155.  Unfortunately, this does not 
provide accurate prognostic information156,157.   A test that could allow the identification of 
markers of implantation could in some way complement the currently used methods or 
replace them entirely.  
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One method of characterising the potential of endometrial embryo implantation is to sample 
the endometrial fluid.  This is the small volume of fluid that can be collected from the 
endometrial cavity158.  Animal studies, investigating endometrial fluid, have identified a 
number of different markers that seem to signify that the endometrium has entered the 
window of implantation.  This includes growth factors, cytokines, chemokines and lipids.  In 
particular, epithelial growth factor, IL-6 and IL-11, leukaemia inhibitory factor (LIF), and 
prostaglandins have been studied as they show differential concentrations during the time 
of implantation when compared with other stages of the menstrual cycle159,160.  
  
From a reproductive medicine and IVF perspective, this data provides scope for further 
research.  It has been found to be safe to collect the endometrial fluid close to the time of 
insertion of the embryo into the endometrial cavity (at embryo transfer)161,162.  Moreover, 
sampling of endometrial fluid at this time could provide a snap shot of the uterine milieu 
and, importantly, allow clinicians to identify whether the endometrium is receptive.  
Sampling of endometrial fluid would not require endometrial biopsy, which has been found 
to have a deleterious effect on the endometrium and the process of implantation if 
performed at the time of embryo transfer163.   
 
The emergence of the “omics” disciplines has allowed for high throughput, real time and 
large scale identification of multiple prognostic markers164.  There is no longer the need to 
search for one biomarker at a time.  This could accelerate the potential discovery of a 
putative panel of markers predictive of successful embryo implantation, if the endometrial 
fluid is used as the examined bio-fluid.   
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Research studies have attempted to identify potential markers that are predictive of 
successful implantation and those that predict implantation failure in IVF treatment.  Some 
research has aimed at identifying genes and epi-genetic markers that signify that the 
endometrium is conducive to embryo implantation (genomics)165, whilst others have focused 
on the presence of particular peptides and proteins within the endometrial fluid 
(proteomics)166.  The immunological constituents of the endometrial fluid as well as the 
microbiological nature of the endometrial fluid have also been studied167. 
 
The purpose of this systematic narrative review is to identify all published studies that have 
investigated the use of endometrial fluid in prediction of IVF success. 
 
Methods 
Literature Search  
The aim of the literature search was to identify all studies investigating the use of 
endometrial fluid as a prognostic tool in IVF treatment.  In particular, we wished to seek all 
studies that used endometrial fluid, sampled at the time of embryo transfer, to identify 
biomarkers predictive of IVF treatment success or failure.   
 
The electronic databases EMBASE, MEDLINE and CINAHL (from inception to December 2015) 
were used to perform the literature search (see appendix 6) .  The following keywords and 
MESH headings were used in the search strategy: ‘endometrial fluid’, ‘endometrial 
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receptivity’ and ‘IVF treatment’.  No language restrictions were applied in any of the 
searches or study selection. 
Study Selection 
Inclusion criteria were set prior to undertaking the literature search.  Study selection was 
performed by two independent reviewers.  The titles and abstracts of the electronic 
database search results were examined by both reviewers.  The decision to include or 
exclude the study was made independently according to the pre-set inclusion criteria.  In an 
effort to be as inclusive as possible, any disagreements regarding inclusion or exclusion 
between the two reviewers resulted in the inclusion of the study.    The full manuscripts of 
the included titles and abstracts were retrieved for further examination.  If there were 
duplicate studies, the most recent and complete versions were chosen.  The full manuscripts 
were scrutinised further by both independent reviewers.  Further exclusions were made if 
the full manuscripts did not fulfill the pre-determined inclusion criteria. 
 
Studies that did not explicitly report results of the use of endometrial fluid as a prognostic 
tool were excluded.  Additionally animal studies and manuscripts reporting on the non-IVF 
population were also excluded.  Lastly, studies that did not report results from endometrial 
fluid sampled at the time of embryo transfer were excluded. 
Results 
 
Figure 14 shows the PRISMA flow diagram52,53 of the review process.  The search of 
electronic databases produced 1367 citations.  One thousand two hundred and nineteen of 
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these citations were excluded after examination of the titles and abstracts as they did not 
meet the inclusion criteria.  The full manuscripts for the remaining 148 citations were then
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Figure 15. Study selection for review on the use of endometrial fluid for predicting in vitro fertilisation treatment success 
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retrieved.  A further 133 citations were excluded after reading the full manuscripts.  Fifty-
one citations did not study the IVF population, 26 citations were excluded as they studied 
endometrial tissue biopsies, 16 citations were excluded as they were duplicate publications, 
nine citations investigated the effect of endometrial scratching on IVF treatment outcome, 
seven citations investigated the effect of endometrial ultrasound appearance on IVF 
treatment outcome, six studies investigated endometrial receptivity in animal models, three 
citations summarised the effects of obesity on IVF treatment outcome, two studies 
investigated seminal fluid, two studies investigated serum endometrial receptivity markers, 
two were letters, two studied the effects of serum oestradiol on endometrial receptivity, 
one study explored the effects of the combined oral contraceptive pill on the endometrium, 
one study investigated the effects of uterine pathology on IVF treatment outcome, one 
study investigated embryo prognostic markers, one citation explored the effect of embryo 
freezing on implantation, one citation studied the effect of FSH up-regulation on 
endometrial receptivity, and one study investigated the methods of embryo transfer.  
Therefore the total number of studies that fulfilled our inclusion criteria was 16. 
 
The study characteristics of the 16 studies included in this review are presented in table 6.  
The 16 studies can be divided into several groups; those investigating protein biomarkers 
(seven studies), those investigating genetic biomarkers (one study), those investigating 
immunological biomarkers (five studies), and a miscellaneous group (lipid and 
microbiological biomarkers) (3 studies). 
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Table 6: Study characteristics of included studies. Endometrial fluid and IVF treatment 
Author 
(year) 
Study 
design 
 
Study population 
 
Method of 
endometrial fluid 
aspiration 
Biomarker explored Method of 
measuring 
biomarker 
Results Summary 
Bentin-Ley et 
al., (2011) 
Prospective 
cohort 
21 fertile women 
and 75 infertile 
women 
Denmark 
Endometrial 
flushing 1 day and 
7 days after 
ovulation in the 
natural cycle prior 
to start of IVF 
treatment cycle 
Glycodelin 
PROTEIN 
Glycodelin assay 
 
Glycodelin concentrations were higher in 
infertile women with tubal causes 
compared to fertile women. 
 
Receiver operator curve 
analysis showed that 
glycodelin concentrations 
were of no predictive 
value for IVF outcome.   
Bhattacharya 
et al., (2012) 
Prospective 
cohort 
156 infertile women 
India 
Endometrial fluid 
aspiration 7 days 
after ovulation in 
the natural cycle 
prior to start of 
IVF treatment 
cycle  
Integrin beta 3 
HOXA 10 gene expression 
PROTEIN and GENETIC 
Intergin beta 3 
assay 
PCR for HOXA 10 
gene 
Integrin beta 3 expression was higher in 
women with unexplained infertility who 
conceived in their IVF treatment cycle.  
HOXA 10 gene expression was higher in 
women of lower age groups.  
Integrin beta 3 (an 
adhesion molecule) aids 
with embryo 
implantation. HOXA 10 
gene expression is vital in 
pinopod formation 
increasing embryo 
receptivity of the 
endometrium.  Poor 
expression of integrin 
beta 3 and HOXA 10 gene 
correlates with poor 
endometrial receptivity. 
 
Damario et 
al., (2001) 
Prospective 
cohort 
101 infertile women 
USA 
Endometrial fluid 
aspiration in a 
mock IVF 
treatment cycle 
prior to planned 
IVF treatment 
cycle 
αvβ3 integrin and glycodelin. 
PROTEIN 
Immunochemical 
staining of 
endometrial fluid 
for αvβ3 integrin 
and glycodelin 
αvβ3 integrin and glycodelin staining 
intensity strongly correlate with 
endometrial dating and each other. 
The putative window of 
implantation shows an 
increase expression of 
αvβ3 integrin and 
glycodelin 
Das et al., 
(2007) 
Prospective 
cohort 
63 women with 
unexplained 
infertility 
India 
Gentle suction of 
endometrial fluid 
on the day of HCG 
trigger during the 
index IVF 
64-0-kDa human uterine fluid 
protein 
PROTEIN 
Gel electrophoresis 64-0-kDa human uterine fluid protein 
correlated with endometrial thickness and 
IVF treatment pregnancy outcomes. 
64-0-kDa human uterine 
fluid protein plays in 
important role in 
endometrial receptivity 
to support pregnancy. 
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treatment cycle 
Halperin et 
al., (1995) 
Prospective 
cohort 
109 infertile women 
Israel 
Endometrial fluid 
aspiration on the 
day of embryo 
transfer 
Human decidua-associated 
protein 200 
PROTEIN 
ELISA  Participants were divided in to four 
groups dependent on the concentration 
of human decidua-associated protein 200.  
The group with the highest concentration 
of human decidua-associated protein 200 
had the highest implantation and clinical 
pregnancy rates. 
Human decidua-
associated protein 200 
may be involved with the 
implantation process and 
could be used as an 
endometrial marker of 
receptivity. 
Heng et al., 
(2015) 
Prospective 
cohort 
N not provided 
Australia 
Endometrial 
washings taken in 
women 
undergoing IVF 
treatment.  Time 
of fluid collection 
not described 
Proprotein covertase 5/6A 
PROTEIN 
ELISA Monoclonal antibodies developed to 
assay proprotein covertase 5/6A which 
was found to be higher in receptive 
endometrial fluid. 
Proprotein covertase 
5/6A ELISA can be an 
important tool in the 
development of non-
invasive strategies to 
detect endometrial 
receptivity. 
Ledee-
Bataille et al., 
(2002) 
Prospective 
cohort 
33 infertile women  
France 
Endometrial 
flushing at day 26 
of the natural 
cycle prior to 
start of IVF 
treatment cycle 
Leukaemia inhibitory factor 
(LIF) 
PROTEIN 
 
ELISA LIF was not detectable in women that 
became pregnant and detectable in 
women that did not become pregnant. 
Low concentrations of LIF 
are predictive of embryo 
implantation and its use 
should be considered to 
predict IVF treatment 
outcome. 
Parks et al., 
(2013) 
 
Prospective 
cohort 
24 infertile women 
undergoing frozen 
embryo transfer 
USA 
Endometrial fluid 
aspiration 
immediately 
before transfer of 
embryo 
29 cytokines and 229 micro 
RNAs 
GENETIC 
Cytokine multiplex 
with tandem mass 
spectrometry panel 
and microRNA 
array 
6 cytokines were found to correlate to 
pregnancy outcome from frozen embryo 
transfer treatment.  These included IL-6, 
VEGF and IL-8 which are known to be 
involved in embryo-endometrial 
communication.  MicroRNAs miR-891-a, 
miR-522 and miR-198 were absent from 
the endometrial fluid of women who did 
not become pregnant after frozen embryo 
transfer. 
 
Abnormal microRNA 
expression may 
characterise implantation 
failure.  Fine tuning may 
help increase the chances 
of treatment success. 
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Boomsma et 
al., (2009) 
Prospective 
cohort 
210 infertile women 
Netherlands 
Endometrial fluid 
aspiration 
immediately 
before transfer of 
embryo 
IL-1β, IL-5, IL-6, IL-10, IL-12, IL-
15, IL-17, IL-18, tumour 
necrosis factor-α, interferon-
ϒ, macrophage migration 
inhibitory factor, eotaxin, 
interferon-ϒ protein-10, 
monocyte chemotactic 
protein-1, Dickkopf homolog-
1, heparin-binding epidermal 
growth factor and vascular 
endothelial growth factor 
IMMUNOLOGICAL 
 
Multiplex 
immunoassay 
All biomarkers apart from interferon ϒ 
listed could be detected from endometrial 
fluid aspiration. 
Cytokine profiling could 
be a useful non-
disruptive and safe tool 
to analyse the uterine 
environment prior to 
embryo transfer.   
Boomsma et 
al., (2009a) 
Prospective 
cohort 
210 infertile women 
Netherlands 
Endometrial fluid 
aspiration 
immediately 
before transfer of 
embryo 
IL-1β, IL-5, IL-6, IL-10, IL-12, IL-
15, IL-17, IL-18, tumour 
necrosis factor-α, interferon-
ϒ, macrophage migration 
inhibitory factor, eotaxin, 
interferon-ϒ protein-10, 
monocyte chemotactic 
protein-1, Dickkopf homolog-
1, heparin-binding epidermal 
growth factor and vascular 
endothelial growth factor 
IMMUNOLOGICAL 
 
Multiplex 
immunoassay 
Monocyte chemotactic protein-1 and 
interferon-ϒ protein-10 were associated 
with failed embryo implantation after IVF 
treatment.   
IL-1β and tumour necrosis factor-α were 
associated with clinical pregnancy and 
were as predictive for pregnancy as 
embryo quality. 
The identified cytokines 
may offer a profile that is 
can predict IVF treatment 
success. 
Boomsma et 
al., (210) 
Prospective 
cohort 
198 infertile women 
Netherlands 
Endometrial fluid 
aspiration 
immediately 
before transfer of 
embryo 
Bacterial vaginosis  
IL-1β, IL-5, IL-6, IL-10, IL-12, IL-
15, IL-17, IL-18, tumour 
necrosis factor-α, interferon-
ϒ, macrophage migration 
inhibitory factor, eotaxin, 
interferon-ϒ protein-10, 
monocyte chemotactic 
protein-1, Dickkopf homolog-
1, heparin-binding epidermal 
growth factor and vascular 
endothelial growth factor 
IMMUNOLOGICAL 
Gram staining for 
bacterial vaginosis 
and multiplex 
immunoassay 
Bacterial vaginosis was associated with IL-
1β.  No significant differences found in the 
ratios of pro and anti-inflammatory 
cytokine profiles. 
Bacterial vaginosis is not 
associated with a pro-
inflammatory cytokine 
profile in endometrial 
fluid.  It is therefore 
unlikely to have an effect 
on endometrial 
receptivity. 
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Flyckt et al., 
(2012) 
Prospective 
cohort 
35 infertile women  
USA 
 
Endometrial fluid 
aspiration 
immediately 
before transfer of 
embryo 
IL-1a, IL-6, IL-8, IL-10, IL-1β , 
MCP1, GMCSF, TNF-α and 
VEGF  
IMMUNOLOGICAL 
 
Multiplex 
immunoassay  
High endometrial fluid concentrations of 
all the listed cytokines were found.  MCP1 
had an inverse correlation with clinical 
pregnancy 
Endometrial fluid 
aspiration at the time of 
embryo transfer is a safe 
and effective method of 
exploring endometrial 
receptivity. 
Ledee-
Bataille et al., 
(2004) 
 
Prospective 
cohort 
133 infertile women 
France 
Uterine flushing 
at the time of 
oocyte retrieval 
IL-18 
IMMUNOLOGICAL 
 
ELISA Pregnancy rate in the IL-18 positive group 
was 15%.  Pregnancy rate in the IL-18 
negative group was 37.9%.  In patients 
who had a top quality embryo 
transferred, the pregnancy rate in the IL-
18 positive group was 20% and the 
pregnancy rate in the IL-18 negative group 
was 51%.   
IL-18 detectable in 
endometrial fluid is 
associated with poor 
fertility outcomes in 
women undergoing IVF 
treatment.  IL-18 
detection is a simple and 
non-invasive method to 
predict inadequate 
uterine receptivity, which 
is independent of embryo 
quality/ 
Moreno et 
al., (2015) 
Prospective 
cohort 
19 infertile women 
Spain 
Endometrial fluid 
aspiration 24 
hours prior to 
embryo transfer 
Endometrial fluid microbiome 
MICROBIOLOGICAL 
PCR Analysis of the endometrial fluid 
microbiome established different profiles 
based on the bacteria found.  These 
profiles were: 
1. Normal (>90% Lactobacillus) 
2. Pathological (>10% of 
pathogens) 
3. Dysbiotic (>10% of bacteria 
changing the endometrial 
environment 
Patients with a pathological microbiome 
had the lowest embryo implantation 
rates. 
Reversion of pathological microbiome to 
normal resulted in better pregnancy rates 
The data provides new 
information regarding 
the clinical relevance of 
the microbiological 
environment for embryo 
implantation.  Treatment 
of a pathological 
microbiological 
environment may 
improve IVF treatment 
success rates. 
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Vilella et al., 
(2013)  
Prospective 
cohort 
173 women 
undergoing natural 
menstrual cycles, 
hormone 
replacement 
therapy, controlled 
ovarian stimulation 
and refractory 
endometrium 
induced by 
intrauterine device 
Spain 
Endometrial fluid 
aspirated.  IN 
women 
undergoing 
controlled 
ovarian 
stimulation, 
endometrial fluid 
was aspirated 24 
hours prior to 
embryo transfer 
 
PGE2 and PGF2α 
PROSTAGLANDINS 
Liquid 
chromatography 
and tandem mass 
spectrometry 
PGE2 and PGF2α concentrations were 
increased during the window of 
implantation in women with natural 
cycles and in women undergoing 
controlled ovarian stimulation.   
PGE2 and PGF2α may be 
new non-invasive 
biomarkers of 
endometrial receptivity. 
Braga et al., 
(2014) 
Prospective 
cohort 
22 infertile women 
undergoing 
hormone 
replacement 
therapy for frozen 
embryo transfers 
Brazil 
Endometrial fluid 
collected at the 
time of embryo 
transfer 
Lipid profiling 
LIPIDS 
Tandem mass 
spectrometry 
14 lipids were found to be of significant 
importance in women that achieved 
pregnancy from frozen embryo transfer.  
These were glycerolipids, 
glycerphospholipids and polyketides.  
Receiver operator curve analysis showed 
98.7% area under the curve.   
 
Mass spectrometry of 
endometrial fluid for lipid 
profiling is a useful 
method of investigating 
endometrial receptivity. 
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Endometrial fluid protein biomarkers to predict IVF treatment outcome 
 
Proteomics is now considered to be an important method of biomarker research.  This 
reflects the advances in mass spectrometry techniques, particularly the emergence of high-
throughput technology.  However, proteomic study is very complex, as protein synthesised 
by a particular tissue may not fully reflect the mRNA product from transcription.  This is due 
to profound post translational and epigenetic changes that occur after transcription168,169.   
The endometrium is no exception.  Nevertheless, proteomics has been used to search for 
biomarkers of receptive endometrium.  Studies have investigated the proteome of 
endometrial tissue; however, the use of endometrial fluid uncomplicates analysis as the ever 
changing nature of cellular composition is not as much of an issue when examining the fluid 
when compared with tissue170.   
 
Initial research suggests that there is a protein profile in endometrial fluid that is 
characteristic of the window of implantation.  Studies have been performed to understand 
the difference in endometrial fluid proteome of fertile women when compared to infertile 
women167.  Additionally, the same types of experiments have been conducted to understand 
the difference in endometrial fluid proteome when comparing with endometriosis versus 
those that do not171.  These studies found that there were clear differences in the expression 
of cytokines, growth factors, phosphatases and kinases162,171,172.  Frustratingly, however, 
some of these proteins, as they are large molecules, are sometimes found fragmented 
despite careful endometrial fluid sampling173.  In particular, this has been the case when 
trying to investigate the endometrial fluid for proteins that have been found to be highly 
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expressed in previous research, such as LIF and glycodelin174.  Perhaps this is due to the 
fracturing of these proteins on endometrial fluid sampling.  
 
In addition, another problem for proteomic study of the endometrial fluid is the abundance 
of plasma derived albumin and haptaglobins within the fluid.  These large proteins must be 
removed so that the proteins derived from the endometrium can be better studied.   
 
Our literature review identified seven studies that investigated protein biomarkers in 
endometrial fluid to provide prognostic information regarding IVF treatment outcome.   
 
Bentin-Ley et al.,175 performed a prospective cohort study in 21 fertile women and 75 
infertile women to investigate the glycodelin expression in women undergoing IVF 
treatment.  Endometrial fluid washings were sampled in the natural cycle immediately prior 
to commencement of IVF.  The group found that the levels of glycodelin in endometrial fluid 
were higher amongst the infertile group who had tubal infertility.  Additionally, their results 
found that women with unexplained infertility also had higher glycodelin levels when 
compared to the fertile controls.  However, receiver operater curve analysis showed that 
endometrial fluid flushing glycodelin levels had no predictive value for IVF treatment 
outcome.   
 
Bhattacharya et al.,176 collected endometrial fluid samples from 156 women prior to IVF 
treatment.  The aim of this study was to investigate the expression of integrin beta 3.  This 
protein is a product of HOX10A gene, which must be highly expressed in order for embryo 
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implantation to take place.  The group found that integrin beta 3 expression was similar 
through different age groups.  Interestingly, integrin beta 3 expression was lower in women 
with unexplained infertility when compared to women with other causes of infertility.  
Additionally, the group observed that the integrin beta 3 expression was lower amongst 
women who did not succeed with their IVF treatment attempt.  These findings did not reach 
statistical significance, however in endometrial fluid samples taken in the same cohort at 
different times of the menstrual cycle, integrin beta 3 expression was statistically 
significantly higher during the secretory phase of the menstrual cycle when compared to the 
proliferative phase (p<0.001).   
 
Damario et al.,177 controversially used mock IVF treatment cycles in 101 oocyte recipients to 
sample endometrial fluid.  The investigated protein biomarkers were αvβ3 integrin (found to 
be decreased in women with endometriosis, hydrosalpinges and unexplained infertility) and 
glycodelin.  Results showed that expression of αvβ3 integrin and glycodelin were strongly 
correlated to the age of the endometrium within the mock hormonal treatment.  Also a 
strong inverse correlation was found between the expression of αvβ3 integrin and 
glycodelin. 
 
Das et al.,178 performed a prospective study of 81.  Eighteen of these participants acted as 
parous controls, whilst 63 had unexplained infertility.  The 63 women with unexplained 
infertility underwent no stimulation, clomiphene citrate ovulation induction or FSH injection 
ovulation stimulation.  The primary outcome was the concentration of 64-0-kDa human 
uterine fluid protein, a protein that had previously been hypothesised by the same authors 
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as important in regulation of embryo implantation.  The results showed that 64-0-kDa 
human uterine fluid protein correlated with endometrial thickness as well as pregnancy 
outcomes. The authors postulate whether 64-0-kDa human uterine fluid protein could play a 
role in endometrial receptivity. 
 
Halperin et al.,179 collected endometrial fluid samples from 109 women undergoing IVF 
treatment in a prospective cohort study.  The endometrial fluid was sampled immediately 
prior to embryo transfer with a mock embryo transfer catheter used to check cervical 
patency.  The aim was to examine the relationship between human decidua-associated 
protein 200, a glycoprotein thought to have function in embryo implantation, and affect the 
embryo implantation rate.   The group’s results indicated that human decidua-associated 
protein 200 had a significantly positive correlation to IVF implantation rate and clinical 
pregnancy rate.  The 109 participants were divided in to four groups dependent on their 
human decidua-associated protein 200 endometrial fluid concentration.  The group with the 
lowest human decidua-associated protein 200 concentration had an implantation rate of 
2.3% and pregnancy rate of 5.6% when compared to the group with the highest 
concentration who had an implantation rate of 29% and pregnancy rate of 50% (p=0.005 and 
p=0.003 respectively).  
 
Heng et al.,180 reported their findings of an assay that is in development to detect proprotein 
covertase 5/6A.  Previous research work had found that this enzyme is highly expressed in 
receptive endometrium and that the enzyme is also secreted into the endometrial fluid, with 
high concentrations suggestive of high endometrial receptivity.  Monoclonal antibodies as 
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well as ELISA techniques have been used to develop this assay.  Unfortunately, the group 
have not yet yielded any results. However, the objective for this research group is to develop 
a real time assay that can be used to provide prognostic implantation and endometrial 
receptivity information in women undergoing IVF treatment.   
 
Lastly, Ledee-Bataille et al.,181 studied the association between the concentration of LIF and 
embryo implantation in IVF treatment.  Endometrial fluid was sampled in 33 women who 
were either undergoing IVF for premature ovarian failure or unexplained infertility.  Previous 
research182 had shown that LIF was absolutely necessary for murine implantation by 
monitoring the reproductive outcomes of LIF knockout mice.  LIF protein is also only found in 
the luteal phase of the menstrual cycle183.  The study by Ledee-Bataille et al., demonstrated 
contrasting findings, where median LIF concentrations were lower in the women that 
became pregnant when compared to those that did not become pregnant from the index IVF 
treatment (0pg/ml versus 203pg/ml, p=0.0013).  The group recognised the dramatically 
different results and concluded that the contrasting results could be due to the 
measurement of the incorrect LIF transcript (as there are three different LIF proteins; LIF-D, 
LIF-M and LIF-T).  Importantly, Ledee-Bataille et al., were able to reproduce consistent 
concentrations of LIF in subsequent cycles, suggesting that their method of endometrial fluid 
sampling provided consistent results.  The group summarised their findings by stating that 
endometrial fluid could detect the unreceptive uterus before IVF treatment, to allow for 
normalisation of the environment before women embarked on treatment.  However, a 
better comprehension of protein profiles was required before this approach could be used in 
clinical care. 
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Endometrial fluid genetic biomarkers to predict IVF treatment outcome 
 
Developments in genetic technology have allowed the advancement of genomic association 
studies to identify single nucleotide polymorphisms associated with disease.  These whole 
genome association studies have now become the most commonly used methodology to 
search for genetic loci to identify association between gene and disease state164.   
 
Genome wide studies on the endometrium and endometrial fluid have been more limited.  
Previous genomic studies have been performed to identify genetic associations in 
endometriosis184,185 and endometrial cancer186.  Results have been inconsistent due to 
heterogeneity in populations, techniques as well as small sample sizes.  Large sample sizes 
are required to confirm that risk loci are associated with endometriosis and endometrial 
cancer so that they can then be further tested in different ethnic populations187.   
 
The clinical potential from genomic research carried out in the fields of endometriosis and 
endometrial cancer is substantial; providing risk potential data as well as targets for future 
disease therapy.   Similarly, identifying single nucleotide polymorphisms that are associated 
with embryo implantation failure would also hold great potential.  Many studies have been 
published to investigate the genomic expression and epigenetic micro RNA expression within 
receptive and non-receptive endometrium.  Of special note, Diaz-Gimeno et al., have 
suggested that a gene array tool could be used to inform IVF specialists when to carry out 
embryo transfer, personalising transfer to the individual patient188–191.  This gene array tool, 
called the endometrial receptivity array, is based on endometrial expression of 238 selected 
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genes that can be used to date the endometrium, ensuring that embryo transfer occurs at 
the optimal time after adequate endometrial priming.  Initial studies have shown great 
promise with high sensitivity and specificity but it still requires further clinical validation189.  
In particular, the practical and clinical value of the test remains a hurdle to its use as it 
requires endometrial biopsy before the IVF cycle begins.   
 
In this review, only one study was identified that investigated genetic biomarkers in 
endometrial fluid to provide prognostic information regarding IVF treatment outcome.  
Parks et al.,192 conducted a study of 30 patients with recurrent implantation failure who 
were due to undergo frozen embryo transfer.  Recurrent implantation failure is diagnosed 
when a patient has undergone two or more embryo transfers where the embryo has been 
graded as top quality.  The aim of Parks et al., study was to investigate whether the 
microRNA present in endometrial fluid was associated with implantation.  All of the 
participants underwent pituitary down regulation followed by oestrogen and progesterone 
replacement therapy.  Uterine secretions were then collected by gentle aspiration 24 hours 
before FET or at the time of FET.  Blinded uterine fluid analysis was performed using human 
microRNA array and tandem liquid chromatography mass spectrometry (LC-MS/MS).  The 
study group found that 29 cytokines were associated with positive implantation with a p-
value <0.05.  Interestingly Park et al., found three microRNAs (miR-891am miR-522 and miR-
198) were not present in any uterine fluid aspirated from those patients that did not have 
successful implantation.  The group concluded that aberrant microRNA expression within 
uterine secretions may be the cause of implantation failure.  Furthermore, predicting the 
maternal molecular microenvironment before transfer of embryo could mean that subtle 
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changes to the preparation of recurrent implantation failure patients could improve embryo 
implantation outcomes. 
 
Endometrial fluid immunological biomarkers to predict IVF treatment outcome 
 
A large proportion of the research performed to investigate the value of endometrial fluid in 
predicting IVF treatment outcome explored immunological biomarkers.  These include 
cytokines, interleukins and chemokines.  The interest in immunological mediators stems 
from the theory that receptive endometrium is immune-modulated with a resultant anti-
inflammatory environment.  This would allow for a ‘guest embryo’ to invade into the ‘host’ 
endometrium193.  However, this theory of immunomodulation for successful implantation is 
probably too simplistic as it has also been found that some pro-inflammatory cytokines are 
essential for successful implantation194.   These findings have led numerous research groups 
to search for a favourable immunological profile predictive of successful implantation in 
women undergoing IVF treatment. 
 
Our literature review identified five studies that investigated immunological biomarkers in 
endometrial fluid to provide prognostic information regarding IVF treatment outcome.   
 
Boomsma et al.,195 aspirated the endometrial fluid of 210 women undergoing IVF treatment.  
The fluid was aspirated just before embryo transfer and then underwent multiplex 
immunoassay. The immune mediators assayed were IL-1β, IL-5, IL-6, IL-10, IL-12, IL-15, IL-17, 
IL-18, TNF-α, IF-ϒ, macrophage migration inhibitory factor, eotaxin, IF-ϒ protein-10, 
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monocyte chemotactic protein-1, Dickkopf homolog-1, heparin-binding epidermal growth 
factor and vascular endothelial growth factor.  As a proof-of-principle study, the results 
showed that sufficient endometrial fluid was sampled in all but one participant and that all 
of the immune mediators were detectable with the multiplex assay technique apart from IF-
ϒ.  Importantly, Boomsma et al., were able to confirm that gentle aspiration of endometrial 
fluid just before embryo transfer is a safe technique as pregnancy rates from the 210 
participants was comparable to age matched controls.  The same research group went on to 
identify a cytokine profile which was predictive of pregnancy in IVF treatment162.  Using 
multivariate regression analysis significant associations for failed embryo implantation were 
found for monocyte chemotactic protein-1 and IF-ϒ protein-10.    Positive associations were 
found for clinical pregnancy and IL-1β and TNF-α.  This predictive value of IL-1β and TNF-α 
for clinical pregnancy was strong, being equivalent to embryo quality.  The group concluded 
that endometrial secretion cytokine profiling offers a new, safe approach to study embryo 
implantation and that it predicts pregnancy in women undergoing IVF treatment.  
  
In a separate study population Boomsma et al.,196 investigated whether bacterial vaginosis 
was associated with a pro-inflammatory cytokine profile in 198 women undergoing IVF 
treatment.  Bacterial vaginosis has been postulated to reduce the chance of embryo 
implantation and increase the risk of miscarriage197.  In this study, endometrial fluid was 
aspirated before embryo transfer and the same multiplex assay was performed.  Seventeen 
women were diagnosed as carrying bacterial vaginosis, their endometrial secretions had a 
significant negative association for IL-1β.  No significant differences were found in any other 
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pro or anti-inflammatory cytokine and therefore a cytokine profile for bacterial vaginosis 
was not found.   
 
In a prospective cohort study, Flyckt et al.,198 collected endometrial fluid from 35 women 
undergoing IVF treatment immediately before embryo transfer.  Multiplex assay was 
performed to identify nine cytokines and growth factors from the endometrial fluid.  The 
endometrial fluid of women achieving pregnancy was then compared to that of women that 
had failed treatment.  Similar to the findings by Boomsma et al.,162 monocyte chemotactic 
protein-1 was found to be strongly associated with failed IVF treatment.  This finding 
reached statistical significance (p=0.045). 
 
Ledee-Bataille et al., sampled endometrial fluid at the time of oocyte retrieval in 133 
patients undergoing IVF treatment199.  The group aimed to investigate whether the 
detection of IL-18 by ELISA in uterine luminal secretions could predict embryo implantation 
failure.  Endometrial fluid was sampled by flushing the uterine cavity.  The participants were 
divided into two groups dependent on whether IL-18 was detected in their endometrial fluid 
(the IL-18 positive group and the IL-18 negative group).  The IL-18 positive group was found 
to have a clinical pregnancy rate of 15% whilst the IL-18 negative group had a clinical 
pregnancy rate of 37.9% (p=0.02).   Ledee-Bataille et al., also performed sub-group analysis 
of 65 women who had a top quality embryo transferred, this showed that the difference in 
clinical pregnancy rates was even more pronounced (20% in the IL-18 positive group and 
51% in the IL-18 negative group).   
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Endometrial fluid: Other biomarkers used to predict IVF treatment outcome 
 
Microbiological endometrial receptivity biomarkers 
In addition to the bacterial vaginosis and endometrial fluid study performed by Boomsma et 
al.,196.  Other research has investigated the merit and usefulness of microbiological markers 
in predicting IVF treatment outcome.   Moreno et al.,200 studied the microbiome of 
endometrial fluid in 19 women undergoing IVF treatment.  They sought to understand the 
functional relevance of different bacterial species in the human endometrium during the 
window of implantation.  The group found that the microbiome within the endometrial fluid 
could be classified into normal (where lactobacillus constituted 90% of the microbiome), 
pathological (where the microbiome was comprised of pathogens such as Gardnerella) or 
dysbiotic (where the microbiome was made up of bacteria that subtly changed the 
endometrial environment).  When Moreno et al., related this classification to IVF treatment 
outcomes, the group found that implantation rates were lowest in the pathological class.  
Additionally the miscarriage rate was also higher in the pathological class.  Treatment of 
bacteria in the pathological class normalised the microbiome and subsequent cycles had a 
higher success rate.  Given the low sample size, the authors concluded that further work 
needed to be explored, however, they recognised the new insights and hope that 
improvements can be made to implantation in women in the future.   
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Prostaglandin as a biomarker of endometrial receptivity 
The effect of prostaglandin concentrations in endometrial fluid has also been studied. 
Aberrant prostaglandin synthesis has been associated with poor implantation in animal201 as 
well as human models202.  In the field of reproductive medicine, it has also been linked with 
recurrent implantation failure203.  Vilella et al.,204 obtained endometrial fluid from women 
who had natural menstrual cycles, women using hormone replacement therapy and women 
who were undergoing controlled ovarian stimulation in IVF treatment.  Lastly, the group 
obtained endometrial fluid from women who had an intrauterine contraceptive device in 
situ, where the endometrium was least likely to be favourable for implantation.  The group 
compared the prostaglandin E2 and prostaglandin F2α concentrations between these groups 
and found that prostaglandin E2 and F2α were significantly raised in the window of 
implantation in women having natural menstrual cycles and also women undergoing IVF 
where treatment was successful.  They postulated that prostaglandin concentrations could 
be used as a non-invasive marker for endometrial receptivity.   
Lipid endometrial receptivity biomarkers 
Lastly, Braga et al.,205 collected the endometrial fluid of 22 women undergoing hormone 
replacement therapy for FET.  The endometrial fluid was collected at the time of embryo 
transfer and mass spectrometry was used to analyse the fluid.  Participants were divided in 
to two groups; those that achieved pregnancy and those that did not.  The lipid profiles of 
the pregnant group were compared to that of the failed treatment group.  Fourteen lipids 
were identified as potential biomarkers as they were detected at higher concentrations in 
women who achieved pregnancy after FET.  These lipids included glycerolipids, 
glycerphospholipids and polyketides.  Receiver operator curve analysis demonstrated an 
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area under the curve of 98.7% suggesting that the lipid profile identified in women with a 
receptive endometrium was very predictive.  Braga et al., concluded that the use of mass 
spectrometry on endometrial fluid for lipid profiling was a novel and non-invasive method of 
predicting endometrial receptivity but conceded that further work with a larger sample size 
was required to validate their findings. 
Discussion 
The use of ART is increasing along with the prevalence of couples affected by infertility.  
Embryo implantation and endometrial receptivity represents an area of research that is 
novel and exciting.  It is also an area of research that needs further advancements to ensure 
that the chances of fertility treatment success are maximised for patients.  Additionally, 
funding restrictions mean that optimising the chances of pregnancy is paramount to couples 
that may not be able to self-fund multiple attempts at IVF treatment. 
    
The advantages of perfecting a non-invasive method to investigate the endometrial 
environment are clear.  It offers the opportunity to provide clarity for patients’ prognosis 
and more excitingly may offer a method to identify women that could benefit from 
treatment to increase the chances of successful treatment.  Sampling endometrial fluid at or 
close to the time of embryo transfer would offer the closest opportunity both in time and 
space for this assessment to be performed.  Furthermore, aspiration of endometrial fluid has 
been found to be safe and does not cause detrimental effects to the chances of successful 
treatment161.  The use of endometrial fluid as a predictive tool has been investigated by 
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many study groups and will be further researched in years to come. This review has 
identified the publications that have used this method in the IVF population. 
 
This review was strengthened by several factors.  It employed a comprehensive literature 
search, using applicable literature databases.  The review was conducted with inclusivity in 
mind, meaning that all relevant citations were identified.  Specifically, no language or 
publication date limitations were applied to aid with the comprehensiveness of the 
literature search.  The major weakness in this narrative review is the small number of 
publications that have been identified.  As the publications have investigated different 
biomarkers, it has not been possible to perform any form of meta-analysis to strengthen 
findings.  However, this was expected prior to beginning the literature search given the 
paucity of research that has been performed making the use of endometrial fluid as a 
prognostic tool for IVF treatment outcomes. 
   
It is anticipated that as technological advances in systems biology ‘omics’ disciplines are 
made, biomarker research will grow and more publications will result.  This same trend is 
likely to be evident with the use of endometrial fluid as the bio-fluid for endometrial 
receptivity biomarker discovery.  The major strength of the ‘omics’ disciplines is in the high-
speed throughput that is achievable.  Further advances in technology may allow IVF 
physicians of the future to be able to sample fluid prior to embryo transfer, process it for a 
biomarker panel and delay or proceed with embryo transfer dependent on the result.   
 
126 
 
As implantation represents such a complex nature, it is unlikely that a single biomarker will 
be found that is strongly predictive however a panel may achieve high prediction.  Selection 
of the panel in itself is a difficult process, this review has demonstrated several areas 
(proteins, genetics, immunological etc.) which have been investigated without offering a clue 
as to which area may be the most likely to reveal best to perform future research.  However, 
glycodelin, adhesion molecules (integrin β3 and integrin αvβ3) have been investigated 
thoroughly and are providing exciting results.  HOX10-A gene expression has also been 
investigated and has been shown to have an association with endometrial receptivity.  
Cytokine profiling of endometrial fluid also represents an exciting research area, where IL-8, 
IL-10, vascular endothelial growth factor and TNF-α have been shown to offer high predictive 
value.  Unfortunately and disappointingly, none of these promising biomarkers have had any 
practical applications so far, mainly due to low sample sizes.  Perhaps a combination of these 
biomarkers may offer the best prognostic panel available.  However, this scatter gun 
approach to biomarker discovery may not be the best method to identify important 
biomarkers indicative of receptive endometrium.  Perhaps a better approach would be to 
fully investigate healthy, fertile women first to identify and validate the best biomarkers that 
confirm receptivity.  In that way, a targeted approach could then be adopted in the IVF 
population. Further validation of any proposed biomarker panel would also be required to 
test its predictive value in large sample sizes.  This may require international collaborations 
of differing omics disciplines and research groups to establish a global dataset of biomarker 
discovery from endometrial fluid.  Further refinement of endometrial fluid sampling is also 
required so that biomarker assay can be standardised to achieve precise and reliable 
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results150.  Lastly, a quick turnaround from endometrial fluid sampling to result would be 
ideal to allow for maximal impact in clinical use.   
 
Performing this narrative review did not reveal any publications investigating the 
metabolomics profile of endometrial fluid.  Metabolomics is the ‘omics’ discipline which best 
represents the phenotype of any bio-fluid.  This would be an exciting area that has not yet 
been researched and potentially could unlock the black box that is embryo implantation. 
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CHAPTER 6: ENDOMETRIAL FLUID METABOLOMIC PROFILING IN 
WOMEN UNDERGOING IN VITRO FERTILISATION TREATMENT – A 
PROSPECTIVE COHORT STUDY 
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Introduction 
Infertility affects 10-15% of couples and is a disorder with emotional, psychological and 
occasionally physical consequences. The prevalence of infertility is growing.  In 2011, 61726 
IVF or ICSI cycles were performed on 48147 women in the UK.  The latest figures show that 
24.5% of these cycles led to live births in 201131.  
 
Through technological advances, success rates have improved since the first successful IVF 
cycle was performed in 1978.  However, there is still great room for improvement both in 
treatment outcomes and in our understanding of fertilisation and implantation of the 
embryo.  In IVF or ICSI treatment the goal is to produce a high quality embryo with artificial 
fertilisation.  Following this, embryo transfer is performed with the aim of causing embryo 
implantation in the uterine cavity, which achieves clinical pregnancy.  Embryo implantation is 
a complex process, and abnormal implantation leads to a high frequency of pre-clinical 
pregnancy loss (where trophoblastic invasion never occurs)4.  It is embryo implantation, 
which remains the rate-limiting step in improving IVF treatment success. This has led to 
much research aimed at investigating the peri-implantation environment within the uterus, 
and the factors that determine receptivity to implantation and the initial maternal-embryo 
interface, as this is still not well understood.   
 
In a physiological menstrual cycle, the human endometrium is receptive during the mid-
luteal phase. During this implantation window the endometrium is primarily determined by 
the sex steroids oestrogen and progesterone201, which affects the concentration and 
expression of gene transcription factors, growth factors and cytokines.   The exact nature of 
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this receptive endometrial environment in physiological cycles has not been fully 
investigated.  However, this knowledge could prove vital in mimicking the environment prior 
to embryo transfer for women undergoing IVF treatment.  Therefore, research groups have 
studied a range of different factors including; endometrial genetic expression164,206,207, 
uterine immunology195,196,204,208,209, the importance of the endometrial cavity microbiological 
environment196 and endometrial protein expression188,210,211. The findings from these studies 
were discussed in the previous thesis chapters but broadly they all have the aim of 
identifying and hopefully replicating the optimum environment for embryo implantation.  
 
The emergence of the “omics” disciplines has allowed the study of the maternal-embryo 
interface in much greater detail.  Omic strategies are designed to investigate complex 
biological interaction as a whole instead of targeting specific compounds212.  Over the past 
fifteen years, genomics (the study of the whole genetic compartment) has led to the 
development of other omics disciplines; proteomics (proteins), lipidomics (lipids) and 
metabolomics (metabolites).   
 
Metabolomics provides a snapshot of the interaction between genotype and the 
environment in a biofluid. It is therefore considered to be the closest representation of 
tissue phentotype213 and has been used in IVF research in recent years, particularly in 
fertilisation.  Studies have been performed to use metabolomic techniques to compare the 
profile of follicular fluid aspirated during oocyte retrieval.  The metabolome of the follicular 
fluid is assessed to investigate whether certain metabolites could provide an indication of 
embryo quality214,215.  In addition, other research groups have sought to identify the ideal 
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metabolome of spent embryo culture media in order to identify differences in molecular 
secretions between embryos that implant and those that do not216–218.  
  
Both of these areas of research (follicular fluid and spent embryo culture media 
metabolomics) aim to help embryologists’ select the embryo, which has the greatest 
pregnancy and implantation potential.  Metabolomics has not yet been applied to the study 
of the interface between embryo and endometrium.  Ideally, endometrial secretions 
collected at the time of embryo transfer in IVF treatment could undergo metabolomics 
analysis.  This would provide a true representation of the micro-environment within the 
uterus at the time of embryo implantation. 
 
Researchers have shown that the sampling of endometrial fluid immediately before embryo 
transfer is safe.  Van der Gaast et al.,161 published a cohort study of 66 patients in 2003 
where trans-cervical endometrial fluid aspiration was performed prior to embryo transfer.  
Importantly, the study found that when compared to matched controls, the implantation 
rate in the study group was not reduced.  Following this study Boomsma et al.,162 confirmed 
the safety of this technique by conducting a similar cohort study of 210 women undergoing 
IVF treatment.  Once more, endometrial fluid was aspirated trans-cervically immediately 
before embryo transfer.  When treatment outcomes were compared to matched controls, 
no reduction in treatment success was observed in the study group.  Endometrial fluid 
aspirated by Boomsma et al., was investigated for a pre-selected panel of immunological 
biomarkers.  The research group was able to find significant associations between monocyte 
chemotactic protein-1 and IL-10 cytokine levels and implantation and between IL-1β and 
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TNF-α and clinical pregnancy.  However, this research group only examined 17 soluble 
regulators of implantation and the metabolome was not investigated.  
 
The research studies described above have prompted others to consider that endometrial 
fluid aspiration before embryo transfer offers a novel tool for assessing endometrial 
receptivity during treatment cycles without affecting implantation rates166.  This current 
proof of principle cohort study was conducted with the aim of identifying whether 
endometrial fluid sampling at the time of embryo transfer for the purposes of metabolomics 
sampling is possible.  Furthermore, the discovery of a putative metabolic biomarker panel, 
which predicts successful IVF treatment was a secondary aim.  Lastly, this study aimed to 
improve the knowledge and understanding of how the endometrial fluid milieu affects 
implantation, and how this could lead to novel diagnostics, therapies to achieve better 
treatment outcomes. 
Methods 
Ethical approval was obtained from the Centre of Human Reproductive Sciences (ChRS) 
department, a HFEA Research Centre (#0209) and approved tissue bank (NRES 
REC 13/EM/0272) at the Birmingham Women’s Fertility Centre (see appendix 7).  
Participants consisted of patients undergoing IVF or ICSI treatment between May and 
September 2015.  Only participants with normal ovarian reserve were considered for 
inclusion into the study as these were perceived to be the women most likely to complete 
treatment with an embryo transfer and the least likely to have their IVF treatment cancelled 
due to under or over response to recombinant follicular stimulating hormone injections.  
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Patients identified to have a uterine cavity abnormality from ultrasonography of the pelvis or 
hysteroscopy in their initial infertility investigations were excluded.  Potential participants 
were approached after their nurse led injection tutorial appointment.  A brief counseling 
consultation was undertaken with each participant regarding the nature of the study.  A 
participant information sheet was provided for the participant to take home (see appendix 
8).  At their next appointment (the first follicle tracking ultrasound appointment) each 
participant was re-approached and, if willing, provided two-stage informed consent to 
participate in the study (see appendix 9).   
 
Between May and September 2015, 20 participants were recruited into the study.  All 
participants were attending for their first or second IVF or ICSI treatment cycle.   
 
IVF and ICSI Treatments 
All participants undergoing fresh cycle IVF or ICSI underwent pituitary suppression using 
either a short GnRH antagonist (Cetrotide, Merck Serono, France) down regulation protocol 
or a long GnRH agonist (Buserelin, Sanofi-Aventis, France) protocol injected subcutaneously.  
Complete pituitary suppression was confirmed with ultra-sonogropahic evidence of little or 
no follicular activity and an endometrial thickness of less than 5mm.  Following down 
regulation, participants underwent ovarian stimulation to encourage growth of multiple 
ovarian follicles with daily subcutaneous injections of purified urinary gonadotrophin 
(Follicular stimulating hormone-luteinising hormone: Menopur, Ferring, France) at a dose of 
150-450 international units per day.  Starting doses depended on the patient’s age. The 
starting doses were 150iU of menopur if women were less than 35 years, 225iU is women 
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were 36-38 years, 300iU if women were 39-42 years and 300 to 450iU in the woman was 
over the age of 42.  Additionally, if baseline FSH was greater than 10iU/ml in women less 
than 31 years, the start dose of menopur would be increased to 225iU.  In women with a 
baseline FSH greater than 10iU/ml over 31 years, the start dose of menopur would be 
increased to 300iU. In women with anovulatory cycles with polycystic ovarian syndrome, an 
individualized stimulation protocol was planned.  Previous poor responders would also have 
a higher starting menopur dose.  
 
According to the ovarian response (monitored by transvaginal ultrasonography) the dose of 
follicle stimulating hormone was altered to optimise ovarian stimulation.  When three 
follicles or more had reached a diameter of at least 17mm, 5000 IU of Human Chorionic 
Gonadotrophin (Ovitrelle, Merck Serono, France) was used as a trigger for ovulation and 
final maturation of the oocytes.  Thirty-six hours after trigger injection, trans-vaginal oocyte 
retrieval was performed under ultrasound guidance by needle aspiration to obtain oocytes 
for fertilisation and embryo culture. After oocyte retrieval, all participants received 
micronized progesterone (Cyclogest, Actavis, UK) (400mg daily, per vagina) for endometrial 
preparation.  Grading of embryos was performed to select the best quality embryo for 
uterine transfer.  Fresh embryo transfer was undertaken in line with the Birmingham 
Women’s Fertility Centre unit embryo transfer policy.  Endometrial fluid sampling was 
performed immediately before embryo transfer. 
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Endometrial fluid collection 
All participants had endometrial fluid sampled immediately before embryo transfer.  With 
the patient in the lithotomy position, a Cusco speculum was inserted to visualize the cervix.  
The cervix was cleaned and an empty embryo transfer catheter (Rocket Embryon, Rocket 
Medical, UK) was inserted into the cervical canal of each participant under ultrasound 
guidance.  The outer catheter occupied the cervical canal to a length of 4cm, whilst the inner 
catheter was inserted a further 2cm to a total length of 6cm.  This meant that the inner 
catheter was inside the endometrial cavity swathed in endometrial secretions.  No suction 
was applied to the embryo transfer catheter.  The inner catheter was then withdrawn to lie 
inside of the outer catheter tubing to protect it from cervical mucus and the whole embryo 
transfer catheter was then removed from the uterus and cervix.  The inner catheter was 
then placed in a sterile 15ml centrifuge tube (Falcon, Corning, USA) ready for sample 
processing.  The participant then proceeded with their embryo transfer with an embryo 
transfer catheter loaded with the embryo, under ultrasound guidance. 
 
 
 
 
 
Figure 16. Positioning of embryo transfer catheter to obtain endometrial fluid 
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Processing of endometrial fluid sample 
With the inner catheter of the embryo transfer catheter in the 15ml centrifuge tube, 2ml of 
80:20 methanol: water mix was injected into the centrifuge tube to render the endometrial 
fluid sample cell free.  A 2ml syringe was then used to flush and aspirate the catheter a total 
of ten times to ensure that all of the endometrial fluid was left in the solution.  The embryo 
transfer inner catheter was then discarded.  The endometrial fluid sample was then vortexed 
within the 15ml centrifuge tube for a total of two minutes.  The sample was then centrifuged 
at 100G for 30 minutes.  After centrifuge the sample was poured into a 2ml micro-centrifuge 
tube (Eppendorf, Sigma-Aldrich, USA), labeled with a study identification number and stored 
at -20°C.  Three control samples were processed with unused embryo catheters 
implementing the technique outlined above, these unused embryo catheters had not been 
in contact with any endometrial fluid and were processed directly from their packaging.  The 
three unused embryo transfer catheter samples were used for quality control. 
 
Metabolic profiling 
Metabolic profiling of all samples was performed by applying Direct Infusion Mass 
Spectrometry (DIMS) analysis followed by statistical data analysis to define metabolic 
changes associated with (1) IVF outcome and (2) age (below and above 35 years of age). 
Figure 17. The Rocket Embryon embryo transfer catheter 
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Direct Infusion Mass Spectrometry (DIMS) analysis. 
DIMS analysis was undertaken by coupling a Triversa NanoMate ion source (Advion 
Biosciences, Ithica) to an LTQ-Orbitrap Elite (Thermo Scientific Ltd, UK). Prior to analysis, 
samples were dried under a nitrogen gas stream, reconstituted in 70µL of 80/20 methanol: 
water (v/v) with 20mM ammonium acetate, vortex mixed for 15 seconds and centrifuged at 
13,500G for 15 minutes at 4 °C. Samples were then loaded onto a 384 well plate (Thermo 
Scientific Ltd, UK) for analysis in positive ion mode. NanoMate conditions consisted of a 
nitrogen backing pressure of 0.3psi, with a voltage of +1.7kV applied to the nanoESI chip. 
The total sample volume aspirated from each well was 6µL with total time infused through 
the nanoESI chip of 3.2 minutes. The capillary inlet for the mass spectrometer was set at 
200°C. MS data was collected in two scan windows (50 – 450 Da and 250 – 1000 Da) in 
positive ion mode. Mass resolution was set at 240,000 (FWHM defined at m/z 400) with a 
scan speed of 0.4 seconds and an AGC setting of 5x105. 
Data pre-processing.  
DIMS data was exported from Thermo Xcalibur software and processed using an in-house 
developed R script (Thomas Lawson) to construct a data matrix, which allowed further data 
analysis. The data matrix was composed of all detected mass-to-charge (m/z) ratios as rows 
and each sample as a column. For a specific m/z, which was detected in a specific sample a 
response (proportional to the metabolite concentration) was reported. 
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Univariate and multivariate analysis.  
Processed data was analyzed in ‘R’ applying the unsupervised multivariate principal 
components analysis (PCA), supervised multivariate Partial Least Squares-Discriminant 
Analysis (PLS-DA) and univariate non-parametric Mann Whitney U test.  A critical p-value of 
<0.05 was applied with no correction for false discovery rate applied. The fold change 
(median peak area before treatment/median peak area after treatment) was calculated. 
Metabolites were manually annotated by calculation of all molecular formula matching to 
the accurately measured m/z value within a +/-5ppm mass error and subsequent matching 
of molecular formula to metabolites present in the Human Metabolome Database219. 
 
Participant data collection 
The primary outcome was clinical pregnancy rate.  This was defined as the appearance of 
fetal heart activity at pelvic ultrasonography seven weeks after embryo transfer was 
performed.  Additionally, participant baseline characteristics (age, ethnicity, body mass 
index, smoking status), fertility history (cause and duration of infertility), IVF or ICSI 
treatment cycle variables (baseline early follicular phase follicular stimulating hormone, 
number of previous IVF treatments and outcomes, parity, index treatment [IVF or ICSI], 
treatment protocol, follicular stimulating hormone starting dose, total number of follicular 
stimulating hormone ampoules used, endometrial thickness at last follicle tracking 
ultrasound, number of oocytes retrieved, fertilisation rates, day of embryo transfer, and 
embryo quality) and biochemical pregnancy rate (positive pregnancy test two weeks after 
embryo transfer) were collected from patient hospital records seven weeks after each 
participant’s embryo transfer. 
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Results 
Endometrial fluid samples were collected on all 20 recruited participants.  As planned, the 
mock embryo transfer catheters were inserted into the endometrial cavity and then 
processed as described above.  Table 7 shows the demographic data of the cohort.  The 
pregnant and non-pregnant groups were similar in age, BMI, ethnicity and smoking status.   
No discomfort above what was experienced during the real embryo transfer was reported by 
any of the participants. 
All 20 participants had fertility treatment data collected, as there were no abandoned IVF or 
ICSI treatment cycles.  The flow of participants is shown in figure 15. Six women (30%) 
achieved a clinical pregnancy.  Additionally, one participant achieved a biochemical 
pregnancy, where a urinary pregnancy test performed two weeks after embryo transfer was 
positive, however a clinical pregnancy was not achieved.  We performed a univariate 
analysis comparing the IVF cycle characteristics between the pregnant and non-pregnant 
group (table 8).  This showed that the IVF cycle characteristics were comparable between 
the two groups.  The group of women that achieved clinical pregnancy and the group that 
did not were similar in duration of infertility, type of infertility (primary or secondary), cause 
of infertility, base line follicular stimulating hormone, treatment type (IVF or ICSI), starting 
dose of follicular stimulating hormone, number of follicular stimulating hormone ampoules 
administered, endometrial thickness at last monitoring ultrasound scan, the proportion that 
received a day five embryo transfer, the proportion of women having single or double 
embryo transfer, and the proportion of women having a top grade quality embryo 
transferred. 
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Parameter 
Clinical pregnancy outcome  
 
p-value 
Pregnant  
(n=6) 
Non-pregnant 
(n=14) 
 
Age-years(SD) 
 
32.8 (3.13) 
 
34.0 (4.35) 
 
0.562 
BMI  
24.3 (4.50) 
 
24.0 (3.76) 
 
0.866 
Ethnicity    
 
White(%) 
 
6/6 (100.0) 
 
3/14 (21.4) 
 
0.219 
 
South Asian (%) 
 
0/6 (0) 
 
11/14 (78.6) 
Smoking    
 
Non-smokers (%) 
 
3/3 (50.0) 
 
14/14 (100.0) 
 
0.061 
 
Smokers(%) 
 
3/3 (50.0) 
 
0/14 (0) 
Table 7: Patient demographic data – Endometrial fluid metabolomics profiling in 
women undergoing IVF treatment 
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Figure 18: Participant flow chart - Endometrial fluid metabolomics profiling in women undergoing IVF 
treatment 
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Table 8.  IVF cycle variables of pregnant and non-pregnant women  
 
 
IVF cycle parameter 
Clinical pregnancy outcome  
 
p-value 
 
Pregnant (n=6) 
 
Non-pregnant (n=14) 
Duration of infertility in 
months - Median (IQR) 
 
48 (36-72) 
 
42 (30-72) 
 
0.688 
Type of infertility    
Primary (%) 6/6 (100) 13/14 (92.9)  
0.752 Secondary (%) 0/6 (0) 1/14 (7.1) 
Cause of infertility    
Unexplained (%) 1/6 (16.7) 6/14 (42.9)  
 
 
0.420 
An ovulatory (%) 1/6 (16.7) 1/14 (7.14) 
Tubal disease (%) 2/6 (33.3) 2/14 (14.3) 
Diminished ovarian 
reserve (%)  
1/6 (16.7) 1/14 (7.14) 
Male factor (%) 1/6 (16.7) 4/14 (28.6) 
FSH (iU/ml) – mean (SD) 7.60 (2.05) 7.73 (3.78) 0.939 
Treatment type    
IVF (%) 4/6 (66.7) 8/14 (57.1)  
0.690 ICSI (%) 2/6 (33.3) 6/14 (42.9) 
Starting FSH dose    
150 or less (%) 2/6 (33.3) 6/14 (42.9)  
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225-300 2/6 (33.3) 3/14 (21.4) 0.941 
300 or more 2/6 (33.3) 5/14 (35.7) 
Number of FSH 
ampoules-mean (SD) 
 
48.2 (20.3) 
 
50.9 (17.1) 
 
0.757 
Endometrial thickness-
mean mm (SD) 
 
10.5 (1.54) 
 
11.0 (2.34) 
 
0.656 
Num. of oocytes 
retrieved- mean (SD) 
 
11.8 (4.96) 
 
10.1 (5.18) 
 
Embryo transferred on 
day 5 
   
No (%) 1/6 (16.7) 7/14 (50)  
0.163 Yes (%) 5/6 (83.3) 7/14 (50) 
Mean number of 
embryos transferred 
1.67 1.43 0.435 
Num. of embryo 
transferred 
 
 
 
 
 
 
Single embryo (%) 2/6 (33.3) 8/14 (57.1)  
0.329 Double embryo (%) 4/6 (66.7) 6/14 (42.9) 
Top grade embryo 
transfer  
   
No (%) 4/6 (66.7) 8/14 (57.1)  
0.690 Yes (%) 2/6 (33.3) 6/14 (42.9) 
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Endometrial fluid metabolomics analysis 
Sufficient bio-fluid was collected for metabolomic analysis in all 20 endometrial fluid samples 
collected from the participants.  The three control samples taken using unused embryo 
transfer catheters enabled baseline metabolomics profiling to be calibrated for 
metabolomics analysis of the study samples. 
 
Metabolomic analysis was performed in the study samples to identify statistically significant 
fold changes in metabolic concentrations of all metabolites found in the endometrial fluid 
samples.  Fold changes were detected by dividing the 20 participants by age (those above 
the age of 35 years and those below 35 years) and also by clinical pregnancy outcome.  This 
was conducted to ensure adequate blinding during sample metabolic analysis. 
 
Endometrial fluid analysis by age 
A total of 29 different metabolites were identified to have significant fold changes when 
metabolomics analysis was performed according to age group (Table 9).  The most significant 
fold change was a metabolite with the molecular formula C26H35NO7.  This produced a fold 
change of 35.97 (p<0.005).  Unfortunately, this metabolite is yet to be identified.  A further 
24 unidentified metabolites were also found to have significant` fold changes when 
participants were stratified according to their age.  A significant fold change of 0.420 
(p=0.03) is found in metabolite molecular formula C16H22O4, which represent 3-carboxy-
alpha-chromanol, 4-prenylphlorisovalerophenone or alpha-cyano-4-hydroxycinnamic acid.  
Similarly, a fold change of 4.09 (p=0.04) was found in metabolite C22H26O8 representing 
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syringaresinol (a lignan), euparotin acetate or liatrin (a lactone).  Triethanolamine 
(C6H15NO3), an organic amine, was found to have a fold change of 0.54 (p=0.05).  Lastly, 
didesmethyl tocotrienol (C25H36O2), which is an antioxidant, was found to have a fold 
change of 3.44 (p=0.05).  
  
Endometrial fluid analysis by IVF treatment outcome 
When the participants were stratified according to IVF treatment outcome, more 
metabolites were identifiable when compared with analysis by age (table 10).  A total of 33 
metabolites were found to have a significant fold change.  Of these 26 were identifiable.  The 
metabolite with the most statistically significant fold change of 1.71 (p=0.001) is currently 
unidentified.  Six further unidentified metabolites also showed significant fold change 
differences between participants who achieved clinical pregnancy versus those that did not.  
Identified metabolites with significant fold changes between the two reproductive outcome  
groups included those with the following molecular formulae; C8H8O2, C11H14O3, C5H8O2, 
C13H22O, C10H16O2, C13H22O, C10H18O3, C8H6O2, C5H12O4, C12H22O2, C4H10O3, 
C12H22O3, C8H14O, C4H10O3, C12H24O3, C16H26O, C7H14O5, C13H22O, C7H6O2, 
C10H16O2, C17H26O2, C16H24O2, C10H14O, C5H8O3, C3H4O and C7H12O.  The 
metabolites that these molecular formulae represent can be grouped into aromatic 
compounds (such as Toluate, Phenylacetic acid, hydroxyacetophenone and 3,4- 
Dihydroxystyrene), short chain organic acids (angelic acid, tiglic acid and seneciocic acid), 
carbohydrates (D-apiitol), fatty alcohols (hexadecatrienal) and fatty acids (hydroxyl-
dodecenoic acid and oxo-dodecenoic acid). 
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Table 9: Metabolite fold changes stratified by age (>35 years and <35 years)– Endometrial fluid metabolomics profiling in women 
undergoing IVF treatment 
 
Metabolite ID Fold change p-value Ion type Molecular formula Metabolite(s) 
474.2481 35.966 0.0048481 [M+H]+ C26H35NO7 currently unidentified 
342.29225 2.41 0.014544     currently unidentified 
450.3783 0.30557 0.014544     currently unidentified 
450.8801 2.9829 0.014544     currently unidentified 
476.3345 2.9635 0.014544     currently unidentified 
486.9088 3.2925 0.014544     currently unidentified 
522.93755 3.5893 0.014544     currently unidentified 
558.4645 3.824 0.014544     currently unidentified 
283.11735 3.9615 0.0202     currently unidentified 
83.0489 0.44901 0.027311     currently unidentified 
301.1407 0.42008 0.027311 [M+Na]+ C16H22O4 3'-carboxy-alpha-chromanol; 
4-prenylphlorisovalerophenone; 
Alpha-CEHC 
427.1338 0.60273 0.027311     currently unidentified 
427.1426 0.61657 0.027311     currently unidentified 
149.0231 0.79709 0.036522     currently unidentified 
277.1407 2.784 0.036522     currently unidentified 
332.3308 4.5399 0.036522     currently unidentified 
419.1696 4.0941 0.036522 [M+H]+ C22H26O8 (+)-Syringaresinol; 
Euparotin acetate; 
Liatrin 
 
440.3058 3.903 0.036522     currently unidentified 
96.9215 0.50877 0.047673     currently unidentified 
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98.9186 0.5108 0.047673     currently unidentified 
104.9926 0.14444 0.047673     currently unidentified 
150.1123 0.54394 0.047673 [M+H]+ C6H15NO3 Triethanolamine 
238.8803 0.4788 0.047673     currently unidentified 
285.1822 0.64852 0.047673     currently unidentified 
387.3082 4.6537 0.047673     currently unidentified 
391.26025 3.4399 0.047673 [M+Na]+ C25H36O2 didesmethyl tocotrienol 
441.1515 2.4852 0.047673     currently unidentified 
492.9597 0.64128 0.047673     currently unidentified 
530.981 2.9712 0.047673     currently unidentified 
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Table 10: Metabolite fold changes stratified by clinical pregnancy outcome – Endometrial fluid metabolomics profiling in women 
undergoing IVF treatment 
Metabolite ID Fold change p-value Ion type Molecular formula Metabolite(s) Type of metabolite 
109.1009 1.7175 0.0019392 UNIDENTIFIED UNIDENTIFIED unidentified Other 
137.0595 1.3712 0.010343 [M+H]+ C8H8O2 Hydroxyacetophenone 
3,4-Dihydroxystyrene 
3-methoxybenzaldehyde 
3-Methylsalicylaldehyde 
3-Vinylcatechol 
4-Hydroxyphenylacetaldehyde 
Benzylformate 
methylbenzoate 
o-Toluate 
p-Anisaldehyde 
Phenylacetic acid 
Toluate 
Aromatic compounds 
195.1014 1.4288 0.010343 [M+H]+ C11H14O3 unidentified Other 
101.0594 1.6464 0.010343 [M+H]+ C5H8O2 2-Ethylacrylic acid 
3-methyl-4-cis-hydroxy-2-butenal 
3-Methylbutyrolactone 
5-Valerolactone 
Allyl acetic acid 
Angelic acid 
beta-ethyl acrylic acid 
beta-penteic acid 
Isopropenylacetic acid 
Methyl methacrylate 
Pentane-2,4-dione 
Senecioic acid 
Tiglic acid 
Short chain organic 
acids 
212.20075 1.7683 0.010343 [M+NH4]+ C13H22O unidentified Other 
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169.1222 1.5264 0.014544 [M+H]+ C10H16O2 (+)-exo-5-Hydroxycamphor 
(+)-Iridodial 
(1S,4R)-1-Hydroxy-2-oxolimonene 
6-Isopropenyl-3-methyl-2-oxo-oxepanone 
Isopropenyl-7-methyl-2-oxo-oxepanone 
(Z)-3,5-Hexadienyl butyrate 
1,2-Campholide 
decadienoic acid 
8-Epiiridodial 
Aleprestic acid 
Ascaridole 
Chrysanthemic acid 
cis, cis-stillingic acid 
cis-2-Methyl-5-isopropylhexa-2,5-dienoic 
acid 
Diosphenol 
Geranic acid 
hydroxy-beta-cyclocitral 
Iridodial 
Iridomyrmecin 
Lilac aldehyde 
nerolate 
Tiglyl tiglate 
trans, cis-stillingic acid 
trans-2-Methyl-5-isopropylhexa-2,5-
dienoic acid 
Mixed classes 
217.0057 1.6955 0.014544 UNIDENTIFIED UNIDENTIFIED unidentified Other 
195.1742 1.8669 0.014544 [M+H]+ C13H22O unidentified Other 
187.1327 1.8956 0.014544 [M+H]+ C10H18O3 (2s,4s)-Alpha-Campholinic Acid 
6-Hydroxy-3-isopropenyl-heptanoate 
6-Hydroxy-5-isopropenyl-2-
methylhexanoate 
1,3S-dihydroxy-8E-decen-5-one 
hydroxy-decenoic acid 
Oxodecanoic acid 
Short/medium chain 
organic acids 
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135.0439 1.9834 0.014544 [M+H]+ C8H6O2 Octene-2,4-diynoic acid 
phenylglyoxal 
Mixed classes 
159.0626 2.0631 0.014544 [M+Na]+ C5H12O4 D-Apiitol Carbohydrate 
199.1691 1.4307 0.0202 [M+H]+ C12H22O2 Menthyl acetate 
dodecenoic acid      
Citronellyl acetate 
Linderic acid 
methyl-undecenoic acid 
Mixed classes 
107.07 1.4477 0.0202 [M+H]+ C4H10O3 Diethylene glycol Other 
215.164 1.4707 0.0202 [M+H]+ C12H22O3 hydroxy-dodecenoic acid 
oxo-dodecanoic acid 
Fatty acids 
127.1115 1.8203 0.0202 [M+H]+ C8H14O octenal 
Sulcatone 
Mixed classes 
124.0966 1.3475 0.027311 [M+NH4]+ C4H10O3 Diethylene glycol Other  
217.1796 1.3569 0.027311 [M+H]+ C12H24O3 hydroxy-dodecanoic acid Fatty acid 
235.20545 1.6544 0.027311 [M+H]+ C16H26O hexadecatrienal Fatty alcohol 
201.0732 1.9934 0.027311 [M+Na]+ C7H14O5 Methyl Fucose 
beta-D-Digitalopyranose 
D-Thevetose 
Carbohydrate 
217.1561 2.1261 0.027311 [M+Na]+ C13H22O unidentified Other 
238.9821 0.41094 0.036522 UNIDENTIFIED UNIDENTIFIED unidentified Other 
321.1491 0.41168 0.036522 UNIDENTIFIED UNIDENTIFIED unidentified Other 
123.0438 1.3623 0.036522 [M+H]+ C7H6O2 Hydroxybenzaldehyde 
Benzoate 
Salicylaldehyde 
Tropolone 
Aromatic compounds 
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186.1487 1.4917 0.036522 [M+NH4]+ C10H16O2 (+)-exo-5-Hydroxycamphor 
(+)-Iridodial 
(1S,4R)-1-Hydroxy-2-oxolimonene 
6-Isopropenyl-3-methyl-2-oxo-oxepanone 
4-Isopropenyl-7-methyl-2-oxo-oxepanone 
(Z)-3,5-Hexadienyl butyrate 
1,2-Campholide 
decadienoic acid 
6-Oxocineole 
8-Epiiridodial 
Aleprestic acid 
Ascaridole 
Chrysanthemic acid 
cis, cis-stillingic acid 
cis-2-Methyl-5-isopropylhexa-2,5-dienoic 
acid 
Diosphenol 
Geranic acid 
hydroxy-beta-cyclocitral 
Iridodial 
Iridomyrmecin 
Lilac aldehyde 
nerolate 
Tiglyl tiglate 
trans, cis-stillingic acid 
trans-2-Methyl-5-isopropylhexa-2,5-
dienoic acid 
Mixed classes 
173.1171 1.6182 0.036522 UNIDENTIFIED UNIDENTIFIED unidentified Other 
263.2003 1.3133 0.047673 [M+H]+ C17H26O2 heptadecadiynoic acid Fatty acids 
249.1847 1.3196 0.047673 [M+H]+ C16H24O2 hexadecatetraenoic acid 
4-[3]-ladderane-butanoic acid 
Fatty acids 
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151.1116 1.3957 0.047673 [M+H]+ C10H14O (-)-Isopiperitenone 
(+)-menthofuran 
(+)-Sabinone 
2,4,7-decatrienal 
2-sec-Butylphenol 
2-tert-Butylphenol 
3-tert-Butylphenol 
4-Isopropyl-3-methylphenol 
4-n-Butylphenol 
4-sec-Butylphenol 
4-tert-Butylphenol 
adamantanone 
Carvacrol 
Chrysanthenone 
Isopiperitenone 
Menthofuran 
Myrtenal 
p-Cumic alcohol 
Perillyl aldehyde 
Pinocarvone 
Piperitenone 
safranal 
Thymol 
Umbellulone 
Verbenone 
Mixed classes 
227.164 1.4805 0.047673 UNIDENTIFIED UNIDENTIFIED unidentified Other 
139.0364 1.6766 0.047673 [M+Na]+ C5H8O3 2-Methylacetoacetic acid 
Oxopentanoic acid 
3-Methyl-2-oxobutanoic acid 
Levulinic acid 
Methylacetoacetic acid 
Tetrahydrofuran-2-Carboxylic Acid 
Short chain organic 
acids 
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74.0597 1.7283 0.047673 [M+NH4]+ C3H4O 2-Propyn-1-ol 
Acrolein 
Mixed classes 
113.0958 1.9514 0.047673 [M+H]+ C7H12O 2-Cyclopropylmethylenepropanal 
heptenal 
Mixed classes 
225.102 3.7061 0.047673 UNIDENTIFIED UNIDENTIFIED unidentified Other 
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Discussion 
This small cohort study shows that the metabolic profile of endometrial fluid collected at the 
time of embryo transfer is different in women who achieve pregnancy compared to women 
who do not achieve pregnancy from IVF treatment. 
 
Review of the published literature shows that this is the first study of its type.  No other 
study has ever been performed to use metabolomics testing in the endometrial fluid of 
women undergoing IVF treatment.  Other studies have used metabolomics in IVF patients in 
the past, however metabolomics profiling was conducted on spent embryo culture fluid or 
follicular fluid collected at the time of oocyte retrieval220–222.   
 
As this is a small cohort study of 20 women, firm conclusions cannot be drawn from the 
results. However, this study demonstrates that it is possible to sample endometrial fluid at 
the time of embryo transfer from women undergoing IVF using a mock embryo transfer 
catheter inserted into the uterine cavity immediately prior to embryo transfer. Importantly, 
the technique used to sample endometrial fluid appears to be safe, with the 20 women 
studied achieving a clinical pregnancy rate (30%) that is representative of the overall IVF and 
ICSI treatment success rates at the Birmingham Women’s Fertility Centre. This suggests that 
the endometrial fluid sampling used in this study does not adversely affect the reproductive 
treatment outcomes of women undergoing the sampling.  The safety exhibited in this cohort 
study supports what has been demonstrated by other author groups who have also sampled 
endometrial fluid at the time of embryo transfer161,195,196.  Most excitingly, the study shows 
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that the small volume of fluid, in the order of microliters, collected by passing a mock 
embryo transfer catheter trans-cervically into the uterine cavity is suitable for metabolomics 
analysis, with all recruited participants’ endometrial fluid samples yielding data.  All of the 
above suggests that the technique used for collection of endometrial fluid could represent a 
clinically useful method of studying the endometrial factor in embryo implantation. 
 
The data yielded from this study demonstrates significant differences in the fold changes of 
metabolites in the endometrial fluid from women achieving pregnancy versus the 
endometrial fluid in the women that did not get pregnant.  This is despite the demographic 
data and the IVF treatment cycle variables of the pregnant and non-pregnant groups being 
comparable.  Of particular note, statistically significant differences in fatty acid and 
carbohydrate concentrations were found in the two groups.  One potential explanation for 
this may be the difference in energy substrate required for the metabolism of an implanting 
or non-implanting embryo.  It has been well described that an implanting embryo must be 
metabolically quiet. Implantation is most likely to be achieved, if the metabolic processes 
within the embryo are occurring at a lower rate compared to embryos with higher metabolic 
rates223–225.  Given that the endometrium plays a key role in implantation, the differences in 
metabolic substrate seen in the endometrial fluid could represent the contrast between an 
endometrial environment that is amenable to embryo implantation and one that is not.   
 
Previous studies that have reported the collection of endometrial fluid at the time of embryo 
transfer have analysed the fluid for immune biomarker assays195,196.  Significant differences 
were seen in the mean concentration of individual immune mediators.  IL-1β and TNF-α 
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were found to be predictive of pregnancy whereas a significant negative correlation was 
found between monocyte chemotactic protein-1 and embryo implantation195.  Although 
these results are exciting, the search for an individual biomarker that is predictive of IVF 
treatment outcome is likely to represent an over-simplification of the endometrial fluid 
properties that would be conducive to embryo implantation.  It is more likely that a systems 
biology approach to identify a panel or profile of biomarkers will eventually be clinically 
useful. 
 
In the present study, significant differences in metabolite profile were also seen when the 20 
participants were divided in to two groups according to their age.  Importantly, it should be 
noted that the use of mass spectrometry in any analytical process is very sensitive and this is 
the likely reason that the significant fold changes in the metabolites were demonstrated 
when age was stratified.  Very significant p-values (<0.005) must be used for data 
interpretation when using liquid chromatography and mass spectrometry as there is always 
an inevitably high false discovery rate226.  However, the effect that age has on the fold 
changes of metabolites could be a significant finding in itself.  In older women undergoing 
IVF treatment, one of the main focuses of clinical management is to reduce the effects of 
ageing ova on reproductive treatment outcomes.  Older oocytes are more likely to hold 
chromosomal abnormalities leading to abnormal fertilisation and failed implantation227.  This 
is why in older women, who have had previously unsuccessful attempts at IVF treatment, 
the option of acting as an ova recipient (using the oocytes from a younger egg donor) is 
offered.  The significance in the differences in the endometrial fluid collected from older 
women compared to younger women undergoing IVF treatment should not just be 
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dismissed and attributed to the use of highly sensitive mass spectrometry.  One may argue 
that the difference in endometrial fluid metabolome between the two age groups may in 
fact be a product of the effect of age on the endometrium itself. 
 
Metabolomics is a relatively new format of systems biology.  Great advances have been 
made in the systems biology field of genomics, whereas metabolomics is relatively more 
junior in its development as a field of science.  Because metabolomics is still an omics 
discipline that is still developing, many of the metabolites that have significant fold change 
differences between the pregnant group and the non-pregnant group, seen in this cohort 
study, are still to be identified.  In fact, the metabolite demonstrating the greatest fold 
change with the highest level of statistical significance between the pregnancy outcome 
groups remains unidentified.  Furthermore, at certain selected mass and charges, there are 
multiple compounds that the metabolite could represent.  Therefore, more work must be 
performed to improve the metabolome library before mechanistic research can be 
conducted to understand the biological mechanisms by which the change in metabolites 
affects reproductive treatment outcomes when endometrial fluid is studied in this context. 
 
Future work in this field would involve the use of a much larger sample size.  This would 
allow more confidence in the identification of potential metabolite profiles that are 
predictive of fertility treatment success.  After this biomarker discovery phase, targeted 
metabolomics could then be conducted to verify that the putative metabolite profile was 
indeed predictive of IVF success or failure.  Another potential research direction could be to 
study the metabolomics of endometrial fluid of fertile women who are ovulating 
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physiologically.  This could allow the identification of a pattern of metabolites that appear 
during the physiological implantation window that may become the target to mimic in 
women undergoing IVF treatment.  
 
In summary, although the results of this cohort study are unable to suggest a clinically useful 
metabolome of endometrial fluid predictive of IVF treatment outcome, promising results 
have been achieved.  Further research in this area may unlock the exciting potential in the 
understanding of implantation.  Additionally, if a predictive endometrial fluid metabolome 
can be identified, this could be a great aid to all infertile women and reproductive medicine 
physicians in the future, by assisting in the decision making required for successful embryo 
transfer.  
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CHAPTER 7: SALPINGOSTOMY IN THE TREATMENT OF HYDOSALPINX 
– A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
This work has been published in Human Reproduction30 (see appendix 10) 
Chu J, Harb HM, Gallos ID, Dhillon R, Al-Rshoud FM, Robinson L, Coomarasamy A. 
Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis.  
Hum Reprod. 2015 Aug; 30(8):1882-95.   
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Introduction 
Female infertility can be caused by a number of different pathologies.  Fallopian tubal 
disease is the causative factor in female infertility in roughly one quarter of these 
patients228.  The vast majority of infertility caused by tubal disease is the consequence of 
ascending infection from sexual transmitted infections (such as Chlamydia trachomatis and 
Neisseria gonorrhoeae).  The ascending infection leads to infection and subsequent 
inflammation in the pelvis causing pelvic inflammatory disease (PID)229. Unfortunately, if PID 
is untreated, it may lead to chronic inflammation of the fallopian tubes.  Distal tubal 
inflammation can cause obstruction to the distal tube, which then causes fluid to collect 
inside the tubal lumen.  This is called hydrosalpinx and can be diagnosed by 
hysterosalpingogram, ultrasound or at laparoscopy. 
 
Current research evidence suggests that hydrosalpinx should be treated before the use of 
IVF or ICSI treatment.  Treatment involves sterilizing surgery, which can involve placing clips 
to the fallopian tubes (tubal occlusion) or removing the hydrosalpinges altogether 
(salpingectomy).  If this surgical treatment is not undertaken, hydrosalpinx approximately 
halves the chance of successful IVF treatment and clinical pregnancy230–242.  How 
hydrosalpinx causes this deleterious effect on IVF treatment outcome is not fully 
understood.  However, it is thought that the hydrosalpingeal fluid exerts two effects on the 
embryo that is transferred into an endometrial cavity that is affected by this fluid.  The first 
effect is that the hydrosalpingeal fluid is toxic to the embryo, reducing the chances of the 
embryo adhering to the endometrium to achieve implantation231,243.  The second effect is 
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more mechanical, it is postulated that the fluid within the fallopian tubes can wash the 
embryo out of the endometrial cavity, thereby causing failed IVF treatment232.     
 
Prior to the widespread availability of IVF and ICSI treatment for tubal infertility, 
reproductive surgeons corrected tubal disease.  Tubal surgery was a specialised domain of 
gynecological surgery with reconstruction and normalisation of tubal anatomy the goal.  
Tubal surgery was delicate and placed emphasis on minimizing trauma to fallopian tissue to 
preserve tubal function.  Great importance was also placed on haemostasis to reduce the 
risk of adhesions post-surgery, which may in turn cause further tubal obstruction.   Tubal 
surgeons performed peri-tubal adhesiolysis to free fallopian tubes of scarring, fimbriostomy 
to correct mild distal fallopian tube obstruction and salpingostomy in more severe forms of 
hydrosalpinx233,244–246. 
 
As the use of IVF and ICSI has increased and its availability has widened, tubal surgery such 
as those listed above have become less common.  In more severe tubal disease, which has 
caused tubal infertility, the preference has shifted to performing sterilising surgery, such as 
salpingectomy and tubal occlusion, to ensure that hydrosalpingeal fluid is kept separate 
from the endometrial cavity where the embryo is transferred.  This ensures that the fluid 
cannot have its embryotoxic and mechanical washout effects.  Indeed, there is evidence that 
using these sterilising surgical techniques doubles the chances of IVF or ICSI success28,232,247.  
Consequently, it has now become common clinical practice in reproductive medicine to 
perform sterilising surgery prior to the initiation of IVF and ICSI treatment when hydrosalpinx 
has been identified.   
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The main disadvantage of sterilising surgery is that the patient with bilateral hydrosalpinges 
(where bilateral tubal disconnection or bilateral salpingectomy is performed) is then reliant 
on IVF or ICSI treatment for all future attempts at achieving pregnancy. There is no option to 
ever try for natural conception after sterilising surgery unless the couple self-funds a tubal 
re-anastamosis, which may not even be possible. As the funding restrictions in the UK mean 
that many couples are only eligible to one cycle of IVF or ICSI treatment, many women with 
hydrosalpinx may be left with very few therapeutic options to become pregnant if the IVF or 
ICSI cycle should fail.  Even if the one funded IVF or ICSI treatment is successful, couples are 
required to fund further cycles of treatment if they wish to have more children.    
 
An alternative management strategy, which conserves a patient’s fallopian tubes by 
correcting tubal pathology, would be to perform salpingostomy followed by a trial of natural 
conception.  If pregnancy is not achieved, women can then be offered IVF treatment with or 
without sterilising surgery.  
 
The aim of this systematic review was to investigate the chances of natural pregnancy after 
salpingostomy is performed for hydrosalpinx.   Furthermore, the aim was also to explore the 
chances of live birth, miscarriage and ectopic pregnancy after salpingostomy treatment of 
hydrosalpinx. 
 
163 
 
Methods 
Literature Search  
The population of interest consisted of women who underwent salpingostomy for 
hydrosalpinx.  The primary outcome of interest was natural clinical pregnancy.  Secondary 
outcome measures included live birth rates, ectopic pregnancy and miscarriage rates in 
women that had undergone salpingostomy for hydrosalpinx.  
 
A literature search strategy was developed based on the following key words and/or MeSH 
terms: tubal surgery, salpingectomy, salpingostomy, in vitro fertilisation, intracytoplasmic 
sperm injection, assisted reproductive techniques, hydrosalpinx, fallopian tube disease and 
pregnancy.  The search strategy was used on several electronic medical literature databases 
including: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL 
(from inception to March 2015).  The reference lists of all primary research study articles and 
review articles were examined to ensure that all relevant articles that were not captured by 
the electronic medical literature database searches.  No language restrictions were applied 
in any of the searches or study selection. 
 
Study Selection 
Criteria for inclusion in the study were established prior to the literature search.  In 
particular, studies that reported the reproductive outcomes of women that had undergone 
salpingostomy for hydrosalpinx were included. Studies that did not explicitly report results 
from salpingostomy for hydrosalpinx were excluded.  In particular, we excluded studies that 
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did not provide clarity in their description of the surgical treatment performed and those 
studies that did not report specifically on salpingostomy.  Additionally, studies that did not 
report on the primary outcome of natural clinical pregnancy were also excluded.     
 
Study selection was carried out by four independent reviewers.  Firstly, the titles and 
abstracts of research articles identified by the electronic searches were examined.  Each title 
and abstract were included or excluded independently according to the predefined inclusion 
and exclusion criteria; any disagreements regarding inclusion were resolved by a further 
reviewer.  The full manuscripts of the titles and abstracts that were considered to be 
relevant for inclusion were obtained.  In cases of duplicate publication, the most recent and 
complete versions were selected.   
 
Data were extracted from full manuscripts by two independent reviewers. 
 
Validity Assessment 
Validity assessment was performed by two reviewers who completed the quality assessment 
independently. The Newcastle-Ottawa Quality Assessment Scales for Observational studies 
were used to ensure that each study was of good quality. The Newcastle-Ottawa Quality 
Assessment Scale for Observational studies quality checklist awards one star as maximum 
for all items except comparability where a maximum of two stars can be awarded. An 
arbitrary score was used based on the assumption of equal weight of all items included in 
the Newcastle-Ottawa Scale. This score was used to give a quantitative appraisal of overall 
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quality of the individual studies. The total score ranged from 0 to 9, with a score of either 0 
or 1 for each item.  
 
From each included study, relevant outcome data were extracted by two reviewers 
independently. 
 
Statistical Analysis 
The clinical pregnancy, ectopic pregnancy, live birth and miscarriage rates were extracted 
from each of the included studies.  The log of the ratio and its corresponding standard error 
for each study was computed.  Meta-analysis using inverse-variance weighting was 
performed to calculate the random-effects summary estimates. The square root of this 
number is the estimated SD of the underlying effects across studies. Because we had relative 
measures of effect, the confidence intervals were centered on the natural logarithm of the 
pooled estimate and the limits exponentiated to obtain an interval on the ratio scale. Forest 
plots were created for each outcome, showing individual study proportions with confidence 
intervals (CIs) and the overall DerSimmonian-Laird pooled estimate. Heterogeneity of the 
treatment effects was assessed graphically with forest plots and statistically analysed using 
the χ2 test. Statistical analyses were performed using Stata 12.0 (StataCorp, College Station, 
TX). 
 
Lastly, we performed a stratified analysis splitting studies from 1972 to 1999 and from 2000 
to 2014 to explore the temporal effects on clinical pregnancy rates.  
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Results 
The PRISMA flow diagram52,53 of the review process is presented in figure 16.  The search 
strategy yielded 14396 citations from the electronic databases.  Of these, 14231 publications 
were excluded because it was clear from the title or abstract that they were not relevant to 
the search criteria outlined above. Therefore, full manuscripts of 165 articles were retrieved. 
One hundred and forty-three of these publications were excluded because 63 were review 
articles, opinion letters, case reports or questionnaires; two were duplicate articles; 17 
articles did not specify the nature of the tubal disease and 46 performed tubal surgeries 
other than salpingostomy e.g. salpingectomy, essure or transvaginal drainage of 
hydrosalpinx; six reported outcomes that were not of interest e.g. ovarian response after 
tubal surgery or endometrial receptivity; two articles reported salpingostomy in the IVF 
population and seven articles reported data that could not be extracted.  The remaining 22 
articles were suitable for inclusion into this review244,246,248–267.  All of these articles were 
observational in design. 
 
Study characteristics 
The study characteristics of the 22 articles are presented in table 11.  The earliest date of 
publication was 1972.  The most recent article was published in 2014.  There was also 
variation in sample size; the smallest sample size was 10, the publication with the largest 
sample size presented results from 467 women.  
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Figure 19. Study selection for review on salpingostomy treatment for hydrosalpinx and natural conception 
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Table 11. Study characteristics of included studies for review on salpingostomy treatment for hydrosalpinx and natural conception 
Author 
(year) 
Study 
design 
 
Study 
population 
 
Age of study 
population 
Method of 
diagnosis 
Salpingostomy 
group 
Unilateral 
or bilateral 
disease 
Classification of 
hydrosalpinx 
Surgical 
technique 
Outcomes 
(pregnancy rate) 
Duration 
of follow 
up 
Cumulative pregnancy data Mean time 
to 
conception 
Audebert et 
al., (1980) 
Retrospective 
Cohort 
172 
patients 
with 
hydrosalpin
x 
1976-1979 
France 
Range 20-40 
years 
laparoscopy 96 
salpingostomy 
to ampulla, 
isthmic, type 1 
and type 2. 
 
Mixture  
 
By stage of 
hydrosalpinx 
Laparotomy 
and 
microsurgery 
IUP 29/96 (30.2%) 24 months  
  
1-3 month 1/96 (1.0%) 
4-6 months 7/96 (7.3%) 
7-9 months 14/96 (14.6%) 
10-12 months 22/96 (22.9%) 
12-23 months 27/96 (28.1%) 
At 24 months 29/96 (30.2%) 
Not 
reported 
Audebert et 
al., (2014) 
Retrospective 
Cohort 
434 
patients 
with distal 
tubal 
occlusion 
1988-2000 
France 
Range 21-42 
years 
HSG and 
laparoscopy 
434 patients 
underwent 
everting 
neosalpingosto
my 
Mixture Classified 
according to 
mucosal 
appearances and 
adhesions  
Laparoscopy IUP 125/434 
(28.8%) 
LBR 106/434 
(24.4%) 
EP 43/434 (9.9%) 
60 months At 10 months half of all IUP 
achieved 
At 21 months three quarters 
of all IUP achieved 
Specific numbers not 
reported 
Not 
reported 
 Bayrak et al., 
(2006) 
Retrospective 
Cohort 
40 patients 
hydrosalpin
ges  
1999-2002 
USA 
Mean age 
35.5+/-5.5 years 
 
Range 21-42 
years 
HSG 40 patients 
underwent cuff 
salpingostomy 
Authors noted 
high age of 
study 
population. 
Bilateral 
30/40 
(75.0%)  
Unilateral 
10/40 
(25.0%)  
By size of the 
hydrosalpinx, 
presence of rugae 
and adhesions. 
Laparoscopy 
32/40 (80.0%)  
 
Laparotomy 
8/40 (20.0%) 
IUP 2/40 (5.0%) 
EP 1/40 (2.5%) 
22 months 
 
At 4 months IUP 1/40 (2.5%) 
At 7 months IUP 2/40 (5.0%) 
At 22 months IUP 2/40 
(5.0%) 
Not 
reported 
Beyth et al., 
(1982) 
Retrospective 
Cohort 
31 patients 
with 
hydrosalpin
x 
1976-1979 
Israel 
Range 20-
43years 
 
HSG and 
laparoscopy 
31patients 
underwent 
salpingostomy 
Mixture By size of 
hydrosalpinx 
Laparotomy 
and 
microsurgery 
 
 
IUP 5/31 (16.1%) 42 months Not reported Not 
reported 
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Boer-Meisel 
et al., (1986) 
Retrospective 
Cohort 
108 
patients 
with 
hydrosalpin
x tubal 
infertility 
1974-1981 
The 
Netherland
s 
Mean age 27.5 
years 
 
Range 20-40 
years 
HSG and 
laparoscopy 
108 patents 
underwent 
terminal 
salpingostomy  
Mixture 
 
Bilateral 
74/108 
(68.5%)  
Unilateral 
34/108 
(31.5%)  
Classified by size 
of hydrosalpinx, 
thickness of tubal 
wall and condition 
of endosalpinx 
Laparotomy  IUP 50/108 
(46.3%) 
term pregnancy 
24/108  (22.2%) 
EP 19/108 (17.6%) 
miscarriage 7/108 
(6.5%) 
Unable to 
extract 
data 
Not reported Not 
reported 
(only 
median 
time of 
10.5 cycles 
reported) 
Bontis et al., 
(2000) 
Retrospective 
cohort 
258 
patients 
with 
hydrosalpin
x  
Greece 
Not reported Not reported 258 patients 
underwent 
surgery for 
salpingostomy 
Not 
reported 
Classified by 
degree of severity 
Stages I-IV 
39/258 (15.1%) 
patients 
laparoscopy 
 
219/258 
(84.9%) 
patients 
laparotomy and 
microsurgery 
IUP 44/258 
(17.1%)  
EP 23/258 (8.9%)  
 36 months 
 
At 36 months 
IUP 44/258 (17.1%) 
Not 
reported 
Channelles et 
al., (2011) 
Retrospective 
Cohort to 
assess a 
management 
protocol 
81 patients 
with 
hydrosalpin
x managed 
with a tubal 
surgery 
protocol 
2003-2007 
France 
Mean age 32.6 
years +/- 4.7 
years 
HSG or USS 
and 
laparoscopy 
10 patients 
underwent 
unilateral 
salpingostomy 
 
Unilateral Classified by 
mucosal and tubal 
stages I-IV 
Not reported IUP 3/10 (30%)  12 months 
 
At 12 months 
IUP 3/10 (30%) 
2 months 
Chong et al., 
(1991) 
 
Retrospective 
Cohort 
34 patients 
with 
bilateral 
hydrosalpin
x 
1982-1988 
USA 
Mean age 30.2 HSG 19 patients 
underwent cuff 
technique 
salpingostomy 
15 patients 
underwent 
Bruhat 
technique 
salpingostomy 
Bilateral Not reported Laparotomy  
and 
microsurgery 
IUP  9/34 (26.5%)  
EP 2/34 (5.9%)  
Not 
reported 
No reported Not 
reported 
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Cohen et al., 
(1972) 
Retrospective 
cohort 
706 
patients 
undergoing 
tubal 
surgery 
France 
Not reported Not reported 188 patients 
underwent 
unilateral 
salpingostomy:  
70 terminal 
salpingostomy 
 68 medio-
ampullar 
salpingostomy. 
 
279 patients 
underwent 
bilateral 
salpingostomy:  
104 terminal 
salpingostomy, 
122 medio-
ampullar 
salpingostomy. 
 
Mixture  
 
Bilateral 
188/467 
(40.3%) 
Unilateral 
279/467 
(59.7%) 
Not reported Laparotomy IUP 89/467 
(19.1%)  
EP 46/467 (9.9%) 
18 months 
  
At 18 months 
IUP 89/467 (19.1%) 
Not 
reported 
Dubuisson et 
al., (1994) 
Retrospective 
cohort 
81 infertile 
women 
with 
hydrosalpin
x  
1986-1991 
France 
Mean age 
30.1+/-4.7 years 
 
Range 20-39 
years 
HSG 81 women 
underwent 
unilateral or 
bilateral 
salpingostomy 
Mixture  
 
Bilateral 
39/81 
(48.1%)   
Unilateral 
42/81 
(51.9%) 
Classified by 
severity of 
disease. Stages I-
IV 
Laparoscopic 
salpingostomy 
IUP 26/81 (32.1%) 
EP 4/81 (4.9%)  
24 months 
  
 
IUP cumulative 
At 12 months 26.4% 
At 18 months 28.7% 
At 24 months 29.8% 
Not 
reported 
Dubuisson et 
al., (1995) 
Retrospective 
cohort 
123 
infertile 
women 
with 
hydrosalpin
x 
1986-1993 
Mean age 
28.5+/-4.9 years 
 
Range 19-39 
years 
 
HSG 123 underwent 
laparoscopic 
salpingostomy 
 
Not 
reported 
Classified by 
severity of 
disease. Stages I-
IV 
Laparoscopic 
salpingostomy 
IUP 34/123 
(30.4% ) 
EP 9/123 (8%)  
 
Over 24 
months 
IUP cumulative  
23.5% at 12 months 
26.0% at 15 months 
27.7% at 18 months 
28.6% at 24 months 
Not 
reported 
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Jansen et al., 
(1980) 
Retrospective 
cohort 
107 
patients 
with 
hydrosalpin
x 
1966-1975 
Australia 
 
All patients <40 Not reported 91 patients 
underwent 
bilateral 
salpingostomy 
16 patients 
underwent 
unilateral 
salpingostomy  
Mixture 
 
Bilateral 
91/107 
(85.0%) 
Unilateral 
16/107 
(15.0%)  
 
Not reported Laparotomy IUP 24/107 
(22.4%) 
Unable to 
extract   
Unable to extract Unilateral 
salpingosto
my 104 
weeks 
Bilateral 
salpingosto
my 61 
weeks 
Kosasa et al., 
(1988) 
 
Retrospective 
cohort 
93 patients 
with  
hydrosalpin
x  
1981-1986 
Hawaii 
Mean age 31 
years 
 
Range 21-39 
years 
Laparoscopy 93 patients 
underwent 
microsurgical 
everting 
salpingostomy 
Mixture 
 
Unilateral 
27/93(29.0
%) 
Bilateral 
66/93 
(71.0%) 
Not reported Laparotomy 
and 
microsurgery 
Term pregnancy 
34/93 (36%) 
EP 13/93 (14%) 
Miscarriage 3/93 
(3%) 
Not 
reported 
Not reported Not 
reported 
Mage et al., 
(1983) 
Retrospective 
cohort 
68 patients 
with 
hydrosalpin
x 
1977-1981 
France 
Range 20-38 
years 
HSG and 
laparoscopy 
30 patients 
underwent 
salpingostomy 
by 
electrosurgery 
38 patients 
underwent 
salpingostomy 
by CO2 laser 
Mixture  Not reported Laparotomy 
and 
microsurgery 
Term pregnancy 
14/68 (20.6%) 
EP 6/68 (8.8%) 
Miscarriage 3/68 
(4.4%) 
Not 
reported 
Not reported Not 
reported 
McComb et 
al., (2001)  
Retrospective 
cohort 
23 patients 
with 
unilateral 
hydrosalpin
x and a 
patent 
contralater
al fallopian 
tube 
1988-1997 
Canada 
Mean age 31.9 
years 
 
Range 25-39 
years 
Laparoscopy 23 Unilateral 
salpingostomy 
underwent 
laparoscopic 
salpingostomy 
 
18salpingostom
ies sutured, 5 
not sutured 
Unilateral Not reported Laparoscopy IUP rate 10/23 
(43.5%) 
EP rate 1/23 (4%) 
6 years At 72 months 10/23 (43.5%) 13.4 
months 
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Milingos et 
al., (2000) 
Retrospective 
cohort 
61 patients 
with 
hydrosalpin
x 1990-
1997 
Greece 
Mean age 31+/-
3.9 years 
 
Range 23-38 
years 
HSG and 
laparoscopy 
61 patients 
underwent 
laparoscopic 
bilateral 
salpingostomy 
Bilateral  Classified using 
the AFS scoring 
system of distal 
tubal occlusion 
laparoscopy IUP rate 14/61 
(23.0%) 
EP rate 2/61 
(3.3%) 
2 years 
 
 
Unable to extract Not 
reported 
Singhal et al., 
(1991) 
Retrospective 
cohort 
97 patients 
with 
hydrosalpin
x 1983 – 
1989.  
U.K 
Mean age 30.4 
years 
 
Range 20-42 
years 
 
HSG and 
laparoscopy 
97 patients 
underwent 
salpingostomy.  
Mixture of 
unilateral 
and 
bilateral  
Classified by size 
of hydrosalpinx 
Laparotomy 
and 
microsurgery 
LBR 28/97 (28.9%) 
IUP 33/97 (34.0%) 
EP 6/97 (6.2%) 
Miscarriage 5/97 
(5.2%) 
Mean 
duration of 
follow up 
2.8 years 
(range 10 
months to 
6 years)  
 
 
At 12 months 28% 
At 36 months 40% 
Not 
reported 
Smalldridge 
et al.,(1993) 
Retrospective 
cohort 
30 patients 
with 
hydrosalpin
x  
1986-1990 
New 
Zealand 
Not reported HSG and 
laparoscopy 
30 patients 
undergoing 
salpingostomy 
Not 
reported 
Not reported Laparotomy 
and 
microsurgery 
IUP 9/30 (30.0%) 
EP 3/30 (10.0%) 
Miscarriage 0/30 
(0.0%) 
9-36 
months 
Unable to extract Not 
reported 
 Taylor et al., 
(2001) 
Retrospective 
cohort 
139 
patients 
with 
hydrosalpin
x  
1984-1998  
Canada 
Mean age 30.9 
+/-4.1 years 
 
Range 21.4 to 
41.1 years 
HSG and 
laparoscopy 
139 patients 
underwent 
laparoscopic 
salpingostomy 
Unilateral 
in 86/139 
 
Bilateral in 
53/139 
AFS classification 
system of distal 
tubal occlusion 
Laparoscopic 
salpingostomy 
LBR 25/139 
(18.0%) 
IUP 34/139 
(24.5%) 
EP 23/139 (16.5%) 
Miscarriage 9/139 
(6.5%) 
 
36 months Of the patients who 
conceived: 
- 55.2% within 12 months 
- 84.5% within 36 months 
 
17.7 
months 
(range 0.5-
86.4 
months) 
Teoh et al., 
(1995) 
Retrospective 
cohort 
96 women 
with 
bilateral 
hydrosalpin
ges 
1982-1991 
Ireland 
Not reported laparoscopy 96 women 
underwent 
bilateral 
salpingostomy 
Bilateral Not reported Laparotomy 
and 
microsurgery 
LBR 19/96 (19.7%) 
EP 3/96 (3.1%) 
Miscarriage 1/96 
(1.0%) 
10 years Unable to extract Not 
reported 
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Tulandi et al., 
(1984) 
Retrospective 
cohort 
91 women 
with 
bilateral 
hydrosalpin
x 
Canada  
Range 20-37 
years 
HSG 23 women 
underwent 
salpingostomy 
with CO2 laser 
22 women 
underwent 
salpingostomy 
with 
microdiathermy 
needle 
46 women 
underwent  
salpingostomy 
by cold 
dissection 
 
Bilateral Classified by 
mucosal 
appearance, 
thickness of tubal 
wall and peritubal 
adhesions 
Laparotomy 
and 
microsurgery 
IUP 24/91 (26.4%) 
EP 6/91 (6.6%) 
At 5 years 
IUP 24/91 
(26.4%) 
EP 6/91 
(6.6%) 
At 5 years 
IUP 24/91 (26.4%) 
EP 6/91 (6.6%) 
23.5+/-4.3 
months  
(range 6-60 
months) 
Winston et 
al., (1991)  
Retrospective 
cohort 
388 
patients 
with 
bilateral 
hydrosalpin
x 1971-
1988 
U.K 
Mean age 31.5 
years 
 
Range 19 to 
44years 
HSG and 
laparoscopy 
323 women 
underwent 
primary 
salpingostomy 
Bilateral Modified Boer-
Meisel 
classification. 
 
Classified by 
thickness of tubal 
wall, appearances 
of endosalpinx 
mucosa, tubal 
adhesions and 
ovarian adhesions 
Laparotomy 
and 
microsurgery 
LBR 74/323 
(22.9%) 
IUP 106/323 
(32.8%) 
EP 32/323 (9.9%) 
Miscarriage 
32/323 (9.9%) 
Variable 
follow up 
duration.  
Longest 10 
years.   
12% of 
participants 
lost to 
follow up 
and 
reported as 
not 
pregnant 
 
At 1 year   
IUP 55/323 (17.0%) 
 
At 4 years 
IUP 106/323 (32.8%) 
 
Cumulative rates displayed 
graphically 
Not 
reported 
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Not all of the studies reported the ages of the women that had undergone salpingostomy.  In 
total, 13 out of the 22 studies reported the mean age of their sample.  Twelve of the studies 
that reported their sample’s mean age reported results from a younger population with a 
mean age ranging from 27.5 to 32.6 years.  The remaining study had a higher mean age of 
35.5 years.   
 
The methods used to diagnose hydrosalpinx also differed between the included studies.  Five 
of the studies used hysterosalpingogram alone to diagnose hydrosalpinx, whereas four 
studies used laparoscopy to identify hydrosalpinx.  The remaining 13 studies used a 
combination of hysterosalpingogram and laparoscopy to diagnose hydrosalpinx.   
 
The surgical approach used to perform salpingostomy varied between the included studies.  
Thirteen of the 22 studies used an open laparotomy approach followed by microsurgery to 
perform salpingostomy.  Six studies reported a minimal access laparoscopic approach to 
perform salpingostomy with the remaining three studies using a mixture of open and 
laparoscopic approaches.  
 
Only 14 out of the 22 included studies made an attempt to classify the severity of tubal 
disease encountered during surgery.  The remaining eight studies made no reference to the 
severity of tubal disease of the women that they performed salpingostomy on.   
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The majority of the studies (15 studies) reported the reproductive outcomes of women with 
a mixture of unilateral and bilateral disease.  Two studies reported outcomes after 
salpingostomy was performed in women with unilateral hydrosalpinx and five studies 
reported outcomes on women with bilateral hydrosalpinx where bilateral salpingotsomy was 
performed. 
 
The length of follow up varied widely in the included studies.  Follow up was only 12 months 
in some studies with the longest follow up period being 71 months. 
 
Included study assessment 
The Newcastle-Ottawa Quality Assessment of the included studies is presented in table 12.  
All studies scored highly on the Newcastle-Ottawa Quality Assessment Scale achieving scores 
between six and eight.  
 
Clinical pregnancy  
The primary outcome of this review was natural clinical pregnancy after salpingostomy.  All 
22 studies reported the clinical pregnancy rates achieved as an outcome (figure 17).  When 
the clinical pregnancy rates of the 22 studies were pooled, the overall clinical pregnancy rate 
was 27% (95% CI 25 to 29%).  There was a substantial level of heterogeneity in these studies 
indicated by an I2  value of 53.9%, p=0.001.   
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Table 12. Appraisal of methodological quality (Newcastle-Ottawa Scale) of included studies. Salpingostomy for hydrosalpinx 
Study Case-cohort 
representative 
Ascertainment 
of exposure 
Outcome 
negative 
at start 
Comparability 
by design or 
analysis 
Outcome 
assessment 
Duration 
of follow 
up 
Adequacy 
of follow 
up 
Score 
Audebert AJM et al., - 
1980 
* * * * * * * 7 
Audebert AJM  et al.,  - 
2014 
* * * * * * * 7 
Bayrak A  et al., -2006 * * * * * * * 7 
Beyth Y et al., -1982 * * * * * x * 6 
Boer-Meisel M et al.,-
1986 
 
* * * * * x * 6 
Bontis JN et al., -2000 * * * * * x * 6 
Chanelles O et al., -2011 * * * x * * * 6 
Chong AP et al., -1991 * * * * * x * 6 
Cohen J et al., -1972 * * * x * * * 6 
Dubuisson JB et al., -
1995 
* * * ** * * * 8 
Dubuisson JB et al., -
1994 
* * * ** * * * 8 
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Jansen RPS et al., -1980 * * * x * * * 6 
Kosasa TS et al., -1988 * * * * * x * 6 
Mage G et al., -1983 * * * * * x * 6 
McComb P et al., -2001 * * * * * * * 7 
Milingos SD  et al., -
2000 
* * * * * * * 7 
Singhal V et al., -1991 * * * * * * * 7 
Smalldridge J et al., -
1993 
* * * * * * * 7 
Taylor RC et al., -2001 * * * * * * * 7 
Teoh TG et al., -1995 * * * * * x * 6 
Tulandi T et al., -1984  * * * * * * * 7 
Winston RML  et al., -
1991 
* * * * * * * 7 
*Indicates that a feature is present. X that a feature is absent.  However for comparability by design or analysis 
this checklist awards the maximum of two stars (**), one (*) or none if the feature is completely absent (x). 
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Figure 20. Natural pregnancy rates after salpingostomy treatment for hydrosalpinx 
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Clinical pregnancy rates by publication date 
The included studies were grouped according to their publication date.  The first group was 
the articles published before 2000.  The second group was the articles published after 2000.  
In the studies published before 2000, the pooled clinical pregnancy rate was 28% (95% CI 25 
to 30%, figure 18).  In the articles published after 2000, the pooled clinical pregnancy rate 
was 25% (95% CI 22 to 29%, figure 18).  
 
Cumulative clinical pregnancy rates 
Ten of the included studies reported cumulative pregnancy data. The cumulative natural 
clinical pregnancy rates over the follow up period are displayed graphically in figure 19.   The 
cumulative clinical pregnancy rates at six months were provided by three studies. Pooling of 
this data showed a natural clinical pregnancy rate of 8.7% (95% CI 6.6-11.5%) at six months.  
The same three studies reported cumulative pregnancy data at nine months. The pooled 
natural cumulative pregnancy rate at nine months was 13.3% (95% CI 10.6-16.7%).  Seven 
studies reported their natural clinical pregnancy rates at 12 months after salpingostomy.  
The pooled cumulative pregnancy was 20.0% (95% CI 17.5-22.8%) at 12 months.  Four 
studies reported their clinical pregnancy rates 18 months after surgery.  The pooled 
cumulative pregnancy rate was 21.2% (95% CI 18.6-24.1%) at 18 months.  Lastly, five studies  
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Figure 21. Natural pregnancy rates after salpingostomy treatment for hydrosalpinx by date of publication 
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Figure 22. Cumulative natural pregnancy rates after salpingostomy treatment for hydrosalpinx 
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reported their results at 24 months.  The pooled cumulative pregnancy rate was 25.5% (95% 
CI 22.2-29.4%) at 24 months.   
 
Figure 19 demonstrates that there is a plateau in the cumulative natural pregnancy rate 
achievable by salpingostomy at 24 months. 
 
Clinical pregnancy rates in women with bilateral hydrosalpinges 
A post-hoc analysis was performed on the five studies that reported the natural clinical 
pregnancy outcome in women with bilateral hydrosalpinges that underwent salpingostomy. 
In this sub-population, one would expect that without any surgical treatment the natural 
clinical pregnancy rate would be very low or nil.  The pooled clinical pregnancy rate from the 
five studies was 29.0% (95% CI 25 to 34%, figure 20).  There was statistical heterogeneity 
between these five studies as indicated by an I2 value of 17.8%, p=0.301 . 
 
Live birth  
Only ten out of the 22 included studies followed their patients up to live birth.  This is 
displayed in figure 21.  These 10 studies showed that a pooled live birth rate of 25% (95% CI 
22 to 28%) can be achieved when salpingostomy is performed for hydrosalpinx.  These ten 
studies showed a moderate level of heterogeneity indicated by an I2 value of 28.8%, 
p=0.180.   
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Figure 23. Natural pregnancy rates after bilateral salpingostomy treatment for bilateral hydrosalpinges 
184 
 
  
Figure 24. Live birth rates after salpingostomy treatment for hydrosalpinx 
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Ectopic Pregnancy  
Nineteen of the included studies reported the ectopic pregnancy rates after salpingostomy is 
performed for hydrosalpinx (figure 22).  Meta-analysis of the data from the 19 studies 
showed a pooled ectopic pregnancy rate of 10% (95% CI 9 to 11%).  These studies showed a 
moderate level of heterogeneity indicated by an I2 value of 41.8%, p=0.029.   
 
Miscarriage  
Seven of the included studies reported the outcome of miscarriage from their cohorts (figure 
23).  Pooling of the results from the seven studies showed a miscarriage rate of 7% (95% CI 6 
to 9%).  There was moderate heterogeneity between these studies with an I2 value of 42.1%, 
p=0.110. 
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Figure 25. Ectopic pregnancy rate after salpingostomy treatment for hydrosalpinx 
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Figure 26. Miscarriage rates after salpingostomy treatment for hydrosalpinx 
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Discussion 
 
This systematic review identified 22 studies reporting on the reproductive outcomes of 
women with hydrosalpinx undergoing salpingostomy.  The data from these studies suggests 
that in these women, the chance of achieving a natural clinical pregnancy is 27%.  
Furthermore, treating hydrosalpinx with salpingostomy carries a 25% chance of live birth.  
However, salpingostomy is not without its risks, as there is a 10% risk of ectopic pregnancy if 
a pregnancy is achieved after surgery.  
 
This systematic review has been strengthened by several factors.  An extensive search 
strategy was employed.  Independent reviewers were used to identify studies for inclusion, 
which validates our methods of data synthesis.  No language restrictions were applied to our 
electronic data searches and the search strategy was wide, therefore there is a high level of 
confidence that all relevant articles were identified.  A valid quality assessment was applied 
to the included studies in the form of the Newcastle-Ottawa Quality Assessment Scale. The 
included studies scored highly on this scale meaning a low risk of bias. 
 
However, there are also limitations to this systematic review.  There is a high degree of 
clinical heterogeneity of the included studies.  In the surgical studies that are included, some 
clinical heterogeneity must be expected as surgical techniques develop and evolve with 
time.  Furthermore, the methods of diagnosis of hydrosalpinges will have changed 
dramatically with the introduction of laparoscopic surgery and the widening availability of 
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ultrasound.  The management and attitudes of tubal surgeons towards the treatment of 
hydrosalpinx will have also changed with time.   However, the clinical heterogeneity 
between the studies in this review increases the generalisability and therefore may not 
weaken the results.  
 
The variation in publication dates of the included studies is wide.  The oldest study was 
published in 1972 and the most recent study that was included was published in 2014.  The 
surgical techniques implemented to perform salpingostomy have changed greatly over the 
last four decades.  There have been major advancements in technology and equipment that 
are available for tubal surgery268.  In the studies that are included in this review that were 
published earlier, the surgery will have been performed through an open incision in the 
abdomen.  Microsurgical techniques will have then been used to carry out the delicate tubal 
surgery.  This is in contrast to the more recent studies that have been included, where the 
surgery has mainly been performed through a laparoscopic approach.  With the 
advancements in surgical technology and equipment, one might have expected that the 
clinical pregnancy rates achieved to be higher in the more recent publications (those 
published after 2000).  However, the data shown in this systematic review demonstrates the 
opposite, with higher pregnancy rates achieved in the older publications.   One possible 
reason for this is in the difference of the patients that were chosen pre-2000 and post-2000.  
Before IVF and ICSI became widely available, tubal surgeons may have selected patients with 
milder tubal disease whom they would expect more favourable outcomes.  Furthermore, 
before 2000 tubal surgery was more popular as a treatment strategy for infertile women 
with hydrosalpinx.  This would mean that tubal surgeons had greater experience and greater 
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expertise and would therefore have achieved better success rates with improved 
reproductive outcomes.  In theory, one would expect that laparoscopic salpingostomy would 
yield better clinical pregnancy rates when compared to laparotomy and microsurgical 
salpingotomy as there is less chance of adhesion formation from a minimal access approach.  
However, as laparoscopic surgery requires more time to gain higher levels of competence, it 
may be several decades before the change in surgical technique is reflected in the achieved 
clinical pregnancy rates.   
 
Inevitably, there will have also been large differences in the expertise of the surgeons that 
reported their findings.  Furthermore, the tubal surgeons also reported the used of differing 
surgical techniques.  For example, some tubal surgeons preferred cold knife dissection, 
whereas other tubal surgeons preferred to use electrosurgical techniques to create the 
stoma in the fallopian tube to drain the hydrosalpingeal fluid.  Moreover, some surgeons 
attempted to reduce the chances of the salpingostomy healing and closing by everting the 
edges of the stomas created and then suturing the everted edges back.  In contrast, other 
surgeons did not possess the necessary skill to do this and would leave the stoma edges un-
everted.  These differing surgical techniques would also be expected to yield a range of 
natural clinical pregnancy rates.    
 
The majority of the studies that were included reported the reproductive outcomes of 
women of similar ages.  As mentioned above, twelve of the studies reported the clinical 
pregnancy rate of women where the mean age ranged from 27.5 to 32.6 years.  The pooled 
clinical pregnancy rate of these 12 studies was 31%.  One study, published by Bayrak et al.,250 
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had a higher mean age (35.5 years) and had the lowest clinical pregnancy rate (5%).  
Although this was a small study of only 40 women, the contrasting clinical pregnancy rates 
achieved in younger women compared to that achieved in the older women in the Bayrak et 
al., study may suggest that performing salpingostomy on hydrosalpinx and waiting for 
natural pregnancy may not be the be the best strategy in older women with hydrosalpinx.  
 
In some of the studies identified by this review, women had unilateral hydrosalpinx and 
would have undergone unilateral salpingostomy.  In other studies, the sample population 
was all women with bilateral hydrosalpinges.  It would be expected that women with 
unilateral hydrosalpinx may have a more mild form of tubal disease.  However, when 
analysed as a sub-population, the five studies that reported on pregnancy outcomes of 
women with bilateral hydrosalpinges still showed favourable outcome, with a pooled clinical 
pregnancy rate of 29% (n=605).  Reassuringly, the I2 value was low suggesting minimal 
statistical heterogeneity between these five studies.   
 
There was variation in the methods with which tubal surgeons reported the severity of 
hydrosalpinx in their study samples. Indeed, some studies did not report on the severity of 
the tubal disease at all, whilst others classified the degree of severity encountered.  This is 
important as this increases clinical heterogeneity within study and between studies further 
as better fertility outcomes would be expected in those with milder forms of hydrosalpinx.  
 
The duration of follow up of women in the included studies varied widely.  In studies where 
the follow up duration was short (just 12 months in some studies) there may have been 
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under-reporting of the natural clinical pregnancy rates, as women may have become 
pregnant after the follow up duration was complete. 
 
The time interval between salpingostomy and natural pregnancy is an important clinical 
factor.  This is certainly a key issue that must be discussed when counselling a woman who 
may be considering salpingostomy for hydrosalpinx.  These women who are choosing to 
have tubal conserving surgery would want to know the duration of time that they should 
attempt natural conception before considering further treatment in the form of sterilising 
surgery and IVF or ICSI treatment.  The cumulative natural clinical pregnancy data presented 
in this review suggests that there is a plateau at approximately 24 months. This is therefore 
the amount of time that a woman should be counselled to try conceiving naturally after 
salpingostomy is performed for hydrosalpinx. 
 
In 2010, A Cochrane review published by Johnson et al.,28 concluded that surgical sterilising 
treatment (in the form of salpingectomy or tubal occlusion) should be offered for all infertile 
women with hydrosalpinges prior to IVF treatment to improve the chance of successful 
treatment. Importantly, this review did not find any randomised trials that investigated the 
effectiveness of salpingostomy versus salpingectomy or tubal occlusion prior to IVF 
treatment.  To date there have still been no studies to investigate this.  Presumably, this is 
due to the fact that most IVF clinicians prefer sterilising surgery and IVF over tube conserving 
surgical strategies and would not wish to conduct this randomised trial.  The Cochrane 
review recommended that further research is required to assess the value of tubal 
restorative surgery as an alternative (or as a preliminary treatment) to IVF. This systematic 
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review adds further weight to this recommendation from the Cochrane review, as our 
results demonstrate that reasonable clinical pregnancy rates can be achieved with 
salpingostomy in carefully selected patients.   
 
Salpingostomy may be an important alternative option for treatment of hydrosalpinx in 
carefully selected populations.  This is particularly the case in women who may wish to have 
the option to have salpingostomy to continue to attempt natural conception.  If this does 
not result in natural pregnancy then more definitive sterilising surgery in the form of 
salpingectomy can be performed.  This may be preferred by certain groups of women who 
may not wish to be reliant on ART with no further opportunities to try to conceive naturally.    
Another sub-group that may prefer tubal restorative surgery in the form of salpingostomy 
may be younger women who have more time to conceive.  In older women or in women 
with more severe hydrosalpinges it may be more advisable to proceed directly to 
salpingectomy and IVF treatment as time and chances of natural conception are more 
limited.   
 
In the reproductive medicine setting, there has been a general trend for the removal or 
disconnection of fallopian tubes in women who have hydrosalpinx since the increasing 
availability of IVF treatment269.  It is likely that the ability of reproductive specialists to 
restore normal tubal anatomy has been reduced due to an over reliance on tubal removal or 
occlusion followed by IVF treatment.  The reduced abilities for tubal restorative surgery may 
also be the result of de-skilling in the surgical expertise required for such surgery.  
Importantly, women with hydrosalpinx may not be given the full range of treatment choices 
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in the clinical setting and are then left with no other option than to pursue and fund IVF 
treatment.  Women who opt to have tubal restorative surgery must be counselled fully 
regarding the risks involved with salpingostomy.  There was a 10% risk of ectopic pregnancy 
in the included studies, and this must be conveyed to the women.  A balanced consultation 
must be delivered with the potential success rates of IVF treatment, tubal conservative 
surgery, their risks and repercussions should be discussed. 
 
The findings of this systematic review have re-introduced the possibility of considering tubal 
restorative surgery for a carefully selected group of women with hydrosalpinx.  Further 
research is required to identify the women who would benefit from tube conserving surgery 
as opposed to the current management of tube removal.  It may also be beneficial to 
investigate the best technique to perform salpingostomy in these selected patients. 
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CHAPTER 8: THESIS CONCLUSIONS 
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Thesis Conclusion 
This thesis has sought to explore a number of strategies to improve the process of 
implantation in women attempting to conceive using ART or with natural conception.  Four 
strategies have been investigated;  
1. The importance of vitamin D in IVF treatment 
2. The importance of vitamin D in women with recurrent miscarriage 
3. The role of endometrial fluid as a prognostic tool for women undergoing IVF 
treatment and the potential use of metabolomic profiling in this context 
4. The role of salpingostomy in the treatment of hydrosalpinx.   
In this summary the findings from each of these domains is presented.  The potential 
direction of future work in these research fields will also be discussed.   
 
Vitamin D and IVF treatment 
Interesting findings resulted from the vitamin D and IVF treatment systematic review and 
meta-analysis.  The studies identified by the rigorous search strategy found conflicting 
evidence from differing research groups.  It is also clear that this is a relatively immature but 
promising and exciting field of research with all of the studies being published after 2010 
and seven of the 13 studies published since 2014 (see table 1).  The search also did not 
identify any well-conducted trials investigating the potential merits of vitamin D deficiency 
treatment in IVF patients for inclusion into the review.  However, when the data from each 
cohort study was meta-analysed, the overall risk ratios calculated show that vitamin D status 
in women undergoing IVF treatment is an important factor in the outcome of treatment (RR 
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0.79 (95% CI 0.66-0.93).   There was clinical heterogeneity between the studies that were 
included into the meta-analysis.  Specifically, the use of differing vitamin D status 
categorisation by different authors, however the comparison of IVF treatment outcome in 
women that are replete in vitamin D versus those that are non-replete is clear when the 
Endocrine Society reference ranges for vitamin D status are used41.   
 
The findings from the vitamin D and IVF treatment systematic review and meta-analysis 
were mirrored in the vitamin D and IVF treatment cohort study presented in chapter three.  
The cohort study was the first to be conducted in the UK and the sample of patients used is 
representative of the country as a whole.  Vitamin D deficiency and insufficiency prevalence 
was found to be high (84.0% of all participants).  This is an important finding in its own right.  
Vitamin D is now implicated in many obstetric complications such as pre-eclampsia, 
gestational diabetes and intra-uterine growth restriction106,270,271 and the results of the 
cohort study suggest that a high proportion of women that are commencing IVF treatment 
are, in fact, deficient in vitamin D.  Most importantly, the cohort study showed that vitamin 
D deficiency reduces the chances of obtaining a positive pregnancy test, achieving a clinical 
pregnancy as well as a live birth when compared to women with replete vitamin D.  As the 
data generated is observational in nature, ascertainment of whether this association is 
evidence of a causal relationship between replete vitamin D status and fertility treatment 
success is a question that remains unanswered272. 
 
The findings of both the systematic review and cohort study have wider implications.  The 
high prevalence of vitamin D deficiency in the infertile population suggests that there is a 
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high prevalence of vitamin D deficiency in the general population as a whole.  Many studies 
have already demonstrated this273,274.  Importantly, this is a cause for concern in women of 
reproductive age.  Given the proposed mechanisms that have been postulated for the 
importance of vitamin D in implantation (immunomodulation of the endometrium5), vitamin 
D may be an important health issue for all women that are trying to conceive.  Potentially, 
this could mean that vitamin D could be assessed in all pre-conceptual women, both 
attempting conception via natural methods and also with ART.  Vitamin D treatment could 
then be implemented to aid implantation to optimize the efforts at natural conception.  This 
could have the potential to reduce the need for fertility treatments before they are required.  
These conclusions may be far-fetched, however the prospect of a simple oral treatment, that 
is relatively safe and cost effective that could improve the chances of pregnancy would be a 
desirable therapy for clinicians and more importantly women that are desperate to start a 
family. 
 
It is important to note that many pre-conceptual vitamin and mineral supplements contain 
vitamin D and that a significant proportion of women self-administer these preparations.  
However, the vitamin D in these preparations is at a supplementary dose and not at 
treatment doses275.  It is well recognized that vitamin D deficiency treatment must be at 
therapeutic levels to achieve a replete vitamin D status and therefore its desired effect41. 
  
All of the above points suggest that a trial is required to test the effectiveness of vitamin D 
deficiency treatment in improving attempts at conception.  The IVF population, specifically 
women planning IVF treatment offers an easily reachable population to investigate.   Vitamin 
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D status could be screened once a patient is referred for IVF treatment.  If required, vitamin 
D deficiency could then be treated.  However, this simplistic view of conducting the 
necessary trial becomes more complex when trial design is considered.  In order to fully 
investigate the effectiveness of vitamin D deficiency treatment on IVF treatment outcomes, 
a placebo controlled trial would be the ideal design276.  This would require women to either 
receive vitamin D deficiency treatment or placebo.  This poses an ethical dilemma as the 
health benefits of replete vitamin D status are not solely through its role in optimising 
embryo implantation.  As mentioned above, there are numerous obstetric complications 
linked with vitamin D deficiency as well as other health benefits e.g. prevention and 
treatment of diabetes, asthma and cancer277–280.  Therefore trial design for an individual 
placebo-controlled randomised study may be complicated.  One potential method to 
circumvent this ethical dilemma is to perform a cluster trial.  This would involve the use of 
several similar IVF centres, with half of centres offering screening and treatment of vitamin 
D deficiency whilst the other half of centres do not281.     A stepped wedge design74 could 
also be employed, where all centres begin with no screening and treatment of vitamin D 
deficiency and at pre-defined time intervals, IVF centres would be chosen randomly to start 
screening and treating their patients for vitamin D deficiency.  These cluster trial 
methodologies would involve collection of centre specific data rather than individualized 
patients, which is a disadvantage as the effectiveness of vitamin D deficiency treatment may 
become diluted74,281.   
 
Whichever trial methodology is employed, a well-conducted trial for vitamin D is certainly 
required in women undergoing IVF treatment.  Any means to improving fertility treatment 
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outcome should be fully explored not only to aid women in their wishes for pregnancy but 
due to the funding restrictions that apply in the UK.  Many couples are not in the financial 
situation to have multiple attempts at IVF treatment if this is the therapy required.  This 
leads to many couples having only one treatment cycle (the NHS funded cycle).  
Consequently, the optimisation of any correctable condition that improves the chance of 
successful fertility treatment is vital.  If trial findings are positive, concluding that vitamin D 
deficiency treatment does lead to improved fertility treatment outcomes, the next logical 
step would be to perform a similar trial in women attempting natural conception.  All of the 
above contributes to an exciting research field. 
 
Vitamin D and recurrent miscarriage 
 
The nature of the data generated from the vitamin D and IVF treatment systematic review 
and meta-analysis prompted the narrative review investigating the association between 
vitamin D and recurrent miscarriage.  One would logically expect that if vitamin D bears an 
association with implantation that it may also bear an association with recurrent 
miscarriage.  However, this association could not be confirmed.  Using a robust search 
strategy, only a small number of research articles could be found linking vitamin D deficiency 
and recurrent miscarriage.   The speculative association between vitamin D deficiency and 
recurrent miscarriage carries sound biological plausibility and is certainly an area of 
recurrent miscarriage research that will grow in the future.   
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In particular, the basic science studies identified by the systematic narrative review share a 
common theme.  This focuses on the immunomodulatory role of vitamin D on the 
endometrium.  Interestingly, specific pro-inflammatory cytokines have been found to be 
reduced when endometrium from women with recurrent miscarriage is treated with vitamin 
D producing a less hostile environment for the successful completion of the delicate 
implantation process143.  A sound mechanism by which vitamin deficiency may contribute to 
unexplained recurrent miscarriage is therefore presented. 
 
From a clinical research perspective, the association between vitamin D deficiency and 
recurrent miscarriage has yet to be proven or disproven.  This is an area of clinical research 
that is very much in its infancy with little interest recently.  All but one of the eight identified 
clinical research publications was observational in nature and the findings were conflicting.  
The remaining study was interventional and aimed to investigate whether vitamin D 
treatment would be of any benefit in women with recurrent miscarriage130.  However, this 
trial was weak in its methodology.  Firstly the sample was too small to answer the research 
question (40 women) and none of the women diagnosed with recurrent miscarriage had 
their vitamin D status checked prior to vitamin D treatment.  Consequently, vitamin D 
treatment would not have been targeted on the deficient population. 
 
Identification of whether an association between vitamin D and recurrent miscarriage exists 
remains an interesting research area.  Much like in the IVF population, a safe and cost 
effective treatment that could reduce the risk of miscarriage in any further pregnancies 
represents an important avenue to explore.  Although recurrent miscarriage affects a small 
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proportion of the general population (1%), the women affected have profound health 
impact.  Recurrent miscarriage holds psychological and physical health implications and 
therefore, any treatment that carries sound biological plausibility should be fully 
investigated.  The first step would be to conduct a robustly designed observational cohort 
study to identify the prevalence of vitamin D in the recurrent miscarriage population.  The 
outcome of any achieved pregnancy after vitamin D assessment could then be tracked and 
data collected.   
 
The use of endometrial fluid as a prognostic tool in women undergoing IVF treatment  
 
The use of endometrial fluid as a prognostic tool is still at a very early research stage.  The 
narrative review conducted demonstrates this, as only a small number of publications were 
identified.  However, the research published thus far is very exciting, with several groups 
proposing several biomarkers that could be of clinical use.  In particular, the genetic, protein 
and immunological factors that have been suggested have promising potential.  Currently, 
there are still no endometrial fluid tests that show whether a woman will achieve pregnancy 
or not whilst undergoing IVF treatment.  However, it would be anticipated that such a test 
could become available soon.  The tool that is closest to becoming clinically useful is the 
Endometrial Receptivity Array that assesses the expression of 238 selected genes in the 
endometrium190,191.  An endometrial biopsy is taken the month prior to the IVF treatment 
cycle.  This aids clinicians predict when the endometrium is most receptive and offers data to 
assist with a personal embryo transfer that has the maximum potential for implantation.  
This test is currently being used in the private health sector at a substantial cost.  
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Additionally, the test may need to be repeated on multiple occasions to identify the most 
receptive day that embryo transfer should be performed. 
 
Perhaps the most exciting part of this area of research is the potential to collect endometrial 
fluid at close proximity to implantation with respect to time and space.  A number of studies 
identified in the narrative review collected fluid before IVF treatment commenced, whilst 
others collected endometrial fluid at the time of oocyte retrieval.  One could argue that the 
use of endometrial fluid aspirated at the time of embryo transfer as a prognostic tool offers 
the greatest interest with regards to increasing the level of understanding towards embryo 
implantation.  This is due to the fact that the fluid collected is closely representative of the 
uterine environment that the embryo will be transferred into and is therefore the closest to 
the implantation event itself.  The identified literature seems to suggest that this is a safe 
technique that does not disrupt the mechanisms required for embryo implantation to occur 
and the research published by Boomsma et al., highlights this162.   
 
As technology advances, it may become possible to collect endometrial fluid just prior to 
embryo transfer so that a prognostic result can be provided to guide clinicians as to whether 
the embryo transfer should be performed or whether the embryos should be cryopreserved 
and transferred at a later date.  The test and technology required would need to offer a 
quick turnaround to allow a decision to be made that would be clinically important and 
feasible to undertake. 
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The endometrial fluid metabolomics cohort study presented in chapter six has provided 
some novel and exciting results.  The study demonstrated that the novel technique of 
sampling endometrial fluid without active aspiration is safe with an expected number of 
clinical pregnancies achieved by the 20 women recruited that underwent fluid sampling.  
Furthermore, the technique adopted allows for sufficient fluid to be sampled in order to 
conduct metabolomics profiling, which had not been performed before in the context of 
endometrial fluid sampled from women undergoing IVF treatment.  As a proof-of-principle 
study this was the primary aim.  However, the data generated suggested that several 
metabolites could be used to differentiate the endometrial fluid of women that achieved 
clinical pregnancy versus the endometrial fluid of women that did not.  Unfortunately as this 
was a proof-of-principle study the sample size was not large enough for any firm conclusions 
to be found.  But a larger sample size may well yield useful metabolites that indicate a 
receptive endometrium.  The significance of these endometrial fluid metabolites must also 
be investigated and the mechanisms behind their importance understood.   
 
The future direction for the use of endometrial fluid in IVF treatment is a hopeful one.  There 
is a need for the identification of a clinically useful panel of biomarkers that are capable of 
differentiating endometrial fluid that is receptive to embryo implantation versus 
endometrial fluid that is non-receptive.  In the first instance, it would seem logical to explore 
these biomarkers in the endometrial fluid in a large sample of fertile women during the 
receptive mid-menstrual cycle to identify those biomarkers that were consistently present in 
fertile and receptive endometrial fluid.  Once the biomarkers are identified the panel could 
then be tested on women that were having IVF treatment.  Metabolomic profiling would 
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seem an attractive avenue for further enquiry as a testing tool.  The reason for this is that it 
is the omics discipline that is furthest downstream of the endometrial tissue.  It would 
therefore offer the most representative test of the phenotype of endometrial fluid when 
compared with genomics or proteomics for example. 
 
Salpingostomy in the treatment of hydrosalpinx 
 
The clinical pregnancy rates achieved by the studies identified by the systematic review and 
meta-analysis performed in chapter seven are noteworthy.  Before IVF treatment became 
commonplace and available widely it was the role of gynaecologists to perform tubal surgery 
with the aim of achieving the possibility of natural conception in women with tubal 
infertility.  These surgical strategies have now been overtaken in popularity by IVF 
treatment.  In women with hydrosalpinx, current practice involves sterilising surgery to 
prime the uterus and endometrium to optimise the chances of implantation.  The aim of the 
sterilising surgery (whether this be tubal disconnection or salpingectomy) is to reduce the 
deleterious effect of the fluid within the hydrosalpinx causing toxicity to the endometrium or 
from washing out the embryo inserted into the uterine cavity.  Although this does improve 
the chances of IVF treatment success282 it renders the woman sterile and reliant on IVF 
treatment for any further attempts at pregnancy conception, which may be at significant 
financial cost to the infertile couple, as well as the  significant emotional and physical 
distress caused by repeated attempts at ART. 
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The findings of the salpingostomy and hydrosalpinx systematic review demonstrate that the 
clinical pregnancy rates achieved by conservative tubal surgery are comparable to those 
achieved by IVF treatment today.  This is an important finding as it brings to the fore the 
effectiveness of tubal surgery that may have been considered redundant by many working in 
the field of reproductive medicine.  At least in a well-selected population, conservative tubal 
surgery to drain the fluid from hydrosalpinx should be offered so that future attempts at 
natural conception can be made.  Critically, the review identified that there was a plateauing 
of clinical pregnancy rate 24 months post-surgery.  This means that if women have not 
achieved natural pregnancy two years after salpingostomy, then sterilising surgery followed 
by IVF treatment would seem the most sensible treatment strategy.   
 
More research is required to identify the exact sub-population where salpingostomy should 
be used.  However, it would be expected that tubal conserving surgery for hydrosalpinx 
would be best offered to younger women who have more time and ovarian reserve 
compared to those that are older.  Additionally, salpingostomy would be more suited to 
women with more mild forms of hydrosalpinx where the degree of tubal anatomical 
distortion is proportionately less than those with severe hydrosalpinx282.   
 
The review also demonstrated that the risk of ectopic pregnancy in women undergoing 
salpingostomy is relatively high, which is a potential downfall of tubal conserving surgery.  
However, it should be noted that IVF treatment is not in itself risk free, with the risks of 
ovarian hyper-stimulation and the surgical risks of oocyte retrieval being rare but present 
nonetheless.  With appropriate counseling and careful management of patients’ 
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expectations a fuller range of treatment options can be offered to women with hydrosalpinx 
with a balancing of risk of either strategy.   
 
A surgical trial would be difficult to perform given the heterogeneity of surgical technique 
used to perform salpingostomy by different surgeons.  However, a trial has been 
recommended by the Cochrane review published by Johnson et al., in 201028.  The Cochrane 
review calls for a trial to compare the cumulative pregnancy rates achieved by 
salpingostomy in the surgical treatment of hydrosalpinx versus the use of tubal occlusion or 
salpingectomy followed by IVF treatment.  The findings presented in thesis chapter seven 
reinforce this need. 
 
The promising clinical pregnancy rates achieved by salpingostomy in correcting distal 
fallopian tubal occlusion could also inspire interest in other forms of tubal restorative 
surgery.  A similar review is currently underway investigating the effectiveness of tubal 
catheterisation for proximal tubal occlusion, which is mainly treated with IVF treatment 
currently.   
 
As with many facets of clinical medicine, trends in therapy selection rise and fall with time.  
Treatments that had become unpopular (such as fallopian tube conserving surgery) may 
become popular once again.  Importantly, this could be the case with tubal conserving 
surgery, allowing for more treatment options and information to be available to patients 
with tubal infertility.  
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Summary 
 
As a subspecialty, reproductive medicine is a relatively young area of expertise.  Its use of 
high technology treatments means that it also lies at the cutting edge of science and will be 
the subject of many advances in the future.   
 
Over the past four decades, real cultural changes have occurred with regards to how women 
in the UK view fertility.  Prior to the advent of IVF treatment it was not uncommon for 
women to be told that they would be unable to become pregnant and have children.  With 
improvements in IVF care more women are now leaving child bearing until later on in their 
reproductive years.  Unfortunately, this may be due, in some part, to false perceptions of the 
results that modern IVF treatment can achieve.  There have been clear advancements in 
reproductive medicine; however, there remains a plateau in progress concerning the 
improvements in success rates of IVF treatment.  Much of this is due to the imperfect 
knowledge that there is regarding embryo implantation.    
 
Further research work is desperately required to advance embryo implantation knowledge.  
Additionally, the development of novel tools to help identify the correct environment for 
implantation will hopefully continue to improve pregnancy rates both in natural efforts at 
conception as well as in IVF treatment.  
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